GENETIC EPIDEMIOLOGY OF ALLERGY TO BETALACTAM ANTIBIOTICS by Badin, Sevil
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 












Download date: 28. Feb. 2018
 1
GENETIC EPIDEMIOLOGY 













I herby declare that this dissertation is the result of my own work and includes 
nothing that is the outcome of work done in collaboration except where 
specifically indicated in the text and acknowledgment. No parts of the work 
described in this thesis have been published yet. Parts of the work described in 
this thesis have been presented in an oral and poster presentation to the British 
Society for Allergy and Clinical Immunology annual meeting 2013. The work 
presented in this thesis has not been previously submitted for a degree, diploma 
or other qualifications at any other university and is not being concurrently 
submitted for any degree. 
This thesis was undertaken in the Department of Medical and Molecular 
Genetics, the Department of Twin Research and Genetic Epidemiology and the 
Department of Respiratory Medicine and Allergy under the supervision of Dr. 
Michael Weale, Dr. M. Rosario Caballero, Dr. Kourosh Ahmadi (primary 
supervisor for first 18 months of PhD), and Dr. Massimo Mangino (tertiary 
supervisor). This dissertation does not exceed 60,000 words as stipulated by the 





















This thesis would not have been possible without the generous support and 
encouragement from my supervisors Dr. Michael Weale and Dr. M Rosario 
Caballero. I owe my deepest gratitude to them for their caring supervision, their 
enthusiastic involvement in these projects, and their invaluable guidance and 
advices. Their optimism and endless energy has undoubtedly changed my view 
to the field of genetic molecular medicine and pharmacogenomics research and 
impacted my career ambitions. I will be indebted to them for the rest of my 
academic life. 
I would also like to acknowledge the support and advice I received from Dr 
Kourosh Ahmadi, Dr. Massimo Mangino and Professor Tim Spector during these 
years. They had invaluable input and support for different projects of this thesis. 
Dr. Michael Weale has been involved in most of the statistical works of the thesis. 
I hope that my collaboration with him will continue for several coming years. I 
would also like to thank Dr. Michael Weale and Dr Alireza Moayyeri for their kind 
advice, which led to the methodology for estimation of heritability, GWAS and 
MWAS in my thesis. 
A special thank you should go to the Department of Medical and Molecular 
Genetics and the Department of Twin Research and Genetic Epidemiology at 
King’s College London and the Division of Allergy at Guy’s Hospital, who were 
directly or indirectly involved in this thesis. In particular, I would like to thank 
Dr. Adaikalavan Ramasamy and Idel Erte for their support and enthusiasm in 
sharing their vast knowledge and skills. I would also acknowledge the support 
 5
and friendship from Dr. Afrooz Kosari and Dr. Elham Hasanzadeh. The support 
from my family members has been invaluable during this journey, including all 
my uncles; Hamo, Naso, Aziz, Jalal and Saied. My beloved cousins; Nojan, Arshia, 
Dena, Rojia, Nikia, Rudabeh and Roham. I would like to specially thank my 
beloved aunties; Sholeh, Leila, Shahla, Farrin and Donya.   
My PhD journey was a lovely experience and I shared this with several PhD 
students in London. I am also grateful to all my friends who made life in London 
a lovely experience for me.  
Lastly, and most importantly, I am truly and whole-heartedly thankful to my 
parents Abdollah Badin, Jaleh Hatami and brother Sam Badin for their 
unconditional love and support, without whom none of these achievements 
would have been even imaginable. They have always supported and encouraged 




Background: Immediate antibiotic allergic response is an important public health 
problem. Genetic and molecular characterization will improve treatment 
outcomes for truly allergic patients, and also reduce the use (and risk of 
evolution of pathogen resistance) of second-line antibiotics given to patients 
who incorrectly believe themselves to be allergic to first-line antibiotics. 
Objective: To identify genetic and metabolic factors associated with allergic 
responses to beta-lactam antibiotics using the TwinsUK cohort and recruited 
participants from the Guy’s allergy clinic. 
Methods: The TwinsUK cohort is the largest registry of adult twins in the UK, and 
the Guy’s allergy clinic is an outsized clinic covering a large area of the UK. The 
TwinsUK cohort has been extensively molecularly characterized.  After 
characterising the heritability, we conducted the first high-coverage genome-
wide association study (GWAS) between 211 self-reported cases in the TwinsUK 
cohort with questionnaire-defined beta-lactam allergic status and over 1000 
individuals without self-reported allergic reaction to any substances. 
Approximately 2.1 million imputed and genotyped single nucleotide 
polymorphisms were investigated. A second GWAS was conducted on 48 
clinically proven cases from the Guy’s Hospital allergy clinic and ~6000 
population controls. In addition a metabolome-wide association study (MWAS) 
was conducted on the same TwinsUK registry individuals, scanning 510 different 
metabolites. 
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Results: Following refinement of the self-reported beta-lactam allergy phenotype 
via the application of a more detailed questionnaire, we estimated a heritability 
of 21%. The heritability estimates provided positive evidence for a genetic 
component for beta-lactam allergy.  A single hit from the TwinsUK GWAS at the 
MTHFS/BCL2A1 locus was found (p<5x10-8 ),  indicating a provisional “genome-
wide significant” hit. Results from the TwinsUK MWAS demonstrated that all 
metabolites responded as a correlated system to the differences among twins in 
their allergy status. There were also 4 distinct “metabolome-wide significant” 
hits, of which two corresponded to known metabolites, suggesting that people 
who had penicillin allergy had less piperine in their system in comparison with 
our control group and had higher amounts of 4-vinylphenol-sulfate metabolite.  
Conclusion: This study demonstrated a genetic component to beta-lactam 
allergy, and in particular provided evidence for a genetic signal at the 
MTFHS/BCL2A1 locus. Although the MWAS study showed that there was a 
metabolomic difference between the allergic and non-allergic individuals. These 
findings may lead to new personalised treatments based on a combination of 
genotyping and metabolic characterization. The findings of our studies need 
verification in independent cohorts. 
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1.1 Allergy and hypersensitivity 
Hypersensitivity reactions are described as harmful immune reactions that occur 
in response to inherently harmless environmental antigens such as food, pollen 
and drugs. Allergy is the most prevalent type of hypersensitivity reaction. The 
term allergy is defined as an abnormal adaptive immune response of the body 
against non-infectious and harmless environmental substances. The facilitation 
of allergy can be attributed to either cell- or antibody- mediation, the latter being 
typically responsible for allergic reactions. Johansson et al (2001) proposed a 
revised nomenclature for allergic diseases to encourage uniform description, as 
this is a complex area where often more than one type of allergic disease 
presentation is found in a particular individual. The organ-based classification 
schema includes: rhinitis, conjunctivitis, asthma, skin diseases, urticaria and 
contact eczema/dermatitis – all of which are broad categories which will be fully 
explained in the content of this thesis and, in particular, their relatedness to 
allergic reactions as they are not allergic specific symptoms.  The allergen source 
can also be used to classify allergic reactions such as food, drug and venom 
allergy (Baldo and Tovey, Johansson et al., 2001).  Hay fever, asthma, hives, 
eczema, insects, drugs and food allergies are amongst the most common allergic 
reactions (Cookson, 1999). 
In recent years, empirical studies conducted in many countries have reported a 
significant increase in the frequency of allergic reactions and of hypersensitive 
allergic reactions.  The most rapid increase in prevalence of atopic diseases has 
occurred in Western countries in the years between 1960 and 1990, and various 
hypotheses have been proposed to explain this increase in prevalence.  These 
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include: increased awareness and improved diagnostics; genetic susceptibility;  
psycho-social influences; increased allergen exposure; and increased 
environmental pollution. Interestingly, significant differences in the prevalence 
of symptoms of different disease have also been found between countries. The 
highest asthma prevalence rates have been found in Australia, New Zealand, the 
United Kingdom, the USA and some cities in Latin America. Lower prevalence 
rates have been found in non-industrialized countries and more-rural areas 
(Ring et al., 2001, Wold, 1998).  
 
1.1.1  Classifications of hypersensitivity reactions 
In 1963, Phillip Gell and Robin Coombs proposed a seminal formal classification 
system for hypersensitivity reactions to foreign material (Gell and Coombs, 
1963). The classification is known as the Gell and Coombs classification, and the 
hypersensitivity reactions were classified based on immune mechanisms 
(Descotes and Choquet-Kastylevsky, 2001a). As shown in Table 1.1, all 
hypersensitivity reactions were divided into four different types, providing 
clarity to a clinically imperative field (Gell and Coombs, 1963). 
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Table 1.1 Gell and Coombs’ classification of hypersensitivity reaction. 
Based on information from (Descotes and Choquet-Kastylevsky, 2001a). 
Type Other alternative names Mediators 

















Delayed reaction T-cell Contact dermatitis 
According to Gell and Coombs’ classifications, hypersensitivity reactions 
were classified into four types I, II, III and IV. This table describes each type 
of reaction, underlying mechanisms, any other alternative and common 
names for the reaction, and an example of hypersensitivity reactions for 
each type.  
 
1.1.2 Mechanisms of hypersensitivity reactions according to Gell and 
Coombs’ classification 
Type I 
Type I hypersensitivity reactions are known as immediate hypersensitivity 
reactions. These are mediated by immunoglobulin E (IgE) antibodies to a specific 
antigen. The primary cellular component in immediate hypersensitivity 
reactions is the mast cell or basophil. During sensitisation, the cell binding nature 
of IgE to high affinity receptors on the surface of mast cells and basophils 
promotes degranulation of the cells, which results in a rapid and massive release 
of mediators such as histamines. The symptomatic clinical presentation of type I 
IgE mediated hypersensitivity reactions vary in severity, and include rhinitis, 
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urticaria, angioedema, and potentially fatal anaphylactic shock. These reactions 
can occur within a few minutes to an hour of exposure (Rajan, 2003b). 
Type II 
 Type II hypersensitivity reactions are known as cytotoxic reactions, mediated by 
immunoglobulin M (IgM) or immunoglobulin G (IgG) antibodies. The 
pathophysiological mechanism of cytotoxic reactions is described in more detail 
later in this chapter. A special category of type II responses involves IgG 
antibodies against cell-surface receptors that disrupt the normal function of the 
receptor (Descotes and Choquet-Kastylevsky, 2001b).  
Type III 
 Type III hypersensitivity reactions are known as immune complex-mediated 
reactions and may involve tissue injury by immune complexes. Type III 
hypersensitivity reactions occur when antigens react with antibodies and form 
antigen-antibody complexes in the blood, and thereby cause secondary damage 
to cells (Rajan, 2003b). 
Type IV 
Type IV hypersensitivity reactions are known as T cell-mediated, delayed 
reactions. The symptoms usually develop within 2-14 days after exposure to the 
allergen (Descotes and Choquet-Kastylevsky, 2001a).  
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We should note that these hypersensitivity reactions (types I-IV) are tightly 
connected. As an example of these connections, we can note that maturation of B 
cells to IgE- or IgG-producing plasma cells all depend on the help of T-cells 
(Pichler, 2007b).  
In 2001, Descotes and Choquet-Kastylevsky discussed whether Gell and Combs’ 
classification remained valid (Descotes and Choquet-Kastylevsky, 2001a). They 
listed a number of limitations of the classification, such as the diversity of 
immune-mediated hypersensitivity reactions to drugs being far beyond the 
limited categorisation by Gell and Coombs, including such reactions as toxic 
epidermal necrolysis (Lyell's syndrome) and ‘immuno-allergic’ hepatitis. Also, 
allergic drug reactions can be produced by more than one mechanism, and in this 
case the reaction cannot be categorised by this simple classification. For example 
most of the beta-lactam antibiotics can cause anaphylaxis, serum sickness or 
immuno-allergic haemolytic anaemia, which cannot be pigeonholed by this 
classification.  
One of the main arguments in the article was that this classification should no 
longer be used as a general basis for implementing strategies in preclinical drug 
evaluation, because of it not taking into account the complexity of dose 
dependent reactions (Descotes and Choquet-Kastylevsky, 2001a). Another 
limitation of the Gell and Coombs classification is that the classification was 
developed before the discovery of the functional heterogeneity of T-cells 
(Demoly and Hillaire-Buys, 2004). Nevertheless, it remains a simple and logical 
classification with mechanism-based classification to distinguish immune 
sensitivities (Descotes and Choquet-Kastylevsky, 2001b, Rajan, 2003b).  
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1.2 Aetiology of allergy 
Allergy is a complex trait, which is believed to be the result of variation within 
multiple genes and their interaction with behavioural and environmental factors 
(De Swert, 1999, Kaiser, 2004). In developed countries, environmental factors 
and lifestyle changes are becoming more significant risk factors for allergic 
reactions. Also, molecular studies have identified some specific genetic variations 
as risk factors for allergic reactions (Kaiser, 2004). In other words, both genetic 
and environmental factors are involved in allergic reactions. Risk factors for 
allergy can be divided into two general groups: host and environment. Table 1.2 
contains examples of host and environmental risk factors for allergic reactions. 
Gender, race, age and genetics are examples of host related risk factors for 
allergic reactions. Environmental pollution, exposure to infectious agents and 
dietary changes are some of the examples given for environmental risk factors 
for allergic reactions (Kaiser, 2004).  
 
Table 1.2 Risk factors in allergic reactions. 
Host Genetics, race, gender, age 
Environmental 
Environmental pollution, dietary changes, exposure to 
infectious disease 
This table shows the host and environmental factors causing allergic 
reactions. Genetic variations, race, age and gender are examples for host 
related risk factors. Environmental pollution, dietary changes and 
exposure to infectious disease are some of the examples of environmental 





Host factors and their effects on severity of allergy are the major themes of this 
dissertation, and hence will be discussed in detail in the forthcoming chapters. 
However as mentioned above, allergic reactions can also occur due to 
environmental factors, through exposure to harmless and non-infectious 
environmental substances (Zuberbier et al., 2006).   
The factors involved in allergic reactions are not yet all fully understood. This 
has caused difficulties in understanding the biological pathway and the causes of 
the recent increase in the prevalence of allergies. 
 
1.3 Drug hypersensitivity  
Allergic reactions are one of the major factors that limit the use of drugs and 
affect the therapeutic benefits of medicines. Demoly et al. (1999) define drug 
allergy as a hypersensitivity reaction where immunological mechanisms, namely 
IgE or T-cells, are involved.  
 
1.3.1 Epidemiology of adverse drug reactions 
The response to medication is very variable and unpredictable, and sometimes 
can be fatal. In developed countries, up to 5% of all hospital admissions are 
reported to be due to adverse drug reactions (ADR) (Pirmohamed et al., 1998). 
ADRs are estimated to cost the National Health Service (NHS) approximately 
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£466 million per year (Pirmohamed et al., 2004). Causes of variability in drug 
response are complex and may be due to various factors such as age, sex, pre-
existing diseases, environmental and genetic factors (Nguyen et al., 2006).  
 
1.3.2  Adverse drug reactions 
The World Health Organization (Smith et al., 2013) describes Adverse Drug 
Reactions (ADR) as any unintended, undesired, and noxious effects of drugs 
which occur at doses used for prevention, diagnosis or treatment (Khan and 
Solensky, 2010).  
Adverse drug reactions are divided into two main types, type A reactions 
(pharmacological) and type B reactions (idiosyncratic) (Pirmohamed et al., 
1998). 
Table 1.3 shows the classification of adverse drug reactions. Type A reactions are 
reported as being predictable in 80% of the cases. Type B reactions, on the other 
hand, are not predictable. Type A reactions are divided into 3 categories, 
according to pharmacological adverse effects of the drug, drug interactions and 
others. Type B reactions are divided into non-immune mediated and immune-
mediated reactions. Most of the type B reactions are immune-mediated and can 
be partly explained by the Gell and Coombs classification (Schnyder and Pichler, 
2009). 
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Table 1.3 Classification of adverse drug reactions. 
Type A (Predictable) Pharmacological adverse effects  
Drug interactions 
Other 
Type B (Not predictable) Non-immune-mediated 
Immune-mediated 
Table shows the classification of adverse drug reactions. ADRs are divided 
into two types. Type A reactions are predictable and type B reactions are 
not predictable and not dose dependent. Based on information from 
(Schnyder and Pichler, 2009). 
 
Type A reaction 
Type A adverse drug reactions are augmented pharmacologic effects of a drug. 
These types of reactions are usually dose-dependent. Dose-dependent ADRs are 
known to be reversible either by reducing the drug dose or withdrawing the 
drug. Between the two types of ADRs, type A are more common and they have 
been reported as being responsible for over 80% of the adverse drug reactions 
(Pirmohamed et al., 1998). 
 
Type B reaction 
The term idiosyncratic refers to something that is specific to an individual. 
Therefore in the case of type B or idiosyncratic adverse drug reactions (IDRs), it 
is not possible to predict who will develop the reaction to a specific drug 
(Uetrecht and Naisbitt, 2013). 
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 Type B adverse drug reactions are less common, but they are often life 
threatening. The mechanisms of IDRs are not involved in the therapeutic effect of 
the drug and individual susceptibility is determined by host specific factors. 
(Pirmohamed and Park, 2003).  
 
1.3.3  Clinical characteristics of IDRs 
The underlying mechanisms of IDRs are still unclear, but clinical characteristics 
of the reactions provide mechanistic clues (Uetrecht and Naisbitt, 2013). Type B 
(idiosyncratic adverse drug reactions) can affect different organs such as liver, 
skin, heart and muscle and skin (Daly, 2013). Similar pattern of IDRs can be 
caused by different drugs, but there are clear common clinical characteristics for 
most IDRs (Daly, 2013). 
 
1.3.3.1 Skin rash 
Skin rash is known as the most common type of IDR. This can be explained by the 
high immunological activity of the skin and visibility of even a very mild reaction 
on the skin (Uetrecht and Naisbitt, 2013). Below is a list of different skin rashes 
caused by type B ADRs, listed from most common to least common. 
1. Maculopapular rash. 
2. Urticaria 
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3. Fixed drug eruption 
4. Drug-induced hypersensitivity syndrome 
5. Acute generalized exanthematous pustulosis 
6. Steven-Johnson syndrome and toxic epidermal necrolysis 
 
1.3.3.2  Liver injury 
There is heterogeneity in the phenotype of the adverse drug reactions affecting 
the liver. All the idiosyncratic adverse drug reactions affecting the liver are 
referred to as IDILI. Idiosyncratic liver injury (IDILI) is the most common liver 
injury caused by IDRs. The liver is the major site of drug metabolism and IDILI is 
known as one of the most common reasons of drug withdrawal (Daly, 2013). 
Below is a list of some of the different liver injuries caused by IDRs, listed from 
most common to least common. 
1. Hepatocellular  
2. Cholestatic  
3. Hepatocellular/cholestatic mixed 
4. Other types such as fibrosis induced by methotrexate  
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1.3.3.3  Hematologic adverse reactions 
IDRs can also affect blood cells by disturbing production of blood cells or 
damaging blood cells (Uetrecht and Naisbitt, 2013). Below is a list of some of the 




4. Aplastic anemia 
 
1.3.3.4  Drug-induced autoimmunity 
There is a long list of drugs that can be involved in causing autoimmune 
syndromes. Most of the drug-induced autoimmunity responses are resolved 
when the drug is stopped (Uetrecht and Naisbitt, 2013). Below is a list of some of 
the different autoimmune syndromes caused with IDRs.  
1. Drug-induced lupus like syndromes 
2. Drug-induced cutaneous lupus 
3. Organ specific autoimmunity 
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1.4  Drug hypersensitivity reactions  
Pirmohamed et al. (2003) considered drug hypersensitivity reactions to be a 
classic example of type B adverse drug reactions. They explained that 
hypersensitivity reactions to drugs are not predictable; and also that they are not 
dose dependent. As with type B ADRs, drug hypersensitivity reactions affect a 
minority of the patients, which likely means host-related factors are involved in 
the reactions. Also hypersensitivity reactions cannot be replicated in animal 
models (Pirmohamed and Park, 2003). 
Variation in the incidence of drug hypersensitivity reactions can be explained by 
the type of drug, ethnicity of the patients and underlying disease which is being 
treated by the drug (Pirmohamed, 2006). The frequency of reporting of 
hypersensitivity reactions with mild symptoms such as skin rashes for patients 
undergoing active treatment is higher than that for cases with serious 
hypersensitivity syndromes. Skin rash is reported in up to 16% of the patients, 
and hypersensitivity reactions occur in 1 in 5000 to 10000 patients treated with 
particular drugs (Pirmohamed, 2006). 
 
1.4.1  Types of drug hypersensitivity reactions 
Determining the type of the hypersensitivity reactions is mainly based on the 
involved immune response and the site of the antigen formation during the 
reaction (Pirmohamed et al., 1998). As previously discussed, drug 
hypersensitivity reactions are classed as type B adverse drug reactions, which 
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are immune-mediated and not predictable. But it is important to underline that 
some of these reactions are reported to be highly associated with expression of 
specific human leukocyte antigen (HLA) alleles (Pichler et al., 2011). I will briefly 
explain some of these predictable reactions later on. Immune-mediated type B 
reactions can be classified into 4 different types. 
Type I: IgE-mediated drug hypersensitivity 
Type I reactions are IgE mediated and the mechanism of this type of 
hypersensitivity reaction is well understood. Hypersensitivity reactions that are 
induced by penicillins are a well-known example of type I reaction. The 
Incidence of severe IgE mediated hypersensitivity reactions is reported to be 1 in 
2000 patients (Pirmohamed et al., 1998).   
Primary drug sensitization can cause the development of drug specific IgE. After 
the formation of specific IgE in the body, even the reintroduction of a small 
amount of the drug (antigen) can induce symptoms. In type I (IgE-mediated) 
reactions, the allergen (in this case drug) must bind to antigen-binding receptors 
of the corresponding IgE molecules. Type I reaction is also known as an 
immediate reaction and usually occurs within 1 hour after drug administration 
(Schnyder and Pichler, 2009). 
Type II: IgG-mediated cytotoxicity 
Type II (IgG-mediated) reactions are cytotoxicity reactions directed to the 
membranes of cells in the bone marrow, such as erythrocytes, leukocytes, 
platelets and perhaps hematopoietic precursors. Drugs such as methyldopa and 
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aminopyrine are examples of drugs inducing type II reactions (Schnyder and 
Pichler, 2009).  
Type III: immune complex deposition 
Type III reactions result from immune complex deposition. Immune complexes 
are commonly formed during normal immune responses in the body. These 
reactions normally occur without any clinical symptoms, and except in some rare 
cases they are formed as immune complexes bound to endothelial cells. The 
attachment of immune complexes to endothelial cells results in immune complex 
deposition with complement activation in small blood vessels. Symptoms such as 
serum sickness, vasculitis and lupus erythematosus are reported for type III 
reactions. Serum sickness is the clinical symptom of beta-lactam induced type III 
reaction. Also, drug-induced lupus erythematosus is a clinical symptom of type 
III reactions induced by quinidine (Schnyder and Pichler, 2009). 
Type IV: T-cell-mediated drug hypersensitivity 
The underlying mechanisms of T-cell mediated drug hypersensitivity reactions 
are not yet fully understood. This type of hypersensitivity reaction is cell-
mediated. Type IV reactions are also known as delayed reactions. Cellular 
response is generally visible 48-72 hours after drug exposure.  One hypothesis is 
that type IV hypersensitivity reactions may possibly be explained by the 




1.5 Hapten/prohapten concept 
Components with low molecular weight (<1000D), such as drugs, are too small 
to be able to cause an immune response in the body. The hapten/prohapten 
concept is a proposed mechanism to explain how these small molecules can 
stimulate an immune response. The hapten concept also explains how chemically 
reactive drug or drug metabolites can bind covalently to proteins and modify 
them, and how the modified protein can induce an immune response (Pichler, 
2008). Haptens are chemically reactive small compounds that bind to proteins or 
peptides and modify them. There are two main mechanisms by which haptens 
can be responsible for inducing an immune response (Pichler, 2008, Pichler et 
al., 2011).  
1. Stimulating the innate immune system 
Covalent binding of hapten to cellular protein can stimulate the innate 
immune system. The covalent binding of hapten to cellular protein can 
transmit a danger signal, and the danger signal can be the start of the innate 
immune system stimulation (Pichler, 2008).   
 
2. Stimulating the specific immune system 
Haptens can stimulate the specific immune system by forming hapten-
protein complexes. The hapten-carrier complex is presented as a hapten-
modified peptide to T-cells. Hapten modification can happen with cell-bound 
proteins, soluble proteins or with the major histocompatibility complex 




As with haptens, prohaptens are really small molecules that cannot cause any 
immune response by itself. Prohaptens are not chemically reactive, and therefore 
they are not able to bind to proteins via a covalent bridge. These molecules need 
to be converted into a hapten form by being metabolised in order to become 
chemically reactive (Pichler et al., 2011). Prohapten metabolism mainly occurs in 
the liver, which is usually considered to be a tolerogenic environment and thus 
the metabolised hapten may not cause an immune response there (Pichler et al., 
2011).   
 
1.5.2 Pharmacological Interaction with immune receptors (p-i concept) 
As explained above, the drug or the metabolites of the drug need to be chemically 
active in order to covalently bind to the proteins and modify them to induce an 
immune response. But what is missing here is how the immune response occurs 
when the drug is lacking hapten characteristics. In order to explain the 
underlying mechanisms of immune response to these drugs, the 
hapten/prohapten concept has been supplemented by the p-i concept. The p-i 
concept stands for direct ‘pharmacological interaction’ of drugs with immune 
receptors (Pichler, 2008).   
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The p-i concept proposes that drugs can bind directly and reversibly to immune 
receptors and stimulate the cells to cause an immune response in the body. The 
p-i concept can be used in order to explain the hypersensitivity reactions caused 
by drugs that are antigenic in their parental form; drugs that are not in reactive 
form; drugs that do not require antigen processing; and finally drugs whose 
antigen presentations involve reversible binding (Pichler et al., 2011). 
The large variability in unpredictable drug response is a big health concern. The 
main aim of clinicians when they prescribe a drug is to treat patients and cure 
the underlying disease or condition without causing any adverse drug reactions 
in the patient. Prescribing a particular drug to a patient with a particular disease 
needs a careful assessment of the benefit-risk relationship. Pirmohamed (2014) 
highlighted several issues in drug selection and dose recommendation by 
prescribers (Pirmohamed, 2014).  
One limitation refers back to the drug development phase. During the drug 
development process, most of the time the drug dosage is defined based on mean 
values, and often other parameters such as body surface area are not taken into 
account. Therefore clinicians implicitly assume that all patients will respond to 
the drug in the same way.  
A second limitation is our ignorance of the factors that can affect the 
pharmacokinetics of the drug (pharmacokinetics is the study of what the body 
does to drugs). Patients vary according to factors such as ethnicity, age, weight, 
smoking status, dietary habits and alcohol intake. Lack of knowledge regarding 
interacting medications is another factor in the list of ignored factors.   
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A third limitation is that diseases are classified according to easily measurable 
phenotypic markers, but there may be disease subphenotypes which respond 
differently to drug treatment. Developing better molecular markers to stratify 
drug treatments is still needed to personalise treatment. 
Figure 1.1 shows the elements required to achieve the goal of personalised 
medicine and how the factors discussed above are important in this process 
(Pirmohamed, 2014).  
 
Figure 1.1 Necessary required elements to accomplish personalised 
medicine. Based on information from (Pirmohamed, 2014).  
This figure gives information on the different elements that are necessary 
in order to achieve the goal of  personalised medicine.  
 
1.6 Pharmacogenomics 
Pharmacogenomics is the study of genetic factors affecting drug response. The 
term pharmacogenomics may also be expanded to the development of new drugs 
through the use of genomic information (Daly, 2010). After 50 years of studying 










there are many polymorphisms in human genes that can have a significant 
functional effect (Daly, 2010). The incidence of more than one allele at the same 
locus with appreciable frequency among the same population is defined as a 
genetic polymorphism (Daly, 2010). 
Identifying the relationship between response variables and genetics will 
possibly be used to identify people with good response, and those who will suffer 
adverse drug reactions, early. This will lead to personalised medication, which is 
supported by genetic analysis and which aims to achieve the optimal medical 
outcomes for each individual. The aim is to improve the quality of life, health and 
potentially reduce overall health-care cost (Altman et al., 2011). 
Kroemer and Meyer zu Schwabedissen (2010) define personalised medication as 
the management of a patient’s disease or disease predisposition. From the 
clinical point of view, pharmacogenomics should increase the efficiency of the 
prescribed drug and reduce the morbidity associated with adverse drug 
reactions. From a pharmaceutical industry viewpoint, pharmacogenomics should 
help to reduce costs and timelines in clinical trials (Kobayashi and Satoh, 2009).  
In the future, drugs may be developed based on biological markers (DNA, RNA 
and proteins) of each individual. These drugs will, it is hoped, maximise 
therapeutic effects and minimise damage to healthy cells. Therefore, there will 
be no need for the conventional trial-and-error method to finding the right drug 
that matches each patient’s medical requirement.  To this end, analysing a 
patient’s genetic profile will provide an opportunity to prescribe the best 
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available drug for individuals from an early stage of diagnosis. This will also 
reduce the time of recovery and the probability of any adverse drug reactions. 
Another benefit of pharmacogenomics is that it will provide a more accurate 
method to discover how an individual’s body processes medicines, and how long 
it takes to metabolise a drug. This will also help to determine the appropriate 
drug dosage. Furthermore, in the case of complex diseases, having the 
knowledge of being susceptible to certain disease will allow a person to change 
his/her lifestyle and environment in the early stages of life. It also offers the 
advantage of early monitoring and treatment, which can be introduced at a more 
efficacious stage (Altman et al., 2011). 
 
1.6.1 Pharmacogenomic approaches to identify genes that contribute 
to adverse reactions  
In the early years, pharmacogenetic investigations of drug response focussed on 
the function of a single gene. However, in recent times, studies have shown that 
most drug responses occur as a result of a complex interaction between genes 
and environment factors (Pirmohamed, 2006), motivating other approaches.  
Pharmacogenomic studies of adverse drug reactions typically involve 
case/control association studies to investigate genetic susceptibility for the 
reaction. Case/control studies are either done on a candidate gene approach 
(just looking for the specific region of the gene) or as a genome-wide association 
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study (GWAS), which covers the whole genome (Daly, 2013). More detail on the 
genome-wide approach is provided in chapter 3. 
 
1.6.2 Examples of pharmacogenomic studies  
The major histocompatibility complex (MHC) is a set of cell surface molecules 
encoded by a large gene family called human leukocyte antigens (HLA), situated 
on chromosome 6 (Shiina et al., 2009). Given the role of the MHC in immune 
response, many pharmacogenetic studies have focused on this region, and both 
candidate gene and genome-wide association studies on different adverse drug 
reactions have reported significant associations with HLA genes (Daly, 2013). A 
detailed understanding of the association between HLA alleles and drug 
hypersensitivity provides the benefit that these severe and unpredicted ADRs 
might one day become predictable. Here I shall give some examples of drug 
responses associated with the HLA region. 
 
1.6.2.1 HLA association with DILI  
DILI is a rare form of idiosyncratic adverse drug reaction associated with 
commonly used drugs such as flucloxacillin. DILI is known to be a major cause of 
post marketing drug withdrawals. The incidence of flucloxacillin induced DILI 
has been reported as 8.5 in every 100,000 patients treated with flucloxacillin in 
the UK. Flucloxacillin is one of the widely used antibiotics for infections caused 
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by staphylococcal bacteria in some European countries (Daly et al., 2009). The 
pathogenesis of DILI generally involves the participation of the toxic drug or its 
metabolites that stimulate the body’s immune response or directly affect the cell. 
These reactions can cause cell death and lead to hepatotoxicity. As discussed 
before, metabolism of drugs largely takes place in the liver, thus the liver is one 
of the main organs that is affected by metabolism dependent drug induced injury 
(Daly et al., 2009).  
A genome-wide association was conducted on 51 cases with flucloxacillin 
induced liver injury 282 controls matched for sex and ancestry in UK in 2009 
(Daly et al., 2009). This genome-wide association study showed strong 
association for a SNP (rs2395029), with a p-value of 8.7 x 10-
33 in the MHC 
region with flucloxacillin induced liver injury. The SNP (single nucleotide 
polymorphism) was in complete linkage disequilibrium (LD) with HLA B*5701. 
The novel finding of the study was then replicated in another cohort with 23 
cases.   
Another genome-wide association study reported a significant association 
between amoxicillin-clavulanate induced liver injury and class I and class II HLA 
genotypes (Lucena et al., 2011). Amoxicillin-clavulanate (AC) is one of the most 
commonly prescribed antimicrobial agents worldwide, and the clavulanate 
component is known to be the main cause of AC induced DILI. This study 
conducted a genome-wide association study on 201 cases with DILI and 532 
population controls. They reported many associated loci in the MHC region for 
AC induced DILI, but the most strongly associated SNP (rs9274407, p= 4.8 x 10-
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14) was in LD with HLA-DRB1*15:01 (a class II MHC molecule). This SNP was 
correlated with the previously reported SNPs that associated with AC-DILI. They 
also reported a new SNP in LD with HLA-A*02:01 (a class I MHC molecule).  
Genetic susceptibility is a fundamental component of serious adverse drug 
reactions. There is a growing interest in the possibility that developing genetic 
tests to identify all those at risk of adverse events prior to prescription in a 
screening programme may lead to valuable drugs being retained. Thus, I now 
discuss examples of three genetic association studies on abacavir, 
carbamazepine and warfarin induced hypersensitivity reactions.  
 
1.6.2.2 HLA association with carbamazepine induced hypersensitivity 
reactions 
An association between carbamazepine-induced skin rash and HLA B*15:01 was 
first reported in a Taiwanese study, using a candidate gene approach (Chung, 
2004). Because is very rare in non-Han Chinese, studies on Europeans and 
Japanese failed to show that this HLA allele was a risk factor for carbamazepine 
skin rash in these populations. McCormack et al, (2011) presented a GWAS 
which aimed to detect novel genetic risk factors for carbamazepine-induced skin 
rash in a European population. McCormack et al. reported a novel HLA 
association involving HLA-A*31:01 but, as expected, did not find an association 
with HLA B*15:02. The HLA-A*31:01 allele was significantly associated with the 
 39
hypersensitivity syndrome in the Northern European sample, and 
maculopapular exanthema was also found to be associated with HLA-A*31:01. 
 
1.6.2.3 HLA association in abacavir induced hypersensitivity reactions 
The association of HLA-B*57:01 with abacavir was first reported using a 
candidate gene approach in 2002 (Mallal, 2002). A follow-up study investigated 
the merits of a screening test based on this association, via a double-blind 
randomized control trail (N=1956) conducted in 19 different countries (Mallal et 
al., 2008). This latter study is an important example of translational research in 
pharmacogenetics, translating the important findings of allele associations to 
hypersensitivity reactions and extending this knowledge to provide screening 
opportunities in clinical practice settings to help improve patient health 
outcomes. The authors found that genetic screening eliminated all cases of   
immunologically confirmed hypersensitivity reaction in their study (0% in the 
screened group vs. 2.7% in the control group, P<0.0001), with a negative 
predictive value of 100% and a positive predictive value of 47.9%) (Mallal et al., 
2008). This study demonstrated a clear benefit for genetic screening and this led 
to the widespread implementation of testing before prescribing abacavir. 
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1.7 Allergy to beta-lactam antibiotics  
Beta-lactam antibiotics are widely prescribed for the treatment of common 
infections caused by a range of bacteria. They are also used as first-line 
prophylaxis in surgical procedures (Mirakian et al., 2015). Penicillins and 
cephalosporins are the two major classes of the beta-lactam family (Pichler, 
2007a). In the penicillin category, amoxicillin is the most prescribed beta-lactam 
antibiotic in Europe (Treudler and Simon, 2007). Due to their widespread use, 
beta-lactam antibiotics, especially penicillins and cephalosporins, are known to 
be the most common causes of drug hypersensitivity reactions (Lin et al., 2010, 
Mirakian et al., 2015).  
 
1.7.1 Types of beta-lactam allergy reactions  
Depending on the time interval between taking the drug (e.g. beta-lactam 
antibiotics) and the appearance of the symptoms, allergic reactions to beta-
lactams are classified into two types (Mirakian et al., 2015).  
The first type of reaction is called an immediate reaction, which is mediated by 
an IgE response, and symptoms appear within 1 hour of introducing the drug 
(Mirakian et al., 2015).   
The second type of reaction is called a non-immediate or delayed reaction, with 
an interval of 1 to 48 hours. This type of reaction is T-cell mediated (Mirakian et 
al., 2015).  Blanca et.al (2009) argue that there are many lines of evidence 
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showing that the longer the interval between introducing the drug to the body 
and the appearance of allergy symptoms, the less likely it is that the reaction is 
IgE mediated (Pichler, 2007a, Blanca et al., 2009, Treudler and Simon, 2007). 
 
1.7.2 Epidemiology of beta-lactam allergy 
Beta-lactam antibiotics are responsible for 26% of fatalities caused by drug 
anaphylaxis in the UK (Fitzharris, 2008). A more recent study reports that up to 
20% of drug-related anaphylaxis deaths in the UK are caused by penicillin, with a 
higher estimate of 75% for the United States (Mirakian et al., 2015).  
Up to 20% of hospitalized patients self-report beta-lactam allergy (Mirakian et 
al., 2015). Although there is no prospective study to show the prevalence of 
penicillin hypersensitivity in the general population, clinical records show that 
10% of people treated with beta-lactam antibiotics have reported an allergic 
reaction (Demoly and Romano, 2005, Solensky, 2003). However, after 
conducting clinical testing only 1-10% of these patients have evidence of type I 
hypersensitivity reactions (Mirakian et al., 2015).  
Lower prevalences for penicillin allergy have been reported in cohort studies, 
ranging from 0.2% per course of treatment in a large population (Mirakian et al., 
2015) to between 3 and 5% in a drug surveillance study (Mirakian et al., 2015). 
In particular, allergic reactions to penicillin appear to be 10 fold more common 
compared to reactions to cephalosporins (Mirakian et al., 2015).  
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If patients who are wrongly labelled as allergic to the beta-lactam family are 
prescribed unnecessary alternative drugs, this can lead to a risk of developing 
multiple drug-resistant bacterial infections. These treatments can also cost more 
than treatment with beta-lactam antibiotics (Solensky, 2003).  
In order to address the reported heterogeneity in clinical practice of beta-lactam 
hypersensitivity in the UK and to avoid the use of less effective and more 
expensive medications, a detailed guideline was provided recently (Mirakian et 
al., 2015). 
 
1.7.3 Risk factors for immediate response to penicillin 
Although the exact aetiology of immediate IgE-mediated allergy to beta-lactam 
antibiotics is unclear, it is suspected that it has a complex aetiology (Mirakian et 
al., 2015). Host related and environmental factors such as heritability, age, 
underlying infection, asthma and sex have been reported as influential risk 
factors in developing hypersensitivity reactions to beta-lactam antibiotics 
(Mirakian et al., 2015).  
 
1.7.3.1 Genetic risk factors 
The underlying genetic risk factors remain unsolved for beta-lactam allergy. 
However family history data show that beta-lactam induced adverse reactions 
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typically run in the family, and are more likely to be T-cell mediated (delayed) 
reactions (Mirakian et al., 2015). I will give more detail on published genetic 
associated studies on beta-lactam allergy later on in this chapter.  
1.7.3.2 Host related risk factors 
Table 1.4 provides a list of host related risk factors for penicillin allergy. A 
positive skin test is not necessarily obtained in patients with a positive clinical 
history of penicillin allergy. Therefore clinical history is not reliable on its own. 
In the case of childhood reactions, there is a big risk of recall bias. Also in these 
reactions there is a chance that the reaction was related to the underlying 
infection or that it was confused with drug side effects. Patients with a clinical 
history of having a reaction in the last 15 years have been reported to have a 
very low risk of a positive challenge test (0.4%) (Mirakian et al., 2015).  
Women are reported to have a higher rate of penicillin allergy (11.0%) as 
compared to men (6.5%). The higher number of prescribed antibiotics may 
explain the higher frequency of penicillin reactions in women (Mirakian et al., 
2015). 
There is limited evidence to support the case that penicillin intake via the oral 
route is less likely to cause allergic reactions than via other routes such as 
intravenous. Topically applied penicillin is recognized as being highly 
immunogenic, and it is no longer used. Another host related risk factor is the 
frequency of administration of penicillin courses. Patients with conditions such 
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as cystic fibrosis often receive frequent dosages of intravenous antibiotics 
(Mirakian et al., 2015).  
Age is known to be one of the host related risk factors for penicillin allergy. Most 
of the penicillin induced allergic reactions have ben reported in patients between 
20 and 49 years old. But a more recent study shows that the susceptibility of 
having penicillin related allergic reactions increases in patients who are over 80 
years old by 20% (Mirakian et al., 2015).  
 
Table 1.4 Host related risk factors for immediate response to penicillin 
antibiotic. Based on information from (Mirakian et al., 2015). 
Sex 
 
Drug induced penicillin allergy has been reported 
more in female (11.0%)than in men (6.5%) 
Frequency and route of exposure 
 
Some evidence showing that penicillin intake via 
oral route is less likely to induce reactions 
compared to other routes 
Age 
 
Susceptibility to penicillin-induced allergic 
reactions increases with age 
Underlying infection 
 
HIV patients treated with co-amoxiclavand 
reported rashes. 
The table shows information on host related risk factors associated with 
beta-lactam allergy. One example is given for each factor. 
 
 
1.7.4 Molecular structure of beta-lactam antibiotics 
There are four main groups in the beta-lactam antibiotic family, which all share a 
beta-lactam nuclear ring (Demoly and Romano, 2005); penicillins, 
cephalosporins, carbapenems and monobactams. Figure 1.2 illustrates the 
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chemical structure of all four beta-lactam groups, with the beta-lactam rings 
highlighted in red. In penicillins, apart from the beta-lactam ring that is involved 
in bactericidal activity, there is a five-member thiazolidine ring in common.  
Different penicillins are distinguished by the side chain that is fused to position 6 
in the nuclear beta-lactam ring (Pichler, 2007a, Treudler and Simon, 2007, 
Demoly and Romano, 2005). The diversity in the side chain distinguishes the 
different penicillins, and it is an important factor in immunological recognition of 
the penicillin. Also, to some degree, the side chain is responsible for allergic 
cross-reactivity (Mirakian et al., 2015).  
Cephalosporins have two side chains attached in position 3 and position 7. In this 
group, the varieties of the side chains broaden antibacterial activity by affecting 
drug metabolism and resistance to beta-lactamase (Mirakian et al., 2015). 
Carbopenems contain a beta-lactam ring and an adjacent five-member 
thiazolidine ring, but in the place of sulphur, there is a carbon double bond. 
Finally, monobactams contain only one ring (beta-lactam) and there is no fused 






Figure 1.2 Chemical structure of the beta-lactam families. Based on 
information from (Torres et al., 2003). 
 
This figure shows the chemical structure of all four beta-lactam groups. 
The beta-lactam ring is highlighted in red. All four groups contain a beta-
lactam ring, and the main difference between these groups is the fused side 
chain to beta-lactam molecule.  
 
1.7.5 Beta-lactams as an antigen 
Penicillin is a chemical substance with a low molecular weight and, like many 
other medications, is too small to act as a complete antigen. They need to be 
bound to a larger carrier molecule, such as tissue or serum proteins (haptens) - a 
process known as haptenation (Pichler et al., 2011). The resulting new 
immunogenic molecule is large enough to elicit an immune response (Solensky, 
2003, Rosario and Grumach, 2006).  
With regard to the chemical structure of penicillins, the beta-lactam ring, the 
thiazolidine ring, the dihydrothiazine ring and the side chains can all be 




normal physiological conditions, the beta-lactam ring opens spontaneously and 
binds to the nearest protein (Solensky, 2003). Degradation of the beta-lactam 
ring results in a chemically unstable molecule, which can bind to lysine residue 
aminogroups on soluble or cell proteins. Benzyl penicilloyl is formed as a result 
of the beta-lactam ring binding to proteins. This newly created molecule is called 
the "major determinant", and 95% of tissue-bound penicillin exists in this form 
(Solensky, 2003). This molecule is known to be responsible for the majority of 
the beta-lactam related allergic reactions (Mirakian et al., 2015).  
The remaining parts of the penicillin molecule (side chains) after binding to 
proteins are called "minor determinants" (Solensky, 2003).  
 
1.7.6 Clinical symptoms of IgE mediated beta-lactam allergy 
Symptoms of immediate allergic reactions can range from a simple local 
itch/wheal to generalised urticaria and edema, to severe, complex reactions 
called anaphylaxis. In severe cases of anaphylaxis, patients can collapse and/or 
become unconscious often within 15 minutes, or can even suffer a lethal 
anaphylactic shock (Pichler, 2007a, Pichler et al., 2010). 
Clinical symptoms of immediate (IgE mediated) allergic reactions to beta-lactam 
antibiotics are urticarea with or without angioedema and anaphylaxis (Torres et 
al., 2003).  
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• Urticaria: wheals in one or several parts of the body; 
• Angioedema: localised edema in one or several parts of the body; 
• Anaphylaxis: the most severe allergic symptoms occurring 
immediately after introducing the drug to the body, often affecting 
more than one organ  
Symptoms for hypersensitivity reactions are categorised into mild, moderate and 
severe reactions (Brown, 2004). Table 1.5 shows the grading system for 
seriousness of the hypersensitivity allergic reactions according to Brown (2004).  
According to Brown’s grading system, in mild hypersensitivity reactions, 
symptoms such as generalized erythema, urticaria, perorbital edema or 
angioedema appear in skin and subcutaneous tissues only. This grading system 
proposes that moderate hypersensitivity allergic reactions involve respiratory, 
cardiovascular or gastrointestinal effects with symptoms of dyspnea, stridor, 
wheeze, nausea, vomiting, dizziness (presyncope), diaphoresis, chest or throat 
tightness, or abdominal pain. In the case of severe reactions, symptoms include 
cyanosis or SpO2<92% at any age, hypotension (systolic blood pressure (SBP) < 







Table 1.5 Grading system for generalized hypersensitivity reactions. Based 




Clinical feature  Defining symptoms and signs 
1. Mild  
 
Skin and subcutaneous tissues 
only 
 
Generalized erythema, urticaria, 
perorbital edema or angioedema 
 
2. Moderate 
Respiratory, cardiovascular or 
gastrointestinal involvement  
 
Dyspnea, stridor, wheeze, nausea, 
vomiting, dizziness (presyncope), 
diaphoresis, chest or throat 
tightness, or abdominal pain 
 
3. Severe  
Hypoxia, hypotension, or 
neurologic compromise 
 
Cyanosis or SpO2<92% at any age, 
hypotension (systolic blood 
pressure (SBP) < 90 mm Hg in 
adults), confusion, collapse, loss of 
consciousness, or incontinence 
  
The table describes a grading system for the seriousness of the 
hypersensitivity allergic reactions. The hypersensitivity allergic reactions 
are divided in to 3 main categories based on the symptoms and the organs 
involved in the reaction.  
 
1.8 Diagnosis of beta-lactam allergy  
A detailed history of reactions and a description of the symptoms associated with 
the allergic reactions, as recalled by the patient, is often the first step in drug 
allergy diagnosis. Clinical reports are the second source of information that is 
useful to evaluate allergic reactions (Torres et al., 2003).  
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1.8.1 Clinical evaluation of beta-lactam allergy  
A clear and detailed history of the drug reaction is an essential component of 
evaluating a patient with suspected reactions to any drugs. This clinical history 
should be extremely inclusive to help clinicians to choose the best possible and 
safest diagnostic test for the patient (Demoly and Romano, 2005, Khan and 
Solensky, 2010, Torres et al., 2003, Demoly et al., 2010). The clinical history 
should contain all the following questions:  
• What was the patient’s age at the time of the reaction? 
• Is the patient able to recall the reaction? 
• What was the name of the medication?  
• What was the route of administration? 
• What was the exact time of the reaction?  
• What were symptoms and characteristics of the reaction?  
• What was the reason for taking the medication?  
• What were the other medication taken at the time?  
• Did they have any prior treatment for the allergic reaction?  
• Had the patient taken the same drug or any other drug with cross-
reactions before/after the reaction?  
• Since the reaction, has the patient used the same drug? Has the patient 
experienced similar reactions?  
If the patient provides clear and reliable answers to all these questions, then this 
clinical history is deemed to be a sufficient diagnostic tool. However, the patient 
is not usually able to recall all details, and the doctor often cannot precisely 
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evaluate all the requested data (Demoly and Romano, 2005). Therefore, although 
a clinical history helps to distinguish between allergy and allergy-like reactions, 
it is not sufficient on its own to confirm the allergy (Solensky, 2003, Demoly and 
Romano, 2005).  
 
1.8.2 Tests used for diagnosis of immediate allergy to beta-lactam 
antibiotics 
The European Network for Drug Allergy (ENDA) has described a step-by-step 
protocol for all available tests for allergic reactions (Torres et al., 2003). 
However a more recent guideline on management of allergy to penicillins and 
other beta-lactams has been introduced to UK allergic specialists (Mirakian et al., 
2015). This detailed guideline was prepared by the Standards of Care Committee 
of the British Society for Allergy and Clinical Immunology (BSACI) and an expert 
panel.   
Figure 1.3 illustrates the short algorithm used for the diagnosis of immediate and 
non-immediate allergic reactions to beta-lactam antibiotics. This guideline is a 
step-by-step guide through the diagnostic process of the allergic reactions to 
beta-lactam antibiotics. As mentioned before, an accurate history helps in 
understanding the type of the reaction. This guideline highlights all the required 
clinical tests, all the cross-reactivity possibilities, and indicates whether the 
patient should be labelled as being allergic to beta-lactam antibiotics or not 




Figure 1.3 Algorithm for the diagnosis of immediate and delayed allergic 
reactions to beta-lactam antibiotics.  
Based on information from (Mirakian et al., 2015). SPT=skin prick tests; 
IDT=intradermal tests. 
 
1.8.3 Skin tests  
The best known and the most widely used diagnostic tool for the diagnosis of 
allergic reactions to beta-lactams is the skin test (Torres et al., 2003). There are 
three different methods for skin tests: the skin prick test (SPT); the intra-dermal 
test (IDT); and the skin patch test.  
In the case of beta-lactam antibiotics, skin tests usually start with a skin prick 
test. During an SPT, the allergen(s) is introduced to a small skin prick by the use 

































Challenge (if mild 
reactions and no 
systemin feature)
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concentrations of the allergen, increasing to high concentrations in the following 
steps. During skin prick testing, patients are kept under close observation and 
the results are monitored after 15 minutes (Mirakian et al., 2015). 
Skin tests are generally safe, but systemic reactions have been reported in 0.7-
11% of those with positive skin reaction, therefore careful baseline 
measurements of peak expiratory flow rate, blood pressure and pulse is 
necessary (Mirakian et al., 2015). The results are compared with positive 
(histamine) and negative (diluent) controls.  In the skin prick test, the 
appearance of a larger than 3mm wheal is considered a positive result (Mirakian 
et al., 2015). 
According to the guideline (Figure 1.3), if the results for the SPT are negative, the 
clinician prepares the patient for an intra-dermal test (Mirakian et al., 2015). In 
an intra-dermal test, the same (hapten) allergen solution is injected into the skin 
(between the epidermis and dermis). Like the SPT, the results of the IDT should 
be evaluated after 15 minutes. A positive result from the IDT is valid if any wheal 
is larger than 3mm (Demoly and Romano, 2005, Kelkar and Li, 2001). 
In skin tests for beta-lactam antibiotics, hapten solutions are mixtures of minor 
determinants (MDM) and penicilloyl-poly-L-lysine (PPL), known as the major 
determinant. The major antigenic determinants contain benzyl-penicilloyl, and 
minor antigenic determinant contains benzylpenicillin, penicilloate and 
penilloate (Solensky, 2003). In addition to penicillin minor and major 
determinants, amoxicillin and ampicillin are also considered as a part of skin 
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tests for beta-lactam antibiotics more generally (Solensky, 2003, Torres et al., 
2003).  
Between 8.4-30.7% of the patients with a negative skin test have been reported 
as having a positive challenge test (Messaad et al., 2004). According to Mirakian 
et al. (2015), patients with a positive skin test to PPL/MDM should be labelled as 
being allergic to all beta-lactams, and they should avoid penicillins, unless they 
have a negative skin test to amoxicillin/ampicillin. In this case the next step (oral 
challenge) is required. In the case of a negative skin test for all the determinants 
and amoxicillin/ampicillin, the challenge test with the original penicillin that was 
implicated in the allergic reaction should be reported. In the case of a negative 
skin test to PPL/MDM and benzylpenicillin, but a positive skin test to specific 
beta-lactam, the challenge test is required with penicillin V. In this case the 
allergy may be due to the side chain activity (Mirakian et al., 2015). 
 
1.8.3.1 Sensitivity and specificity of skin tests  
Although skin tests are known to be one of the quickest and safest ways to 
diagnose immediate IgE mediate allergic reactions, the specificity of the test is 
far less than 100% (Demoly and Romano, 2005). Toress et al. (2001) and 
Messaad et al. (2004) have previously reported that 8-17% of patients have 
shown false negative skin test results (Messaad et al., 2004, Torres et al., 2001). 
The sensitivity of skin tests with a positive clinical history is calculated to be 
22% for PPL, 21% for MDM, 43% for amoxicillin and 33% for ampicillin. 
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Therefore, the overall sensitivity of skin tests is calculated to be 70% for a 
combination of all allergens. The specificity of the skin test is reported at 97% 
(Pichler, 2007a). 
False-positive skin tests have also been reported. This can occur when there is 
no history of an allergic reaction (negative history). The incidence of false-
positive skin test results is estimated at around 7% (Torres et al., 2001). 
Evidence shows that a long interval between the initial reaction event and skin 
testing reduces the chances of a positive response. After 10 years following the 
allergic reaction to penicillin, only 20-30% of patients show a positive skin test. 
Skin test reactivity completely disappears after 5 years following an allergic 
reaction to amoxicillin. As a positive skin test can reduce the need for drug 
provocation tests, skin testing should be carried out soon after the reaction 
(Mirakian et al., 2015).   
 
1.8.4 Drug provocation test  
Due to the fact that there are high false negative results in the skin test, if there is 
a clear allergy history and a negative skin test then a drug provocation test 
(challenge test) is usually requested before any final clinical decisions are made 
(Holm and Mosbech, 2011). 
The drug provocation test (DPT) is known to have the best sensitivity of all the 
available diagnostic tests (Torres et al., 2003, Messaad et al., 2004). However, it 
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is not usually requested for high-risk patients, including patients who have 
previously developed life threatening reactions to the drug, such as anaphylactic 
shock, or patients who suffer from related disease such as respiratory and 
cardiovascular disease (Torres et al., 2003, Holm and Mosbech, 2011). 
During the drug provocation test, the drug itself is given to the patient. This 
process is performed under strict hospital observations requiring emergency 
room facilities. The process starts from a low dose of the allergen and the patient 
is monitored for 30 minutes. If the first dose is well tolerated, the second dose is 
given but with a time lapse of 30 to 60 minutes from the first dose (Torres et al., 
2003, Demoly and Romano, 2005, Demoly et al., 2010). 
A negative predictive value of 94% has been reported for the oral provocation 
test with beta-lactams. Reports show that patients with a false-negative 
provocation test result generally do not experience any life-threatening reactions 
(Mirakian et al., 2015). 
 
1.8.5 In-vitro test 
Finally, the in-vitro test is used as a complementary technique in the diagnosis of 
immediate allergy to drugs including beta-lactam antibiotics (Blanca et al., 2009). 
The test is based on detecting specific IgE antibodies to any beta-lactam 
determinants in the serum using an immunoassay. Specific IgE is detected by 
using the ImmunoCAP system. The ImmunoCAP capsules contain polymers  
which are covalently bound to the specific beta-lactam which interacts with 
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specific IgE in the patient’s serum. Interaction can then be detected by 
fluorescence (Mirakian et al., 2015).  
However, due to the high cost of the test and the lack of accessibility, it is not 
often used in diagnostic processes unless it is essential. This test is highly specific 
for detecting specific IgE for beta-lactams, but it is not sensitive. Also this assay is 
not available for most of the cephalosporins (only available for cefaclor). 
Sensitivity of this assay for the patients with positive skin test results to 
amoxicillin-and/or benzylpenicillin was reported as 54%, but, for the same 
patients, specificity of the same test was reported as up to 95% (Mirakian et al., 
2015).   
 
1.8.6 Misdiagnosis of immediate allergy to beta-lactam antibiotics 
It is important to highlight the high incidence of self-reported penicillin allergy in 
the population. It is also important to bear in mind that over 90% of these 
“allergic” individuals are able to tolerate beta-lactam antibiotics, as has been 
reported in several clinical evaluations of antibiotic allergy (deShazo and Kemp, 
1997, Satta et al., 2013). 
Lin et al. (2010) tried to explain this discrepancy. They believe that there are 
many factors which could play a role in the over-reporting of beta-lactam 
antibiotic allergy, such as confusing a drug’s side effects with drug allergy, or 
misinterpreting symptoms caused by the illness itself with allergic symptoms. 
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1.8.7 Cross reactivity  
As explained above, all beta-lactam families share a beta-lactam ring in their 
chemical structure. Therefore, when the beta-lactam allergy occurs due to the 
beta-lactam ring, there is a cross reactivity between different beta-lactam groups 
(James and Gurk-Turner, 2001, Sastre et al., 1996). Recent investigations indicate 
that the cross-reactivity among beta-lactams is not only due to a shared beta-
lactam ring but also, and mainly, due to side chain homology (Mirakian et al., 
2015).  
Cross-reactivity with monobactams 
Monobactams are less immunogenic than penicillins or cephalosporins, due to 
the monobactams’ chemical structure. As discussed previously, the chemical 
structure of the monobactam group contains a single beta-lactam ring and there 
is no fused sulphur ring. Aztreonam is a monobactam, and it is generally 
tolerated by patients who had confirmed IgE mediated or T-cell mediated 
reactions to beta-lactams (Mirakian et al., 2015). 
Cross-reactivity with carbapenems 
Cross-reactivity between penicillins and carbapenems was reported at a rate of 
up to 50% for patients with positive history and a positive skin test result to 
penicillins. The similarity in the chemical structure of these two groups likely 
explains this high rate of cross-reactivity. In spite of this, a more recent study 
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reported the rate of cross-reactivity between penicillins allergic cases and 
carbapenams as 9.2-11% (Mirakian et al., 2015). 
Cross-reactivity with cephalosporins  
The degradation processes of penicillins and cephalosporins are very different in 
the body. Therefore, cross-reactivity between penicillins and cephalosporins is 
less likely. The rate of cross-reactivity between penicillins and first and second 
generation cephalosporins is reported to be 8% to 10% (Mirakian et al., 2015).  
 
1.9 The role of genes 
There is growing evidence that genetic factors may play a significant role in beta-
lactam allergy; however, there is a lack of knowledge regarding the genetic and 
epigenetic underpinnings of beta-lactam allergy as a whole. Evidently, having a 
better understanding of the genetic factors that are involved in beta-lactam 
allergy will improve our understanding of the mechanisms of the reaction. 
Therefore, having a clear view of the genetic factors involved can lead us to 
develop better preventive methods and strategies as well as effecting better drug 
design and treatment strategies in the future. 
Up to the present, no consistently replicated reports of genetic variants 
associated with beta-lactam allergy have appeared. So far, 19 studies have been 
published on genetic predictors associated with beta-lactam allergies. There is a 
widespread recognition of the lack of knowledge in this field, despite its 
presumed effect on the individual’s life and the health care system as a whole. 
 60
Among all the published studies there has only been one study which used a 
genome-wide approach, by conducting an association study using the 
Immunochip fine mapping array (Gueant et al., 2014). However it must be 
highlighted that this study was not a fully comprehensive genome-wide 
association study, because the Immunochip only comprehensively covers 
immune-related candidate genes. As is shown in Table 1.6, 12 studies suggested 
that pro-inflammatory cytokine genes such as IL4R, IL4, IL13 are involved in IgE 
mediated beta-lactam reactions (Oussalah et al., 2016). 
 
Table 1.6 Published genetic association studies 
First author, 
year, journal  
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The table shows genetic association studies that reported genetic 
predictors in association with immediate-type hypersensitivity to BL 
antibiotics. 
 
A case-control candidate gene study, based on self-reported beta-lactam allergy 
status, was conducted in 2007 with a title of “Clinical and genetic risk factors of 
self-reported penicillin allergy” (Apter et al., 2008). They identified 23 self-
reported cases (predominantly white female) through the reports of 17 different 
allergist-immunologists. The allergic symptoms for the cases were reported as 
urticaria, angioedema or swelling, shortness of breath or chest tightness or 
wheeze after taking beta-lactam antibiotics. Out of 23 cases, 11 (48%) were 
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reported as having immediate reaction (within 2 hours of most recent intake 
dose), 11 (48%) were reported as having semi-immediate reaction (within 48 
hours) and 1 (4%) was reported as having a delayed reaction. For 78% of the 
cases, the allergic reaction had occurred more than 5 years before enrolling in 
the study. They also recruited 39 healthy controls from the same cohort (Apter et 
al., 2008). 
In this candidate gene study, IL4, IL4R and IL10 genes were selected for their 
previously reported role in IgE-mediated reactions. They also added LACTB gene 
for its known role in penicillin metabolism. They reported 3 significant SNPs in 
the L4 gene; rs11740584 (P=5.012), rs10062446 (P=5.021) and rs2070874 
(P=5.035); and one SNP, rs2729835 (P=5.058), in the LACTB gene, as being 
marginally associated with penicillin allergy (Apter et al., 2008). The limitations 
of this study included small sample size, self-reported allergic cases and 
recruiting cases by different allergists (Apter et al., 2008).  
Another case-control study was conducted involving 44 allergic patients 
(immediate reaction to beta-lactam) and 44 controls matched for age and sex 
(Guglielmi et al., 2006). This study showed no significant evidence for association 
between allergy patients and controls in the 15 SNPs studied (in STAT6, IL13, 
IL4RA, IL4, IFNGR1, IFNGR2 and FCERIB). However, sub-group analysis revealed 
significant associations in IL10 and IL4RA for immediate beta-lactam allergy in 
women with atopy (Guglielmi et al., 2006).  
A further study based on a case-control sample of 210 cases and 265 age and 
gender-matched controls showed that genetic variants in the genes encoding 
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IL13 and IL4A were associated with the risk of immediate allergy to beta-lactam 
antibiotics (Gueant-Rodriguez et al., 2006).  
A case-control study evaluating the association between tumour necrosis factor-
α-308G>A with IgE-mediated allergy was conducted in 2006 (Gueant-Rodriguez 
et al., 2008). The study had a sample size of 427 subjects (167 cases, and 260 age 
and gender paired control). It showed an uncertain influence of this locus on the 
pro-inflammatory pathways on IgE-mediated hypersensitivity to beta-lactams, 
because the GG genotype was found to be associated with allergy risk whereas 
the AA genotype was found to be associated with higher levels of serum IgE 
(Gueant-Rodriguez et al., 2008).  
A case-control study published in 2013 evaluated the association of 
polymorphisms in the NOD1 and NOD2 genes with beta-lactam allergy 
(Bursztejn et al., 2013). 368 Italian and 387 Spanish patients were compared 
with 368 and 326 controls, respectively.  The Italian cohort revealed an 
association between a SNP in NOD2 and both higher risk of beta-lactam allergy 
and elevated levels of IgE, whereas the Spanish cohort revealed an association 
with beta-lactam allergy in a different NOD2 SNP. 
Finally a recent study conducted a regional fine-mapping genome-wide 
association study of the genetic predictors of beta-lactam allergy (Gueant et al., 
2014). They used the Immunochip custom array (which comprehensively covers 
immune-related candidate genes) for genotyping 436 allergic cases from Spain 
and 1218 paired control subjects. They performed the replication study in 299 
allergic Italian patients and 362 paired controls. They found that immediate 
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beta-lactam allergy was influenced by genetic variants in HLA-DRA. Also they 
reported significant association with the SNPs of C5, ZNF300 and HLA-
DRA/HLA-DRB5 genes. 
The paper concluded that genetic variants of HLA-DRA and the HLA-DRA/HLA-
DRB5 region were significant predictors of allergy to penicillins but not to 
cephalosporins. These data suggest genetic variation related to HLA type 2 
antigen may play a crucial role in penicillin allergy.  
 
1.10 Motivation and aims of this thesis  
There is a global importance of penicillin allergy to the health care system, 
related to the outcome of replacing beta-lactam antibiotics with second line 
drugs once the patient is labelled as having an ‘allergy’. Firstly, there is the direct 
economic cost, since second line drugs are more expensive than first line beta-
lactam antibiotics. In a health care system with finite resources this places great 
pressures on resources. Secondly, the patients’ treatment plans may become 
limited as they may build up resistance to the second line drugs, which may have 
detrimental clinical implications as options of third line drugs may be limited 
and less effective. Thirdly, patients may be allergic to second line drug options, 
further limiting their management plans. Fourthly, the unnecessary overuse of 
second-line antibiotics will accelerate the evolution of bacteria resistant to these 
drugs, and will eventually render them useless. 
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Taking into account the complex aetiology of the beta-lactam allergy, the studies 
described in this dissertation aim to make genuine contributions to the field of 
pharmacogenomics by discovering biomarkers related to beta-lactam, allergy. By 
benefiting from having access to the large database of TwinsUK, and using the 
advantage of twin studies, I estimated the heritability of beta-lactam allergy and I 
also conducted a detailed genome wide association study and a metabolome 
wide association study among self-reported twins. There is a paucity of research 
in this highly significant yet complex field, which would therefore benefit from 
further data to help us to unravel the complexities in the field of beta-lactam 
allergy using genetic studies. This is important because of the potential impact 
on the clinical outcomes for patients, and also because there are wider economic 
implications. Genetic biomarkers provide a potentially beneficial route to better 
patient health outcomes, which makes this type of enquiry imperative.  
The twin studies were followed up with a separate study on a newly recruited 
clinically-defined beta-lactam allergy cohort. Both studies used newly developed 
questionnaires to improve diagnostic accuracy.  
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Chapter 2:  Beta-lactam allergy phenotypes 







2.1  Introduction 
In the previous chapter, I reviewed the biology of allergy in a general context, 
covering drug reactions and diagnostic steps of allergic reactions to beta-lactam 
antibiotics. As I discussed in chapter one, previous studies suggest that both 
genetic and environmental factors may influence beta-lactam allergy. In order to 
understand and estimate the effect sizes of genetic variants in beta-lactam 
allergy, in this chapter we aimed to estimate beta-lactam heritability by using 
data from the TwinsUK cohort. Twin studies provide us with one of the most 
powerful designs for separating and quantifying the effects of genetic and 
environmental factors on common complex traits such as beta-lactam allergy. 
 
2.1.1 The twin study design  
Identical or monozygotic (MZ) twin pairs share 100% of their genome whereas 
non-identical or dizygotic (DZ) twins on average share 50% of their genome 
which is the same as normal siblings. Both MZ and DZ twins are assumed to 
share an equal environment; therefore a greater phenotypic similarity between 
MZ twin pairs compared with DZ twins is considered to be indicative of the role 
of genetic factors.  
The classical twin design can be applied to study both quantitative traits, such as 
height, weight, blood count, and qualitative or binary traits such as disease 
status. For binary traits, when both members of a twin pair have the same trait, 
this is known as being concordant otherwise they are discordant for the trait. 
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When the pair-wise concordance rate among MZ twin pairs is significantly higher 
than that of DZ twins, it shows that there is a genetic contribution to a trait.  
Currently there are no reported twin studies of beta-lactam allergy. However, 
previous twin studies on allergic diseases consistently show a significantly 
higher concordance rate in MZ pairs in comparison to DZ twin pairs. One of the 
largest and most comprehensive twin study on “allergic disease”, with a sample 
size of 7000 twin pairs, was conducted by the Swedish twin registry. The study 
was based on self-reported allergy questionnaire data (Edfors-Lubs, 1971). 
Although the results of the study varied depending on the condition, overall the 
study demonstrated that environmental factors play a more important role in 
beta-lactam allergy than genetic factors. 
Another twin study of atopy and allergic sensitisation markers was conducted on 
a sample size of 349 MZ and 533 DZ twin pairs and the result of this study 
confirmed the earlier findings on the importance of environmental factors 
(Strachan et al., 2001). Also they estimated a significantly higher concordance 
rate in MZ twins compared to DZ twins for hay fever, eczema and specific IgE 
positivity. Their estimates however did not apply to self-reported asthma 
(Strachan et al., 2001).  
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2.2   Materials and Methods 
2.2.1 Study cohort (TwinsUK )  
The sample set used in this heritability estimation study is known as the UK 
Adult Twin Registry or TwinsUK cohort. The UK Adult Twin Registry is a cohort 
started in 1993, by recruiting through media campaigns, in order to investigate 
conditions with higher prevalence in women such as osteoporosis and 
osteoarthritis.  The success of the initial early studies, and the high success of 
using the twin model in the study of complex traits, led to the expansion of the 
cohort (Moayyeri et al., 2013). The UK Adult Twin Registry is run by the 
Department of Twin Research and Genetic Epidemiology (DTRGE) at St. Thomas’ 
Hospital King’s College London. Full ethical approval has been given for 
academic and commercial use (for more detail on ethical approval, please see 
section 2.2). 
Twins are recruited without any selection for any particular disease or trait. 
More than 12,000 twins are registered on the TwinsUK research database and 
around 9000 of these twins are currently actively participating in research 
conducted by the Department of Twins Research and Genetic Epidemiology. The 
cohort contains approximately equal numbers of identical MZ (51%) and non-
identical DZ (49%) twins aged 16 to 100. The cohort is predominantly female 
(80%), partly due to historical reasons and partly because female twins are more 
willing to volunteer than males.  
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All clinical, physiological and behavioural data are collected during visits to the 
Department of Twin Research and Genetic Epidemiology after providing patient 
information sheets (see Appendix A) and filling in consent forms (see Appendix 
B). Other health or lifestyle related self-reported information is collected by 
conducting questionnaires either during the visits or by post or email (Boomsma 
et al., 2002, Rijsdijk and Sham, 2002).  
In order to determine the zygosity status of the participant twins in the TwinsUK 
adult registry, the ‘peas in a pod’ questionnaire (PPQ) (see Appendix C) is used 
for the majority of cases. Definitive zygosity scores in the peas in a pod 
questionnaire is an accurate assessment of the zygosity of the adult twins 
(Moayyeri et al., 2013). In the uncertainty after administering of the PPQ, 
additional tests are used to determine zygosity status in TwinsUK (Table 2.1). 
Several different genotyping and screening methods such as genome scan with 
more than 400 markers, DNA 5 markers, DNA 8 markers, DNA 10 Markers and 




Table 2.1 Zygosity status determination on TwinsUK registry. 
Inferred from co-twin/PPQ 
 
Peas in a Pod Questionnaire (paper questionnaire, online, 




Based on self-reported zygosity by twins during the 








Genome Scan (400+ marker test) 
 
DNA 16 markers 
  





 OxfordDNA_47SNPs done at Oxford 
 
DNA 5 markers 
 
 DNA 5 markers done at KCL 
  
This table gives information on how the zygosity status of the participants 
is determined in TwinsUK adult registry. 
 
  
Table 2.2 provides a summary of the TwinsUK adult registry and available 
samples. There are 10,393 FF (female/female) twins, 2,002 MM (male/male) 
twins and 328 FM (female/male) twins. In total there are 6,369 twin pairs. Over 
1000 different clinical and biomarker data are available for most of the 
participants (Moayyeri et al., 2013). 
DNA data for 7,548 twins and 995 parents are available, and 5,710 twins have 
genome wide genotyped data. DNA methylation data are available for 5,000 
twins and next-generation sequencing data are available for more than 2000 




Table 2.2 The TwinsUK adult registry update. Based on information from 
(Moayyeri et al., 2013). 
Name of register UK Adult Twin Registry (TwinsUK) 
Country 
United Kingdom 
Kind of ascertainment 
Volunteers unselected 
Opposite-sex twins (yes or no) 
Yes 
Number of pairs (Separated by birth range 
and sex)  
1900-1920: 22 FF; 2 MM; 2 FM 
1920-1930: 390 FF; 70 MM; 4 FM 
1930-1940: 1,518 FF; 189 MM; 32 FM 
1940-1950: 2,480 FF; 308 MM; 58 FM  
1950-1960: 2,172 FF; 429 MM; 88 FM 
1960-1970: 1,889 FF; 486 MM; 62 FM 
1970-1980: 1,356 FF; 394 MM; 40 FM 
1980-2000: 558 FF; 124 MM; 40 FM 
Grand total 
10,393 FF; 2,002 MM; 328 FM (6,369 pairs) 
Major interests 
Common complex diseases and ageing traits 
Traits measured 
Full questionnaires and clinical examinations on majority of twins 
for wide range of over 1,000 clinical and biochemical traits 
including: cardiovascular diseases, obesity, metabolic syndrome, 
respiratory diseases, dermatology, osteoarthritis, osteoporosis, 
eye diseases, coagulation system, immune function, cognitive 
function, gastro-intestinal system, pain thresholds, allergy, atopy, 
sexuality, pitch perception, and various aspects of personality. 
DNA samples 
13,458 aliquots from 7,548 twins  
9,321 aliquots from 5,95 twins stored as back-up 





119,511 blood samples (5,980 serum, 43,527 plasma EDTA, 
10004 plasma Li heparin) from 7,681 twins  
(16,677 back-up samples) 




Monozygotic: Dizygotic ratio is approximately 1:1 
Majority of twins are female with mean age of 55 years 
5,710 twins with genome-wide association data  
5,000 twins with DNA methylation data by the end of 2012 
2,000 twins with next-generation sequencing data by the end of 
2012  
Data available for transcriptome across multiple tissues, telomere 




2.2.2  Detail of ethics approval  
Study title is “TwinsUK”, the Research Ethics Committee reference is EC04/015, 
and the study approval date is Mar 2004. The body formerly known as the St. 
Thomas’ Hospital Research Ethics Committee (REC) granted the ethical opinion 
for TwinsUK (see Appendix D). Following restructure and merging of REC, 
subsequent amendments were approved by the NRES Committee London – 
Westminster (see Appendix E). 
2.2.3 Information on beta-lactam allergy from existing questionnaire 
data 
The data used in this chapter were collected through a General Health 
Questionnaire (GHQ) administered to 3,755 monozygotic (MZ) and dizygotic 
(DZ) twins, aged between 16 to 82 years old, in the 6 year period between 2004 
and 2010. The questions in the GHQ included two very simple yes/no questions 
related to allergy to penicillin. These questions were: 
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Are you allergic to penicillin?  Yes/No 
If so, have you had any treatment for your allergic reaction?  Yes/No 
These simple yes/no questions and did not provide information on the culprit 
drug (type of antibiotic that caused the allergic reaction), seriousness of the 
reaction or any available treatment/ medication, time delay of the reaction or 
type of the reaction. 
Table 2.3 summarises the general characteristics of the twins participating in the 
General Health Questionnaire. The mean age of the participants was 53 years 
(52.9 ± 13.3) and ranged from 16 to 82. Data were obtained from 1694 DZ twins 
(individuals) and 2051 MZ twins (individuals) and 10 individuals with unknown 
zygosity (UZ). The male to female ratio was approximately 1:10, which is similar 
to the whole TwinsUK cohort.  
























2.2.3.1  Potential limitations of the original health questionnaire  
There are a number of limitations of the General Health Questionnaire that may 
cause bias in our results: 
• Self reported data 
The data from the GHQ is a self-reported data reported by twins. 
Therefore there is a lack of clinically confirmed allergy. We already know 
(see chapter 1) that up to 10% of people taking beta-lactam antibiotics 
report as being allergic to them but only 10% of these reported as being 
allergic after clinical examination. 
 
• Missing data 
There are two main issues in terms of missing data in this study. The first 
problem occurs the yes/no question is unanswered. In this case we do 
not know whether a blank means “unknown” or whether it means “not 
allergic to beta-lactams”. The second problem is reporting bias. If data are 
missing in a biased manner, for example if MZ pairs concordant for 
allergy to penicillin systematically failed to return the questionnaire – 
then this could have a serious effect on our results. 
 
• Lack of detailed information on beta-lactam allergic reaction 
The original question in the GHQ is a simple yes/no question and did not 
provide any further information on the type of reaction, which is 
essential for our further studies. There is no information on clinically 
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approved beta-lactam allergy, type of reaction, time delay of the reaction 
or the culprit drug. 
 
• Recall bias 
A “no” answer could be due to not recalling any mild allergic reaction, or 
in some cases even a more serious reaction. 
 
• Twins report pattern 
Information in TwinsUK indicates that MZ twin pairs are more likely to 
cross-confer and give the same answer to the same question than DZ twin 
pairs.  This will bias heritability estimates. 
 
 
2.2.4  Estimation of the heritability from twin studies  
We used Falconer’s formula to calculate heritability (Hill and Mackay, 2004). 
Falconer’s formula is used to estimate the genetic heritability of a trait based on 
the difference between twin correlations (Hill and Mackay, 2004).  
 
h2 = 2(rMZ – rDZ) 
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In this formula h2 is the heritability, rMZ is the monozygotic (identical) twin 
correlation and rDZ is the dizygotic (non-identical) twin correlation in trait-
sharing. 
The confidence interval was calculated from the formulae below (Rijsdijk and 
Sham, 2002).  
SE(h2) ~ 2*sqrt(SE(MZcorr)+SE(DZcorr)) 
SE(MZcorr) = (1 – MZcorr^2)/sqrt(n – 1) 
SE(DZcorr) = (1 – DZcorr^2)/sqrt(n – 1) 
  
2.2.5  Design and administration of a new questionnaire for beta-
lactam allergy 
We sought to validate and expand the data used in TwinsUK general health 
questionnaire through the development of a more detailed questionnaire, 
specifically designed to extract clinically useful information from the twins who 
self-report suffering from allergic reactions to penicillins and/or other beta-
lactam antibiotics.  
The new questionnaire collected more specific information on the type of 
antibiotic that caused the allergic reaction, the symptoms experienced, family 
history of allergy, seriousness of the reaction, and the time interval between 
taking the medication and occurrence of the symptoms.  
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We sent the questionnaire to all 337 twin pairs (674 individuals) where at least 
one twin (co-twin) had answered ‘yes’ to the question of being allergic to 
penicillin in the GHQ, which included 19 male twin pairs and 318 female twin 
pairs with an age range of 19 to 78. Of these twin pairs, 30 MZ pairs and 18 DZ 
pairs were concordant for allergic status and 152 MZ pairs and 136 DZ pairs 
were discordant for self-reported allergy to penicillin.  
2.2.5.1  European Network Drug Allergy (ENDA) questionnaire 
As a basis for our new questionnaire, we first considered the European Network 
of Drug Allergy (ENDA) questionnaire. ENDA developed the first validated 
questionnaire designed specifically to help the diagnosis of drug hypersensitivity 
in 1999 (see Appendix F). Drug hypersensitivity reactions are difficult to 
diagnose due to a number of reasons including: large variation in the clinical 
picture of drug hypersensitivity reactions; lack of sufficient in-vitro and in-vivo 
tests; and weaknesses in the Gell and Coombs classification. A detailed history 
taking during clinical visits is the most important diagnostic step in order to 
determine the origin of the reaction. It is also an essential tool to verify the type 
and seriousness of the allergic reaction (for more details please see chapter 1) 
(Mirakian et al., 2015).  
 
2.2.5.2  Development of the specific beta-lactam questionnaire 
Although we would have preferred to use an already existing, clinically validated 
questionnaire such as the ENDA questionnaire, to validate basic information on 
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beta-lactam allergy status for the TwinsUK data this was not possible due to the 
difficulties in administering a complicated questionnaire full of clinical jargon to 
members of the general public. The ENDA questionnaire is long and contains 
difficult clinical terminology, as it was designed as a clinical tool. It is therefore 
not suitable as a questionnaire that can be completed by the twins without 
assistance. For these reasons we aimed to make our questionnaire as simple and 
as short as possible.  
In developing the new questionnaire we took into account several factors: (1) 
the ENDA drug hypersensitivity questionnaire: (2) the British Society for Allergy 
and Clinical Immunology (BSACI) guidelines: and (3) a systematic review of the 
available literature. Most of the questionnaires we found were variations of the 
ENDA questionnaire and I BSACI guidelines. I also used the information and 
clinical history taking guidelines as described in Demoly et al. (1999, 2009 & 
2010). From among those questionnaires, and under the supervision of Dr. M 
Rosario Caballero (Department of Respiratory Medicine and Allergy), I selected 
the most suitable questions for my study and its population.  
We developed a single-sheet, 11-item questionnaire to collect clinically useful 
information on beta-lactam allergy status from the twins. The newly designed 
specific beta-lactam allergy questionnaire can be found in Figure 2.1.  The 
questionnaire was designed to address the limitations of the penicillin allergy 
section on the general health questionnaire for TwinsUK and thus obtain better 







Figure 2.1 The newly designed specific beta-lactam allergy questionnaire 
for TwinsUK.  
The questionnaire was designed to address the lack of information in the 
General Health Questionnaire on self-reported allergic reactions to beta-




2.2.6 Using the new questionnaire to define improved definitions of 
beta-lactam allergy response 
2.2.6.1 Study population for the new questionnaire  
The new questionnaire was posted to a total of 337 twin pairs (674 individuals) 
from TwinsUK, where at least one of them had been recorded as being allergic to 
beta-lactam antibiotics according to the General Health Questionnaire. Our pool 
included 184 MZ (monozygotic) twin pairs and 152 DZ (dyzygotic) twin pairs 
and 2 UZ (unknown zygosity) twin pairs. In addition to the questionnaire, each 
participant received an invitation letter, explaining the purpose of the study (see 
Appendix G), and a pre-paid addressed envelope in which to return the 
questionnaire. 
 
2.2.6.2 Collecting information from the new specific beta-lactam allergy 
questionnaire  
Each questionnaire was reviewed using the history taking method (explained 
in detail in chapter 1) under the supervision of Dr. M. R. Caballero. It is 
important to bear in mind that, while each question was chosen in order to 
give us useful information in regards to the patient’s allergy history, none of 
these questions on its own can give us a clear view. Rather, a combination of 
the answers to all questions gives us a much more clear picture of the allergy 
history, to allow us to review and decide on  allergic status. We used this 
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approach to define: (1) a modified penicillin allergy status (yes/no); (2) a 
penicillin allergy seriousness status (mild/medium/severe); (3) a penicillin 
allergy time delay status (immediate/semi-delayed/delayed). 
 
2.2.7 Modified penicillin allergy phenotypes – based on information 
from the new questionnaire. 
1.  Recalculating the allergy status heritability estimate, using information 
from the new questionnaire 
After validating the TwinsUK beta-lactam data and defining the type and 
seriousness of the reaction, we recalculated the heritability in our cohort based 
on the new information. The new modified database contained data on 676 
individuals who had been sent the allergy-specific questionnaire, plus the 
information for all the twins who just completed the General Health 
Questionnaire. 
The heritability for the modified penicillin allergy status (yes/no) was calculated 
for twins who completed the new questionnaire and provided unambiguous 
answers. The results of our careful evaluation based on the new questionnaire 
were transferred over to the database for the full twins cohort, and our new data 
replaced the old data where it was different. 
We re-calculated the heritability of the beta-lactam allergy in our cohort using 
Falconer’s formula.   
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2. Heritability estimate for allergy seriousness 
We also calculated the heritability for penicillin allergy seriousness 
(mild/medium/severe). These severity data were also imported to the dataset 




2.3.1 Heritability estimation for penicillin allergy (yes/no) using the 
data from the General Health Questionnaire  
Table 2.4 provides data for the heritability calculation based on the General 
Health Questionnaire, which was completed by 2115 twin pairs. The table 
indicates the number of 2-twin families which were concordant-YES, discordant, 
and concordant-NO, split by DZ/MZ zygosity.  
 
 
Table 2.4 Number of concordant and discordant twin pairs based on the 
General Health Questionnaire. 











DZ 725 (59%) 148 (12%) 19 (1.5%) 892 
MZ 1005 (82%) 183 (15%) 35 (3%) 1223 
This table provides information on the concordant and discordant twin 
pairs for penicillin allergy status. MZ=monozygotic twin pairs; 
DZ=dizygotic twin pairs. 
 
Table 2.5 shows the heritability estimation for penicillin allergy using the self-
reported data from the General Health Questionnaire. The point estimate for 
heritability is 16%, but we note that the 95%CI for heritability includes 0, so 





Table 2.5 Correlation of DZ and MZ twins based on the GHQ. 
 Corr or h2 N SE Lower 95%CI 
Upper 
95%CI 
DZ 0.112 892 0.033 0.047 0.177 
MZ 0.193 1223 0.027 0.139 0.247 
      
H2 0.1626  0.086 -0.006 0.331 
 
Note that these calculations display:  
              (1) Lack of power (most twin pairs are 0-0) 
(2) A large number of discordant pairs, relative to the concordant-YES 
pairs.  We only had 19 DZ twin pairs who were concordant YES and 35 MZ twin 
pairs who were concordant YES, compared to 148 and 183 discordant DZ / MZ 
twin pairs respectively (see Table 2.4). 
 
2.3.2 Response to the first question in the new questionnaire 
The results from question 1 (“Have you ever had any allergic reactions to any of 
the following drugs?” (penicillins/cephalosporins/other drugs)) are summarized 
in the tables below. This question helped us to get an idea if they had enough 
knowledge of the name or subfamily of the drug that they (or their co-twin) 
claimed to be allergic to.  In terms of penicillin allergy, out of 676 twins 
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(individuals) who were sent the new questionnaire, 301 twins (individuals) 
responded as being allergic, with 220 confirming no allergy and 154 not 
answering the question. With cephalosporin allergy, only 16 twins (individuals) 
responded as being allergic, whereas 321 (individuals) responded as being not 
allergic. 334 twins did not respond to the question with 4 twins unable to 
remember (Table 2.6). 
 
Table 2.6 Results for question 1 in the new questionnaire 
(penicillin/cephalosporin allergy) 





























2.3.3  Results for Question 2 of the new questionnaire 
The table below (Table 2.7) shows the results from question 2 in the new 
questionnaire (“for what infection was the antibiotic prescribed for?”). The table 
indicates that the majority of twins (38.1%) had antibiotics for reasons other 
than chest infection, cold or dental surgery. 27.2% of twins were prescribed 
antibiotics for an episode of chest infection, with only 10.3% taking antibiotics 
post dental procedure. The results also show 11.1% had antibiotics pre/post 
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surgery and only 7.7% were given antibiotics for cold and flu. 5.2% of 





Table 2.7 Summary of responses to Q2 of the new questionnaire 
 




































2.3.4 Results for Question 3 of the new questionnaire 
Out of 301 positive responses to question 1, 250 individuals reported they were 
diagnosed by a doctor at the time of the reaction. Only 37 twins reported not 
being seen by a doctor, and 10 twins did not respond to the question. Table 2.8 
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summarises the responses to question 3 (“Was the allergic condition clinically 





Table 2.8 Summary of responses to question 3 of the new questionnaire 













2.3.5 Comparison of results between the old and new questionnaires 
and new questionnaire 
Table 2.9 shows the results for a comparison of the data between the old (GHQ) 
and new questionnaires. The table shows that most not-allergic responses stayed 
as not-allergic (only 6 converted to being allergic). However, a large proportion 
of positive allergic responses converted back to being not-allergic (58 / 483 
converted).  
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Table 2.9 Comparison of the results for the old (GHQ) questionnaire and 
newly designed specific beta-lactam allergy questionnaire. 
   New    questionnaire     
Old questionnaire Not allergic Allergic 
  Grand 
Total 
Not allergic 4152 6 4158 
Allergic 58 425 483 





2.3.6 Heritability estimation for beta-lactam allergy using the data 
from the new questionnaire  
Table 2.10 summarises the heritability estimation for beta-lactam allergy (either 
penicillin or cephalosporin) after administrating the more detailed 
questionnaire, including the 95% confidence interval.  
The use of the new questionnaire led to an increased heritability estimate from 
16% to 21%.  Also the 95% confidence interval did not include 0, therefore 
indicating a significant result (at the 5% significance level). 
 
Table 2.10 Heritability estimation for beta-lactam allergy from the new 
specific beta-lactam allergy questionnaire. 
 Corr or h2 N SE lower95%CI upper95%CI 
DZ 0.112 892 0.0330 0.0477 0.177 
MZ 0.220 1223 0.0272 0.1676 0.274 
h2 0.2167  0.0856 0.0488 0.384 
h2=heritability; DZ=dizygotic twins; MZ= monozygotic twins  
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2.3.7 Heritability estimate for allergy seriousness of the reaction 
Finally, heritability was estimated for allergy seriousness (mild/medium/severe) 
in our data, assuming that the 3-level seriousness score could be treated as a 
quantitative trait. Table 2.11 indicates that the heritability estimate increased 
after adding more phenotypic detail to our estimation.  
The 95% confidence interval was above zero, which indicated a significant result 
(at the 5% significance level). 
Table 2.11 Heritability estimation for allergy seriousness. 
 Corr or h2 N SE Lower 95%CI Upper 95%CI 
DZ 0.036 892 0.033 -0.029 0.102 
MZ 0.157 1223 0.027 0.103 0.212 







In this chapter, I used the TwinsUK cohort to make additional observations 
regarding the epidemiology and heritability of beta-lactam allergy. There was 
limited phenotypic data (from the General Health Questionnaire) that related to 
beta-lactam allergy. We improved the information on beta-lactam allergy for the 
TwinsUK cohort through the design and administration of a new questionnaire, 
which was used to construct new variables relating to the seriousness and type 
(time delay) of the allergic response. I used this information to calculate 
heritability estimates for allergic phenotypes.  
By using this new specific beta-lactam allergy questionnaire we were able to 
overcome some of the limitations of the old questionnaire. However, a number of 
limitations still remained: 
• Self reported data subject to subjective bias. 
• Because this was a postal questionnaire, co-twins were not blinded to the other 
twin’s response.  
• Some twins may not be allergic to beta-lactam antibiotics, whilst they may be 
allergic to another family of antibiotics. 
• Most people do not have a clear understanding of drug allergy symptoms. 
• Patients are not always able to recall history of prior drug exposure. 
• Childhood history of allergy is common, but unfortunately patients can’t recall 
any evidence of allergy. 
• Sometimes it is unclear whether the symptoms are due to an allergic reaction 
or provoked by an underlying infection. 
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• In some cases, patients are taking more than one drug at the same time. 
• Recall bias. 
Using the available self-reported allergy data for 1223 twins from the GHQ, the 
heritability was estimated as 16% for this definition of beta-lactam allergy, 
which was not significant. However, following the administration of the new 
detailed questionnaire to the twins who reported being allergic plus their co-
twins totalling 676 individuals, a re-calculation of the heritability estimate was 
performed. The result of this calculation showed a significant increase of 
heritability to 21%, which is positive evidence to show that our questionnaire 
was adding valuable information to the data. 
Finally, to allow more specific heritability calculations, we considered 
seriousness and type of reaction for each participant and re-calculated the 
heritability for severity as a quantitative trait. The result shows an even more 
significant increase in the heritability estimation. This therefore also indicates 
that our careful examination of the questionnaire added more value to our data. 
Although the new questionnaire has not been fully validated this new 
questionnaire can be considered in the future as a better replacement for the 
current self-reported questionnaires. The detailed questionnaire provides us 
with better information, making it easier to identify false positive allergic 
reactions as rated by patients in the history-taking phase of the assessment. 
Although there are some limitations to the new questionnaire (see methods 
section), the information on this questionnaire added more value to the TwinsUK 
beta-lactam allergy data. Another important contribution of this questionnaire 
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was that the heritability estimation increased after administering the more 
detailed questionnaire. This questionnaire also helped us to identify 58 non-
allergic cases, who had self-reported positive allergy status in the General Health 
Questionnaire.  
 All our information for beta-lactam allergy in TwinsUK remains self-reported 
but we have reduced the number of the self-reported allergic cases which were 
likely false-positive, just by administering our new questionnaire. Many more 
questions could be added to this questionnaire in order to get a more accurate 
and detailed history of beta-lactam allergic reaction, but this would also have a 
downside, as it is likely that participants would be unwilling to complete a very 



















Chapter 3: GWAS of beta-lactam allergy in 










3.1 Introduction  
A genome-wide association study (GWAS), also known as a whole genome 
association study, is a study that examines a large number of common genetic 
variations among different individuals to observe any variants associating with a 
trait (Stranger et al., 2011). This relatively new method searches the whole 
human genome for (typically) small variations known as single nucleotide 
polymorphisms (SNPs) (Bush and Moore, 2012). Each GWAS study is capable of 
looking for hundreds of thousands of SNPs at the same time to identify any 
genomic variation that may influence the risk of disease (Visscher et al., 2012, 
Wellcome Trust Case Control, 2007). 
In case-control GWAS studies, participants are selected based on their phenotype 
for the specific trait or disease. Individuals with a particular disease are 
categorized as cases based on their clinical manifestations, and similar people 
without specified disease are classified as controls (Daly, 2010a).  
As discussed, a GWAS is a hypothesis-free approach that offers the opportunity 
to overcome the complexity and difficulties that arise from a lack of information 
regarding the pathophysiology of the complex trait (Bush and Moore, 2012).  
Power plays a significant role in a GWAS study (Bush and Moore, 2012). 
Although sample size is a major contributing factor to GWAS power, there have 
been successful GWAS studies on drug response even with small sample sizes 
(see chapter 1) (Cooper et al., 2008). For example, a GWAS study on warfarin 
yielded significant results on contribution of genetic variants in drug response a 
case/control sample size totalling only 181 (see chapter 1)(Cooper et al., 2008). 
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The success of such studies with small sample size in pharmacogenomics has 
encouraged the usage of GWAS in this dissertation. 
Beta-lactam antibiotics are responsible for the most frequent cases of immediate 
reactions to drugs and the reactions can be life threatening. Most of these 
reactions appear within the first hour after drug intake (see chapter 1) (Mirakian 
et al., 2015). Beta-lactam allergy has a complex aetiology with multiple 
environmental and genetic causes (Apter et al., 2008). As explained in chapter 1, 
there have been candidate gene studies of beta-lactam allergy to identify causal 
variants and to prioritize genes and genomic regions. Yet, there is much that is 
still unknown about the aetiology of beta-lactam allergy (Gueant et al., 2014). 
As discussed in chapter 2, estimates of heritability using beta-lactam antibiotic 
allergic cases showed that genetic factors were associated with this trait. 
Although the original beta-lactam allergy data for TwinsUK cohort was self-
reported, administration of a new beta-lactam specific questionnaire to the same 
cohort helped us to exclude 58 cases from the original data, and the use of the 
new questionnaire led to an increased heritability estimate from 16% to 21% 
(see result section in chapter 2).  By using the new questionnaire TwinsUK 
allergy data provided positive evidence of the involvement of a genetic 
component in beta-lactam allergy.  
The factors contributing to running a GWAS on self-reported beta-lactam allergy 
using TwinsUK data include the proven involvement of genetic factors in beta-
lactam allergy in the TwinsUK cohort via heritability estimation (refer to chapter 
2). Other factors include having pre-existing genotyping data for the same 
 98
cohort, and previous examples of successful GWAS studies using self-reported 
data (e.g. Hinds et al 2013).  Finally, there are previously reported examples of 
association between beta-lactam allergy and variants in genes such as 
interleukin-10 (IL10), IL13, IL4, HLA-DRA and TNFA (see chapter 1).  
3.2 Materials and Methods 
3.2.1 Study cohort 
The sample set used in this GWAS study is known as the TwinsUK cohort. Pleas 
refer to Chapter 2 for further details of the TwinsUK cohort.  
 
3.2.1.1 Details of Ethics approval 
Study title: TwinsUK 
Research Ethics Committee reference: EC04/015 
Study approval date: March 2004 
 The committee formerly known as the St. Thomas’ Hospital Research Ethics 
Committee (REC) granted the ethical approval for TwinsUK (see Appendix D).  
Following restructuring and merging of separate RECs, subsequent amendments 
were approved by the NRES Committee London – Westminster (see Appendix E) 
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3.2.2  Subjects 
A total number of 684 individuals were investigated in this study.  
3.2.2.1 Case selection  
After administering a detailed beta-lactam allergy specific questionnaire, 211 
twins of European ancestry were identified as having self-reported beta-lactam 
allergy through the TwinsUK database at St Thomas’ Hospital (see chapter 2). 
These individuals all had genome-wide genotype data available in the DTR 
database. Among the 211 cases, 181 (more than 85%) reported having their 
beta-lactam allergic reaction diagnosed by a doctor (Table 3.1). For this study, 
we made use of a specific consent form included with the beta-lactam allergy 
specific questionnaire administered (see chapter 2).  
 
Table 3.1 Diagnostic status of self reported beta-lactam cases 
 Allergic reaction cases 
Diagnosed by doctor 181(85.7%) 
Not diagnosed 20(9.4%) 
Don’t remember 2(0.9%) 
Not answered the question 8(3.7%) 





3.2.2.2 Control selection  
We identified our control group from the same TwinsUK cohort. As a first step, 
we extracted those individuals with no history of beta-lactam allergy or any 
other drug reactions. To further refine the definition of controls, we then 
excluded individuals with any other allergy symptoms or reaction to any other 
substances. Thus our control group was a set of “super controls”. In total, 473 
individuals were identified as the control group for our TwinsUK GWAS.  
 
3.2.3 Phenotype definition 
We defined various phenotypes in our study cases;  
1. Seriousness of the beta-lactam allergic reaction based on the information from 
the beta-lactam specific questionnaire  (see chapter 2)  
2. Time delay of response (type of reaction) based on the beta-lactam specific 
questionnaire (see chapter 2)  
 
3.2.3.1 Seriousness of the reaction 
From a statistical point of view, in cohort analyses, quantitative or semi-
quantitative traits tend to be better-powered to detect a genetic effect. Taking 
this into account, we ordered our cases and controls based on the seriousness of 
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their type of reaction to beta-lactam antibiotics, to provide a supplementary 
analysis to the case-control analysis. 
Cases were categorized based on the seriousness of the reaction by using the 
Brown classification (for more detail see chapter 1), into mild/medium/severe 
penicillin allergy responders coded as 1/2/3 respectively. For more information 
on the grading system please see chapter 2. Also a set of “non-allergic” 
individuals (controls) was recorded as code “0” (Table 3.2). 
 
Table 3.2 Symptom seriousness status on allergic twins 
 
Seriousness of the reaction 
 
 



















1, Mild reaction; 2, Medium reaction; 3, Severe reaction  
Based on question 5 in the specific questionnaire, followed by review by a 
Guy’s allergy clinic consultant (see chapter2).  
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3.2.3.2 Time delay of the reaction 
 Cases were categorised into immediate/semi-delayed/delayed according due to 
the interval between drug intake and appearance of the first symptoms of beta-
lactam allergic reaction. We used time-delay of the reaction which we also refer 
to as “type of the reaction”, coded as 1/2/3 coded respectively (Table 3.3). Also 
the same set of “non-allergic” individuals (controls) were recorded as code “0” 
(See chapter 2 for more information on time delay). 
 
Table 3.3 Type of reaction status on allergic twins 





1, Immediate; 2, Semi-delayed; 3, Delayed reaction. Based on question 6 in 
the specific questionnaire followed by review by a Guy’s allergy clinic 




3.2.4 Genotyping/ quality control/ imputation 
3.2.4.1 Genotyping 
The genotyping of the samples from the TwinsUK cohort was performed using a 
combination of Illumina arrays: HumanHap300, HumanHap610Q 1M-Duo and 
1.2MDuo 1M (Richards et al., 2008, Soranzo et al., 2009). The normalised 
intensity data was pooled across four genotyping centres at the Centre National 
de Genotypage (France), Duke University NC (USA), Helsinki University 
(Finland), and the Welcome Trust Sanger Institute (UK). The genotype-calling 
algorithm Illuminus was used to assign genotypes. No calls were assigned if an 
individual’s most likely genotype was called with less than a posterior 
probability threshold of 0.95. Validation of pooling was achieved via visual 
inspection of 100 random, shared SNPs for any overt batch effects.  
3.2.4.2 Quality control (QC) 
For quality control purposes, similar exclusion criteria were applied each of the 
four datasets (from the four genotyping centres) independently. Subjects were 
excluded based on genotype data when sample call rate <98%. SNP level QC 
measures included: minimum MAF (>1%MAF); minimum genotyping success 
rate (call rate >95%); test for HWE (P > 10−6). 
3.2.4.3 Imputation 
Imputation was performed using the IMPUTEv2 software package (Howie et al., 
2009). Two different reference panels PO (HapMap2, rel 22, combined 
 104 
CEU+YRI+ASN panels) and P1 (610k+, including the combined HumanHap610k 
and 1M reduced to 610k SNP content) were used in data imputation.  
Imputation quality score was thresholded at info>0.7, leaving a total of ~1.87 
million SNPs post-imputation. In this analysis, only SNPs with minor allele 
frequency ≥0.02 were included in the analysis since the interest was to 
investigate common variants. (Small et al., 2011, Nag et al., 2014). 
 
  
3.2.5 GWAS scan statistical analysis 
As I explained in the previous chapter, when dealing with twin’s data, MZ twin 
pairs are known to share nearly 100% of their genetic variation while DZ twin 
pairs are known to share 50% of their genetic variation, though the percentage 
may vary due to chance difference in sites of recombination among DZ pairs.  
In order to process the TwinsUK GWAS data, we generated a genomic kinship 
matrix from the GWAS data, and used it to correct for the relatedness in the data. 
This matrix was used to correct for family structure by using linear mixed model 
packages. Linear mixed models (LMMs) such as GEMMA and GenABEL are widely 
used to test for association studies.   Note that in addition to correcting for close 
relatedness between twins, this procedure will also correct for more distant 
relatedness (i.e. population stratification due to differences in ancestry among 
twin pairs). 
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There is an increasing interest in using LMMs due to their effectiveness in 
accounting for relatedness and incorporating population stratification when 
analysing twin’s data (Eu-Ahsunthornwattana et al., 2014). The variety of 
different available LMMs raises the question of which package to use to analyse 
our GWAS data. A previous study compared different methods of LMMs for how 
they handled family-based data. This study suggested that there was no 
appreciable difference in power or in the control of Type I error between 
GEMMA and GenABEL, or indeed between any of the LMM packages they 
assessed.  Overall, both the GEMMA and GenABEL packages are able to deal with 
either quantitative or binary data. We decided to use the GenABEL package for 
the analysing the genetically correlated twin data (Eu-Ahsunthornwattana et al., 
2014). 
GenABEL is an R library package for the analysis of binary and quantitative traits 
(http://www.genabel.org/). This package was developed to facilitate genome-
wide association analysis of quantitative traits using data coming from extended 
families or collected from genetically isolated populations. Therefore this 
package is suitable for analysing the TwinsUK data. We treated our data as a 
linear quantitative trait so as to be able to run it with the GenABEL package. 
 
3.2.5.1 GWAS scan tests 
I applied four models to the TwinsUK data. Test 1 was a test of seriousness as a 
quantitative trait, and was applied to all 211 allergy cases plus 473 controls, in 
the hope of maximising power to find general signals.  Test 2 was a test of 
 106 
seriousness as a quantitative trait, applied to only the 57 immediate and semi-
delayed allergy cases plus 473 controls, in the hope of maximising power to find 
signals specific to short time delay cases. Test 3 was a binary case/control test of 
allergy status, applied to all 211 allergy cases plus 473 controls, which removed 
the assumption of linearity implicit in the quantitative analysis of all cases (Test 
1).  Finally, Test 4 was a binary case/control test of allergy status, applied to only 
the 57 immediate and semi-delayed allergy cases plus 473 controls, which 
removed the assumption of linearity implicit in the quantitative analysis of short 
time-delay cases (Test 2). 
 
3.2.6 Post-association analysis  
Our post-association analyses on GWAS results involved the creation of QQ plots, 
Manhattan plots and regional association plots (LocusZoom plots). 
 QQ-plot 
The quantile-quantile plot (Q-Q plot) is a graphical tool that compares the 
distribution of observed ordered negative log P-values against expected negative 
log P-values under the null hypothesis. This plot helps to indicate whether the 
study has achieved more significant results than expected under a global null 
hypothesis. The number of “independent” LD signals in the human genome is less 
than the number of SNPs assessed, and therefore the concentration band 
indicated in grey (indicating the 95% confidence interval under the global null 
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hypothesis) is wider than it should be (Wilk and Gnanadesikan, 1968, Ehret, 
2010).  
Manhattan plot 
The Manhattan plot is a type of series plot used to present GWAS results. In a 
Manhattan plot, the x-axis shows the genomic position of SNP on chromosomes 
1-22 and the y-axis shows the negative log p-value for association for each SNP 
(Ehret, 2010).  
LocusZoom plot 
The LocusZoom plot is a graphical tool to magnify the specific region of the 
Manhattan plot, which gives us detailed information on the genes and SNPs’ 
locations in the region. The LocusZoom plot also displays regional information 
such as area and strength of the associated signal related to genomic position 




3.3.1 Results for Test 1: seriousness as a quantitative trait (all cases) 
3.3.1.1 Q-Q plot 
Figure 3.1 shows the Q-Q plot for the GWAS results on seriousness as a 
quantitative trait (Test 1). The result file contained 1453397 SNPs. Most of the 
SNPs adhere to the “null” (no significant difference between observed and 
expected p-value), The top 2 SNPs have p<5e-8, which is widely regarded as a 
true LD-corrected genome-wide significance threshold.  
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Figure 3.1 QQ plot on seriousness as a quantitative trait.  
The negative logarithms of the observed (y axis) and the expected 
(x axis) ordered P-values are plotted for each SNP. The red line indicates 
the expected distribution under the null hypothesis. The grey shaded 
region represents the 95% concentration band. There is no genomic 





3.3.1.2 Manhattan plot 
Figure 3.2 shows the Manhattan plot of GWAS analysis on seriousness as a 
quantitative trait. The red line indicates the statistically acceptable threshold 
(p=5e-8). A significant hit with a p-value of p<5e-8 on chromosome 15 is seen. 
 
       
 
Figure 3.2 Manhattan plot for GWAS scan on allergy seriousness as a 
quantitative trait (all cases used).  
The x-axis shows the chromosomal position and the y-axis shows the –
log10p value. Chromosomes are shown in alternate colours. The red 
horizontal line indicates a threshold of genome-wide significance at a P-
value of 5e-8. Each point represents a p-value for the SNP association test of 
the 211 case participants and 473 healthy control subjects.  
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3.3.1.3 LocusZoom Plot 
Figure 3.3 shows a LocusZoom plot of the region containing the two SNPs with a 
p-value of p<5e-8. As shown in Figure 3.3, there is one typed and one imputed 
significant SNP supported by a number of SNPs underneath. MTHFS and BCL2A1 
are two main genes under the signal, both of which have a plausible reason to 
have an impact on penicillin allergy (see Discussion).  
 
Figure 3.3 LocusZoom plot of region containing the significant hit for Test 
1.  
The main panel of a LocusZoom plot shows association p-values on the –
log10 scale on the vertical axis, and the chromosomal position along the 
horizontal axis. Genes within the region are shown in the lower panel. Each 
filled circle represents the p-value for one SNP in the discovery cohort, with 
the top SNP rs12438477 shown in purple and SNPs in the region coloured 
depending on their degree of linkage disequilibrium (r2) with rs12438477 
(as estimated internally by LocusZoom on the basis of CEU (Utah residents 
of Northern and Western European ancestry) HapMap). 
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3.3.2 Results for Test 2: seriousness as a quantitative trait (short time 
delay only) 
3.3.2.1 Q-Q plot 
As shown in Figure 3.4, there are no significant results for allergy seriousness 
tested as a quantitative trait on short time delay (immediate+semi-delayed) 
cases (Test 2) and all the SNPs are in the grey area (concentration band 
indicating the likely region for “null” signals). No hits were seen with a p-value of 
less than 5e-8. The plot shows no evidence of population stratification, 




Figure 3.4 Q-Q plot of allergy seriousness as a quantitative trait (short time 
delay only).  
The negative logarithms of the observed (y axis) and the expected 
(x axis) ordered p-values are plotted for each SNP, and the red line 
indicates the expected distributions under the global null hypothesis. The 
grey shaded region represents the 95% concentration band. There is no 
genomic inflation in lower end, but nor are there any significant hits shown 




3.3.2.2 Manhattan plot 
As Figure 3.5 shows, the Manhattan plot of GWAS analysis on allergy seriousness 
status as a quantitative trait (immediate + semi-delayed cases only), confirms 





Figure 3.5 Manhattan plot for allergy seriousness as a quantitative trait 
(short time delay only).  
The x-axis shows the chromosomal position and the y-axis shows the –
log10 p-value. Chromosomes are shown in alternate colours. The red 
horizontal line indicates a threshold of genome-wide significance at a p-
value of p<5e-8. Each point represents a p-value for the SNP association 
test of the 57 case participants and 473 healthy control subjects.  
 
3.3.2.3 LocusZoom plot 
As shown in Figure 3.6, there is still some evidence of a signal in the same region 
as the previously described hit (see result section for Test 1), but it is not a well-
supported significant hit. The real SNP is still the same (rs12438477), but the p-




Figure 3.6 LocusZoom plot for allergy seriousness (short delay cases only). 
The main panel of a LocusZoom plot shows association p-values on the –
log10 scale on the vertical axis, and the chromosomal position along the 
horizontal axis. Genes within the region are shown in the lower panel. Each 
filled circle represents the p-value for one SNP in the discovery cohort, with 
the top SNP rs12438477 shown in purple and SNPs in the region coloured 
depending on their degree of linkage disequilibrium (r2) with rs12438477 
(as estimated internally by LocusZoom on the basis of CEU (Utah residents 
of Northern and Western European ancestry) HapMap). 
 
3.3.3 Results for Test 3: allergy status as a binary  case/control trait, all 
cases 
 
3.3.3.1 Q-Q plot 
As shown in Figure 3.7, there are no significant results for binary allergy status 
and all the SNPs are in the grey area (concentration band). No hits are seen with 
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a P-value of less than 5e-8, and there is no evidence for departure from a global 
null hypothesis.  
 
 
Figure 3.7 Q-Q plot for allergic response as a binary case/control trait.  
The negative logarithm of the observed (y axis) and the expected (x axis) p-
value is plotted for each SNP, and the red line indicates the expected 
distributions under the null hypothesis. The grey shaded region represents 
the 95% concentration band. There is no genomic inflation in lower end, 









3.3.3.2 Manhattan plot 
As Figure 3.8 shows, the Manhattan plot of GWAS analysis on binary allergy 




Figure 3.8 Manhattan plot of allergic response as a binary case/control 
trait.  
The x-axis shows the chromosomal position and the y-axis shows the –
log10p additive value. Chromosomes are shown in alternate colours. The 
red horizontal line indicates a threshold of genome-wide significance at a 
p-value of p<5e-8. Each dot represents a p-value for the SNP association 
test of the 211 case participants and 473 healthy control subjects.  
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3.3.4 Results for Test 4: allergy status as a binary case/control trait, 
short time delay cases only 
3.3.4.1 Q-Q plot 
As shown in Figure 3.9, there are no significant results for allergic response as a 
binary case/control trait (immediate + semi-delayed cases only) and all the SNPs 
are in the grey area (concentration band). No hits are seen with a p-value of less 




Figure 3.9 Q-Q plot for allergic response as a binary case/control trait 
(immediate + semi-delayed cases only).  
The negative logarithm of the observed (y axis) and the expected (x axis) p-
values are plotted for each SNP, and the red line indicates the expected 
distribution under the global null hypothesis. The grey shaded region 
represents the 95% concentration band. There is no genomic inflation in 







3.3.4.2 Manhattan plot 
As Figure 3.10 shows, the Manhattan plot of GWAS analysis on binary allergy 
status (short time-delay only) confirms that there are no significant hits with a p-
value of p<5e-8. 
 
 
Figure 3.10 Manhattan plot of allergic response as a binary case/control 
trait on immediate and semi-delayed cases.  
The x-axis shows the chromosomal position and the y-axis shows the –
log10 p-value. Chromosomes are shown in alternate colours. The red 
horizontal line indicates a threshold of genome-wide significance at a p-
value of p<5e-8. Each dot represents a p-value for the SNP association test 










3.3.5 Checking the results of the previous studies in the clinical GWAS  
We checked our result with the result of previously published studies. Table 3.4, 
shows that previously published results was not replicated in our TwinsUK 
study. 
 
Table 3.4 Comparison of previously published finding within our data. 





HLA-DRA rs7192 6 32519624 NO 
Replicated in IP in 2014 
Immunochip study (Gueant et 
al., 2015) 
C5 rs17612 9 1222765747 NO 
Replicated in IP in 2014 
Immunochip study (Gueant et 
al., 2015) 
ZNF300 rs4958427 5 150258780 NO 
Replicated in IP in 2014 




rs7754768 6 32528157 NO 
Discovery hit in 2014 
Immunochip study, but not 
genotyped in replication phase 
(Gueant et al., 2015) 
HLA-DRA / 
HLA-DRB5 
rs9268832 6 32535767 NO 
Candidate in candidate gene 





6 32521437 NO 
Candidate in candidate gene 
study (Gueant et al., 2015) 
HLA-DRA / 
HLA-DRB5 
rs2213586 6 32521072 NO 
Candidate in candidate gene 





6 32521128 NO 
Candidate in candidate gene 
study (Gueant et al., 2015) 
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HLA-DRA Rs7195 6 32520517 NO 
Candidate in candidate gene 









Replicated in IP in 2014 
Immunochip study (Gueant et 
al., 2015) 
NOD2 rs2066845 - - NO 
Candidate in candidate gene 
study 
NOD1 rs2907749 - - NS 
Candidate in candidate gene 




5 - NO 





- - NO 
(Gueant-Rodriguez et 



















- - NO (Cornejo-Garcia et al., 2012) 
STAT6 Candidate 
 gene 




- - NO 
(Ming et al., 2011) 
 
Table showing the comparison of previously published findings within our data. All 
the significant SNPs and candidate genes in previous beta-lactam allergy studies have 
been checked for replication in all our scans (all-cases clinical-cases scan, amoxicillin-








As reviewed in Chapter 1, beta-lactam allergic response is an important health 
risk. Furthermore, incorrect labeling of patients as “allergic responders” 
contributes to greater use of second-line antibiotics, accelerating the evolution of 
bacterial resistance to these antibiotics. There is currently no comprehensive 
understanding of the relative importance of genetic and/or environmental 
factors that are associated with the elevated risk of allergic reactions to beta-
lactam antibiotics (Mirakian et al., 2015). 
Previously published case/control genetic association studies on beta-lactam 
allergy have been reviewed in Chapter 1. Nearly all case/control studies on beta-
lactam allergies that were conducted on cases with a history of IgE mediated 
reactions (immediate reaction) were supported with clinical diagnoses (either 
Skin test, specific serum IgE or provocation test). However, patients with self-
reported allergic reaction are still a big concern for our health care system due to 
the fact that they are not prescribed first-line antibiotics.  
As discussed in chapter 2, heritability estimates provide positive evidence of a 
genetic component in beta-lactam allergy. Nevertheless, a phenotype derived 
from a self-assessed postal questionnaire cannot be considered as reliable as a 
clinical phenotype, and this remains the most important limitation to the 
TwinsUK GWAS. The fact that these heritability estimates improved (and became 
significant) when more carefully-defined phenotypes were used from the second 
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questionnaire (new specific beta-lactam allergy questionnaire) demonstrate the 
benefit of better phenotype definition. 
I aimed to evaluate novel risk factors for beta-lactam allergy, especially short-
term reactions. I used the self-reported beta-lactam allergy data from the adult 
TwinsUK cohort to carry out a genome-wide association study (GWAS) to 
identify common variants associated with variability to beta-lactam allergy 
among the allergic and non-allergic twins. The TwinsUK cohort consists of over 
12000 volunteer twins. The cohort has been extensively molecularly 
characterized, including genome-wide genotyping and small molecule metabolic 
profiling via mass spectrometry. Using a custom designed questionnaire (see 
chapter 2), we defined more precise phenotypes; (1) seriousness of the beta-
lactam allergy response and (2) type of reaction (time delay of response). 
In the first GWAS scan (Test 1) we treated severity as a quantitative trait, and we 
used all cases regardless of time delays for their allergy status. This gave us an 
advantage of having more cases, which we hoped would increase the power of 
the GWAS. As previously outlined, all types of allergic reactions have a 
commonality in their biological pathways.  Thus, combining all types of allergic 
reaction could also increase the power of the study, and any significant hits 
would in principle be those belonging to the common pathway.  
This GWAS scan succeeded in providing a genetic hit in the MTHFS/BCL2A1 
region that should be followed up in future studies, particularly in light of the 
role in immune function played by BCL2A1, which is a direct transcription target 
of NF-kappa-B in response to inflammatory mediators. MTHFS also has an 
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important role in inflammatory responses as it is involved in folate synthesis and 
is expressed in T-cells (Vajtr et al., 2014). Likewise, BCL2A1 has a significant 
function as it is involved in apoptosis and is directly regulated by NF-kappa-B in 
response to inflammatory mediators (Vogler, 2012). 
The other GWAS scans (Tests 2-4) did not produce any significant results.  In the 
case of Tests 2 and 4, this is likely due to the very small number of cases 
available when restricting to immediate+semi-delayed cases only (n=57).  In the 
case of the binary case/control scan on all cases (Test 3), this is likely due to the 
reduction in power induced by removing the quantitative information on 
response seriousness from the test. 
 
3.4.1 Strength and limitations of our GWAS scans 
Here I discuss some of the strength and limitations of our GWAS scans, in light of 
the positive result that we obtained for Test 1. 
Limitations include: (1) small case sample size (reduces power); (2) self-
reported data via questionnaire (in chapter 2, I discussed limitations and bias 
related to data collection using the self-reported questionnaire); (3) recall bias as 
there were a large number of elderly participants in the cohort who may have 
found it difficult to recall the original reaction; (4) co-twin report bias (twins are 
more likely to report themselves as having a trait if one of the co-twins has been 
diagnosed with a trait); (5) heterogeneity in the phenotype (combining cases 
with all types of reactions (all time delays), could possibly introduce 
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heterogeneity as a result of having different biological pathways amongst our 
cases); (6)  misclassification of cases (it is possible that patients are misclassified 
with respect to penicillin allergy- it is known that the majority of patients who 
consider themselves to be allergic to beta-lactam are not); (7) lack of power 
calculation (we did not run a power calculation for TwinsUK GWAS, due to 
complications on power calculations in a mixed-model analysis and a lack of 
easy-to-use software).  
Strengths include: (1) use of super-controls (not allergic to anything); (2) 
diagnostic status for many cases (although we identified our case group based on 
self-reported questionnaire, 181(85.7%) of them were reported as being 
diagnosed by a doctor); (3) case/control selection from the same cohort (reduces 
possibility for bias); (4) minimised the batch effect (DNA collection and 
genotyping were done in the same facilities).  
As previously explained, many factors such as small sample size, batch effects 
and self-reported data are limitations of this study. Taking into account the small 
case sample size in our study and self-reported data, as a final step, we decided 
to check all the positive findings in the previously published studies and see if we 
could replicate those results, even if there was only a weaker (non-genome-
wide-significant) signal in our study. However as shown in Table 3.4, previously 
published results was not replicated in our TwinsUK study. As previously 
discussed, most of the previous published GWAS studies have used a single locus 
analysis strategy. The locus containing our positive hit has not been assessed in 
previous candidate gene studies.  
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To conclude, the best result from the TwinsUK GWAS scan was the single hit at 
the MTHFS locus, which achieved genome-wide significance (p,5e-8). Knowing 
all the biases of self-reported data, and different biological pathways for 
immediate and delayed beta-lactam related allergic reaction, the question of 
whether this GWAS hit could be a false positive or not still remains. Below I list 
some supporting evidence to support the case that the signal from TwinsUK 
GWAS scan is not a false positive; 
1. The local association plot looks good, with the lead SNP “supported” by 
several nearby SNPs in high LD (see Results section). 
2. The p-value for the lead SNP is genome-wide significant, meaning that 
generating this signal by chance would be very unlikely unless there was 
some systematic bias at work here (see Results section). 
3. The QQ plot shows no evidence of genomic inflation, suggesting there is 
no systematic bias in the data. 
4. Systematic bias is unlikely.  The genotype of this lead SNP would have 
been unknown to the person responding to the questionnaire.  It is 
therefore hard to conceive a mechanism whereby the genotype influenced 
the person’s response on the questionnaire, unless it was because that the 
genotype genuinely influences the outcome.   
This was perhaps the most promising single result from this thesis, but until it 
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Among a wide variety of antimicrobial drugs, beta-lactams are the most 
frequently prescribed antibiotics by clinicians, and the allergic reactions to these 
antibiotics are a major factor limiting their use (Mirakian et al., 2015). As 
discussed in chapter 1, genome-wide association studies have identified several 
risk loci associated to beta-lactam allergic reaction. However, many of these 
signals have yet to be confirmed in large, well-powered studies and the 
underlying biological processes are still largely unknown.  
The recent ongoing revolution in “omics” technologies, such as transcriptomics 
and metabolomics, has enabled the deeper study of complex traits and is 
expected to provide more detail on affected pathways and more directly related 
information on the aetiology of the complex traits (Ma and Lu, 2011). The term 
“metabolomics” was first introduced in 2001 as a comprehensive and 
quantitative analysis of all metabolites in a biologic system (cell or body fluid) 
(Petersen et al., 2014).  
 
4.1.1 Metabolites  
Metabolites are known as products of enzyme-catalysed reactions, which take 
place naturally within all cells (Nicholson and Lindon, 2008). In other words 
metabolites are small-molecular-weight substances existing in all tissues and 
body fluids such as plasma, lymph, serum, urine, bile and sweat. Nuclear 
Magnetic Resonance Spectroscopy (NMR), Mass Spectrometry (MS) and Fourier 
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Transform Infra-Red Spectroscopy are the main metabolite measurement 
techniques used in metabolomic studies (Nicholson et al., 2002). 
There are certain criteria which any compound meet before it can be classified as 
a metabolite (Nicholson and Wilson, 2003); 
• Metabolites are compounds found inside cells 
• Metabolites are recognized and acted upon by enzymes 
• The product of a metabolite must be able to enter into a subsequent 
reaction 
• Metabolites have a finite half-life, and they do not accumulate in cells 
• Metabolites must serve some useful biological function in the cell 
 
Investigation of the metabolic profile of humans provides useful information on 
both influential genetic factors and non-genetic factors such as dietary, lifestyle, 
age, nutrition habits, smoking and alcohol consumption, physical activity and 
environmental exposures (Nicholson and Wilson, 2003, Kastenmuller et al., 
2015). The analysis of this information is expected to provide a new field of 
novel discoveries and understanding of all biological pathways (Nicholson and 
Wilson, 2003). Genetic factors usually cause a permanent change in protein 
function whereas environmental and physiological factors cause a more 
temporary impact on body metabolites (Ma and Lu, 2011). The effect of non-
genetic factors on metabolite levels often reverts to a baseline state after the 
factors are removed (Kastenmuller et al., 2015). 
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At the molecular level, any genetic variations in the coding or regulatory regions 
of a gene can affect the structural or functional change of the target protein or its 
expression level; all of which can cause changes in metabolite levels. 
Furthermore, genetic polymorphisms in drug metabolizing enzymes and 
transporters can lead to changes in pharmacokinetics (Kastenmuller et al., 
2015). As discussed previously, our understanding of the allergic reaction to 
beta-lactam antibiotics remains incomplete. 
 
4.1.2 Beta-lactam metabolites and MWAS 
As I described in chapter 1, hypersensitivity reactions to beta-lactams are due to 
different degradation products produced in vivo when the antibiotic is 
administered. Allergic reactions mainly involve ring-opened penicilloic acid 
molecules which bind covalently to proteins (Mirakian et al., 2015). To better 
understanding of beta-lactam metabolite formation in the human body, it is 
necessary to review the chemical structure of these antibacterial drug families 
once more.   
As explained in more detail in chapter 1, all beta-lactam antibiotics contain a 
beta-lactam ring in their molecular structure (Pichler et al., 2011). Overall, the 
chemical structure of all beta-lactam families is similar and the distinction 
among them is based on the nature of the attached side-chain. After the 
administration of penicillin, the beta-lactam ring opens during nucleophilic 
attack, which results in the formation of penicilloyl metabolites (Solensky, 2003, 
Rosario and Grumach, 2006).  
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These metabolites are relatively small molecules and they cannot induce any 
immune response unless they are covalently bound to a protein (Mirakian et al., 
2015). The covalent binding of these small metabolites to tissue macromolecules 
(proteins) generates the hapten-protein complex, which induces immune 
response. In IgE mediated beta-lactam allergic reactions, the presence of the 
hapten-protein complex is necessary for the formation of the complex antigenic 
determinant (Suhre et al., 2011). 
In metabolomic genome-wide association studies (mGWAS), metabolite 
quantitative trait loci (mQTLs) are identified by associating SNPs with 
metabolite levels (Kastenmuller et al., 2015). In contrast, a metabolome-wide 
association study (MWAS) seeks to associate metabolite levels with a high-level 
trait of interest. For example, a recent MWAS of asthma showed that the 
metabolites from several pathways could distinguish asthmatic cases from 
controls, and also severe asthmatic cases from non-severe asthmatic cases (Singh 
et al., 2013).  
In chapter 3, we described a significant hit associated with self-reported beta-
lactam allergy in the Twins UK cohort. In view of the availability of metabolomic 
data for the same cohort, we decided to run a hypothesis-free non-targeted 
MWAS scan to identify new biomarkers or a metabolomic pathway associated 
with the GWAS signal.   
Metabolites sampled from an individual years after a reported allergy attack are 
of interest for two reasons: (1) genetic differences affecting allergy risk are a life-
long effect (genotypes never change), and may manifest themselves permanently 
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in different metabolite levels; (2) some allergic responses (delayed reactions) 
are long-lasting (e.g. changes to certain immune cell populations), and these may 
also manifest themselves in long-term differences in metabolite levels. 
 
4.2 Materials and Methods 
 
4.2.1  Case and control selection 
In chapter 3, we identified a number of 211 self-reported beta-lactam allergy 
cases from the TwinsUK allergy-response data. Metabolomic data were in 
principle available for all our selected cases. A total number of 1023 non-allergic 
individuals with available metabolomic data were identified as controls. A total 
of 1234 individuals were investigated in this metabolome-wide association study 
(for more details please see chapter 3).  
As previously mentioned, the case and control selection for this study was 
exactly the same as case/control selection for the GWAS study (chapter 3), but 
when we checked for data availability for the same case/control group, 
unfortunately MWAS data were not available for all individuals. This explains the 
difference in the number of cases and controls for the GWAS and MWAS studies.   
 
4.2.2 Phenotype definition (seriousness and time delay) 
Phenotype definitions are as described in Chapter 3 (please see section 3.2.3).  
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4.2.3 Metabolomic profiling and measurement 
The Metabolon data in the TwinsUK registry consists of metabolomic data for 
6055 twins, and these data are available for 510 different metabolites in total 
(Suhre et al., 2011). Metabolic profiling was done on fasting serum, by using non-
targeted gas chromatography-mass spectrometry (GC-MS) and liquid 
chromatography-mass spectrometry (LC-MS) (Suhre et al., 2011).  
TwinsUK blood samples were collected after at least 6 hours of fasting. After 
keeping samples at 4°C for 40 minutes, samples were centrifuged for 10 minutes 
at 2,000g. After the centrifuging process, serum was removed from the 
centrifuged tubes. Four aliquots of 1.5 ml were placed into skirted micro-
centrifuge tubes and stored at -45°C until sampling (Illig et al., 2010).  
Metabolon data were collected over 173 days (35 measurements per day). As 
shown in Table 4.1, Metabolon data were divided into three batches; batch 1 
(serum samples), batch 2 (plasma samples) and batch 3 (plasma samples) (Suhre 
et al., 2011). Batch 1 consists of 280 known and 219 unknown metabolites 
obtained from 1052 twin serum samples. Batches 2 and 3 represent additional 
data obtained from 5004 twin plasma samples (Table 4.1) (Suhre et al., 2011). 
For more details of the metabolites measured by the Metabolon platform please 




Table 4.1 Summary of the TwinsUK Metabolon data. Based on information 
from (Suhre et al., 2011) 
The TwinsUK Metabolon data were divided into three batches. Batch 1 
consists of 280 known and 219 unknown metabolites. There are 281 
known and 175 unknown metabolites for batches 2 and 3. 
 
 
All metabolites in both cases and controls were residual-corrected for age and 
BMI. We only looked at metabolites which were measured in more than 500 
individuals (non-missing values in >500 of the total set of the individuals). 
4.2.4 Summary of MWAS scans of the TwinsUK Metabolon data. 
Motivation  
In this chapter we performed 19 different MWAS scans on our cases and 
controls, all testing for metabolomic differences between levels of seriousness in 
allergic reaction and/or differences between allergic and non-allergic cases. 
Table 4.2 summarises all 19 MWAS tests, including the phenotype, the model 
type used and the case/control selection for each test. We treated the phenotype 
for tests 1, 5, 6, 12, 13, 14, 15 and 19 as an ordinal trait (ordinal logistic 
regression applied). The phenotype for test 3 was treated as a quantitative trait 
 
Batch 
Batch1 (serum) Batch2 (Plasma) Batch3 (Plasma) 
 
N known metabolites 
 









499 456 456 
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(linear mixed model applied), and the phenotype for tests 2, 4, 7, 8, 9, 10, 11, 16, 
17 and 18 as a binary case/control trait (logistic regression applied).  
 

















































































































































































































































































































































































































































































































































Ordered logistic regression 
Many variables of interest such as diseases are ordinal and graded on a scale e.g. 
from least severe to most severe. When one can rank the values but the real 
distance between categories is unknown, then ordered logistic regression model 
is appropriate for the trait (Morris et al., 2010). In this case, we applied the 
model to allergy seriousness as an ordinal trait.  In order to account for the 
family-based genetic structure in the twins data, we fitted ordered logistic 
regression models in the program STATA using the ologit function with a 
clustered error structure defined by the cluster() option within each family.  
Logistic regression (singletons only) 
In order to investigate the causes of inflation in the result of test 1, we applied 
logistic regression to beta-lactam allergy as a binary case-control trait restricted 
to immediate+semi-delayed cases, and using singleton twins only in order to 
remove twin correlation structure by using the glm() function in R.  
Linear mixed model  
The aim of test 3 was to examine whether the inflation in test results seen in the 
QQ plots was the result of the differences between the cases and controls or was 
due to some other bias. By removing the control group and only using singletons, 
we tried to investigate whether the inflation still appeared in our results or not. 
We used the EMMA software to run linear mixed models, recalculating the 
covariance matrix excluding the index metabolite (metabolite of interest) each 
time. The EMMA software is a statistical test available in the R package and is 
 140 
suitable for mixed models analysis and correlation structure correction (Zhou 
and Stephens, 2012).  
 
4.2.5 Post-association analysis 
QQ-plot 
As a post-association analysis of our MWAS scan, we created QQ plots. The 
quantile-quantile plot (QQ plot) is a graphical tool that compares the distribution 
of observed negative log p-values versus expected negative log p-values under 
the global null hypothesis (Ehret, 2010). This plot helps to indicate whether the 
study has achieved more significant results than expected under a global null 
hypothesis (for more information on the Q-Q plot please see chapter 3).  The QQ 
plot also serves as a useful way to control for multiple tests within a single 
MWAS scan, as results are compared to a global null hypothesis across all within-
MWAS tests.  QQ plots do not control for multiple tests across all the different 
MWAS scans conducted in this chapter, so here it is important to appreciate that 
(1) all results presented in this chapter are preliminary; and (2) if equivalent 
results are seen across multiple MWAS scans, then these are unlikely to have 






4.3.1 Correlation structure of the metabolite data 
In order to have a better understanding of the Metabolon data, we visualised 
correlation among the metabolite data by using a Heat-Map. A Heat-Map is a 
graphical tool to represent the correlation between individual/metabolites 
(Sugimoto et al., 2012). High correlation between individual/metabolites was 
represented as light yellow and low correlation between individual/metabolites 





Figure 4.1 Heat-Map representation of the correlation structure of the 
metabolite data.  
Heat-Map shows the correlation across individuals in metabolite levels 
(yellow = high correlation, red = low correlation). There is limited 
between-individual structure in these data, despite the high degree of 




4.3.2 Results for MWAS scans   
Table 4.3 summarises the results of all 19 MWAS scans. As explained in the table 
below, there is an overall inflation in all Q-Q plots. The results for tests 1, 2, 3, 13 
and 14 are explained in more detail in the next section. For Q-Q plots 
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summarizing the results of tests 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 16, 17, 18 and 19 
please see Appendix I.  
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Overall metabolomic inflation 
in the Q-Q plot 
 
 
4.3.2.1 Results for Test 1: MWAS scan using ordered logistic regression 
test on all cases and controls, treating seriousness as an ordinal 
trait 
Q-Q plot and top hits 
Figure 4.2 is the Q-Q plot of test 1 (seriousness treated as an ordinal trait). As 
shown in Figure 4.2 all metabolites are responding together as a correlated 
system. There is an overall metabolomic inflation in the lower end of the plot, 
and in the upper end of the plot there are 4 distinct hits lying outside the 95% 
concentration band of the QQ plot, which can therefore be described as 
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“metabolome-wide significant” following within-scan multiple test correction. As 
we found considerable inflation in our first test results we applied additional 
tests, as described in subsequent sub-sections, to investigate the source of this 
inflation.  
 
Figure 4.2 Q-Q plot for MWAS scan using ordered logistic regression on all 
cases and controls, treating seriousness as an ordinal trait.  
The negative logarithms of the observed (y axis) and the expected 
(x axis) ordered p-values are plotted for each metabolite, and the red line 
indicates the expected distributions under the null hypothesis. The grey 
shaded region represents the 95% concentration band.  
 
 












































Table 4.4 describes the top 4 hits for the Test 1 MWAS scan (clearly separated 
and lying outside the 95% concentration band of the QQ plot). We identified 
these metabolites by using the annotation file for the TwinsUK metabolite data. 
The annotation file for the metabolites consists of all known and unknown 
metabolites in the TwinsUK Metabolon data.  
 
Table 4.4 Top hits for the MWAS scan using ordered logistic regression on 

































4-vinylphenol sulfate+/xenobiotics/Benzoate metabolism 
* Piperine is the main alkaloid from black pepper 
^ Xenobiotics indicates a foreign metabolite found within body 
+ 4-vinylphenol sulfate is a phenolic compound found in wine and beer 
This table shows the top 4 metabolite hits associated with beta-lactam 
allergic reaction in the TwinsUK MWAS scan. The first two metabolites are 




As shown in Table 4.4, there are two known and two unknown metabolite hits. 
The known metabolites are both categorised as being xenobiotics, meaning that 
they are foreign chemical substances that are not naturally produced in the body. 
Therefore, our results suggest that people who had penicillin allergy had less 
piperine in their system in comparison with our control group. Also people who 
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had experienced penicillin allergy had higher amounts of 4-vinylphenol-sulfate 
metabolite, compared to our control group. 4-vinylphenol-sulfate is a phenolic 
compound found in wine and beer.  
Overall, the two known significant metabolites are categorized as being 
xenobiotics, which means that they are not the result of any gene expression 
related to beta-lactam allergic reactions. These metabolites are therefore not 
directly linked to any related gene. Further investigation is required to 
determine the function of the unknown metabolites.  
 
4.3.2.2 Results for Test 2: logistic regression on allergic reaction as a 
binary case/control trait (singleton twins only) 
Q-Q plot 
Figure 4.3 is the Q-Q plot for allergic reaction as a binary case/control trait 
(immediate/semi-delayed cases singleton twins only). The result also shows an 
overall inflation in the test results. As I explained in the methods section, we 
used singleton data in this test to ensure that the inflation was not due to the use 
of genetically-correlated twin data. 
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Figure 4.3 Q-Q plot for logistic regression on allergic reaction as a binary 
case/control trait (immediate/semi-delayed cases singleton twins only). 
 The negative logarithms of the observed (y axis) and the expected 
(x axis) ordered p-values are plotted for each metabolite, and the red line 
indicates the expected distributions under the global null hypothesis. The 
grey shaded region represents the 95% concentration band. This Q-Q plot 
shows the results of an MWAS scan using singletons only, to see if the 
inflation seen in Test 1 is due to presence of twins genetic structure or not. 













































4.3.3 Results for Test 3: MWAS scan, linear regression on seriousness 
as a quantitative trait (singletons only and controls removed) 
Q-Q plot 
The aim of this test was to examine whether the inflation in test results seen in 
the Q-Q plots was the result of the differences between the cases and controls or 
was due to other bias. By removing the control group and only using singletons 
we tried to investigate whether the inflation still appeared in our results or not. 
The Q-Q plot for Test 3 (Figure 4.4) shows no significant hits. After removing the 
control group the inflation is lost in the top end of the Q-Q plot, but it’s still 
present at the bottom end. This may simply indicate that the power is too low to 
detect any hits when controls were removed, but still there is some inflation in 




Figure 4.4 Q-Q plot for linear regression on seriousness as a quantitative 
trait (singletons only and controls removed).  
The negative logarithms of the observed (y axis) and the expected 
(x axis) ordered p-values are plotted for each metabolite, and the red line 
indicates the expected distributions under the null hypothesis. The grey 
shaded region represents the 95% concentration band. This Q-Q plot 
shows the results of an MWAS scan in which singletons and controls are 
removed. Even with no control group there is still some inflation in the 




























































4.3.4 Results for Test 3: MWAS scan, analysis of seriousness of the 
reaction as an ordinal variable (singletons only) 
Q-Q plot 
Apart from Tests 2 and 3, the previous MWAS scans in this chapter were 
conducted on TwinsUK data and corrected for correlation stratification. As 
shown in the results section, there is an overall metabolomic inflation in our Q-Q 
plots. In order to see if this inflation in metabolomic expression is due to some 
family structure, or it is due to the reaction itself, we removed the existing co-
twins from each family. 
By removing the co-twins and just keeping the singletons we treated our data 
with standard regression methods (appropriate for when no twin structure is 
involved). However we applied the same QC methods to our MWAS scan. By 
performing these MWAS scans on singletons and comparing the result to the 
same tests with all the twins’ involvement we were hoping to determine the 
cause of inflation in our results.  
Figure 4.5 is a Q-Q plot for the MWAS scan on seriousness of the reaction on all 
cases and controls. We removed all co-twins, and thus this scan was applied to 
‘singletons’ only. The seriousness of the reaction was analysed as an ordinal 
variable. The results for this test are the same as the results for Test 1. There is 
inflation on the lower end of the Q-Q plot, and the same 4 significant hits are seen 
on the upper end of the plot (see Table 4.4). 
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Figure 4.5 Q-Q plot for seriousness of the reaction as an ordinal variable 
(singletons only).  
The negative logarithms of the observed (y axis) and the expected 
(x axis) ordered p-values are plotted for each metabolite, and the red line 
indicates the expected distributions under the null hypothesis. The grey 
shaded region represents the 95% concentration band. Still there is an 
overall inflation in data. There is inflation in the lower end of the plot, and 




4.3.5 Results for Test 4: MWAS scan, analysis of seriousness of the 
immediate reaction as ordinal variable (singletons only) 
Q-Q plot 
In this MWAS scan we removed all co-twins from the data and we performed a 
metabolome-wide association study on allergic cases with immediate reaction 
and controls. The seriousness of the reaction was treated as an ordinal variable. 
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Figure 4.6 is a Q-Q plot for the MWAS scan on seriousness of the reaction on 
immediate cases and controls. We removed all co-twins, and this scan was 
applied on singletons only. Seriousness of the reaction was analysed as an 
ordinal variable. As shown in Q-Q plot, conducting the same analysis as Test 13, 
just on cases with immediate reaction, we didn’t detect any significant hits, likely 
due to the reduced power in the analysis.  
 
Figure 4.6 Q-Q plot for seriousness of the immediate reaction as an ordinal 
variable (singletons only).  
The negative logarithms of the observed (y axis) and the expected 
(x axis) ordered p-values are plotted for each metabolite, and the red line 
indicates the expected distributions under the null hypothesis. There is 








4.4.1 Previously published metabolomic studies 
Previous studies have identified a few metabolites in human serum that result 
from the breakdown of beta-lactam antibiotics in the biological system. Also, a 
comprehensive study of genetic influences on human metabolism using twins 
data has revealed an atlas of genetic influences on human blood metabolites in 
2014 (Shin et al., 2014). This study was conducted on 7824 adult individuals 
from two European population studies, including 1052 individuals from the 
TwinsUK cohort and 1768 individuals from the KORA (Kooperative 
Gesundheitsforschung in der Region Augsburg) cohort (Shin et al., 2014). They 
investigated 60 different biochemical pathways in their study. In this 
comprehensive metabolomic genome-wide association study, they discovered 84 
new genetic signals affecting metabolic traits. They propose that newly identified 
genetically-influenced metabolites will empower future clinical and 
pharmacological research from better understanding of the genetic 
predisposition to different diseases, and will allow the identification of potential 
new biomarkers for drug targets and causal environmental influences on human 
traits (Shin et al., 2014). 
Here we applied a hypothesis-free metabolome-wide association approach 
analysing >500 metabolites in the serum sample of 1234 individuals from the 
TwinsUK cohort.  
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4.4.2 MWAS scan on the TwinsUK cohort 
In total we ran 19 MWAS scans; each time applying a different phenotype 
(allergy status variables) on all twins, or the same phenotype on singletons 
(twins without their co-twin) or on subsets of the case/control data (e.g. short 
time delay cases only). The aim of applying various MWAS scans was to see if 
there are any metabolomic differences between different types of beta-lactam 
allergy status or not. Out of 19 MWAS scans, 3 of them provided significant hits 
(defined as clearly separated hits lying outside the 95% concentration band of 
the QQ plot).  Here I am going to briefly review the results of the key analyses in 
this chapter.   
As a first test in this chapter, we ran an MWAS scan on all 211 allergic cases and 
1023 controls. In this test we treated the seriousness of the beta-lactam allergic 
reaction as an ordinal variable. The result of Test 1 shows that there is a 
systematic inflation in the data (Figure 4.2). This test also identified 4 significant 
metabolite hits (Table 4.4). The first two metabolite hits are of unknown 
chemical structure, which means that we don’t have any information regarding 
whether they are xenobiotics or protein by-products. The two known 
metabolites are piperine and 4-vinylphenol sulfate. Both the known metabolites 
are xenobiotics. At this stage, before any further investigation on the nature of 
the known metabolites, we ran more tests in order to explore the systematic 
inflation shown in the Q-Q plot (Figure 4.2).  
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As the TwinsUK data was used in this chapter, we suspected that the inflation 
might be due to the high level of relatedness in our data. Therefore, we ran 
another MWAS scan just on singletons (twins without their co-twin) in our data. 
Test 2 was a logistic regression test on seriousness of the reaction, and in this 
test we analysed allergic reaction as a binary case/control trait 
(immediate/semi-delayed cases versus controls, singleton twins only). The test 
results show that the pattern of metabolomic differences still exists between our 
cases and controls, and thus it was not just due to the genetic relatedness 
between twins. Therefore we decided to run another scan to examine whether 
the inflation was the result of the metabolomic differences between allergic cases 
and controls or was due to some other bias.  
Test 3 was a linear regression test on seriousness of the allergic reaction to beta-
lactam antibiotics. In this test we analysed seriousness of the reaction as a 
quantitative trait. In this scan, not only did we remove all co-twins (singletons 
only), but we also removed all controls to allow us to focus on within-case 
contrasts.  
There was still inflation in the results from Test 2, and Test 3. The inflation was 
reduced, but even when all controls were removed we still saw inflation in the 
data.  One of the possible explanations for this systemic inflation is that all 
metabolites biologically respond to allergy in some correlated way; in other 
words, allergy can affect the whole biological system. Another possible 
explanation is due to batch effects as this could also affect all metabolite 
measurements in the same way. 
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Table 4.3 summarises all 19 MWAS scans conducted in this chapter. As I 
discussed in the results section, Test 1, Test 13, and Test 16 generated significant 
hits. The results were the same for all 3 tests, identifying the same set of two 
unknown hits and two known hits. Within-scan correction for multiple testing 
was performed via the application of a 95% concentration band analysis to the 
QQ plots. Hits lying outside this band indicate significant departure from the 
global null hypothesis. Hits were not corrected for between-scan multiplicity (i.e. 
the application of 19 separate scans), but the fact that the same set of 4 hits was 
returned in each case indicates that these scans were not independent, but 
rather were variations on the same theme and that in effect the same results 
were returned for each scan.  
The results indicate that people who had a beta-lactam allergic reaction had less 
piperine in comparison to the control group. On the other hand, people who 
experienced beta-lactam allergic reaction appeared to have higher amounts of 4-
vinylphenol sulfate metabolite in comparison to the control group. The other 16 
MWAS test results were negative most probably due to the reduced number of 
cases and controls (and hence the power of the study was not enough to detect 
any positive results). There is an overall inflation in most test results, and thus 
metabolites appear to act as a correlated system to beta-lactam allergy. 
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4.4.3 Strength and limitations of MWAS on the TwinsUK beta-lactam 
allergy data 
Here I discuss some of the strengths and limitations of the MWAS scans as 
performed in this chapter, which may have contributed to the results that we 
obtained.  
Limitations of the study included: (1) a small sample size, which negatively 
impacts the power of a study; (2) self-reported data via questionnaire (see 
chapter 2 for a discussion of limitations and bias related to data collection using 
the self-reported questionnaire; (3) recall bias for example due to the fact that 
there were a large number of elderly participants in the cohort who may have 
found it difficult to recall the original reaction; (4) twin report bias, for example 
due to twins being more likely to report themselves as having a trait if their co-
twin had also been diagnosed with a trait (but note  this bias would only affect 
the scans involving co-twins); (5) heterogeneity in the phenotype, for example 
due to combining of cases with all type of reactions (all time delays), which could 
introduce heterogeneity as a result of having different biological pathways 
amongst our cases; (6) misclassification of cases with respect to penicillin allergy 
(It is known that the majority of patients who consider themselves to be allergic 
to beta-lactam are not); (7) unknown metabolites (two top hits of the study are 
not characterised yet, limiting biological interpretation); (8) metabolite 
measurement (the TwinsUK metabolites were typically measured a long time 
after the beta-lactam allergy reaction, often  years later); (9) power calculation 
(we did not run a power calculation for the TwinsUK MWAS, due to the 
complications on power calculations in the context of a mixed-model analysis).  
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Strengths of the study included: (1) the use of super controls (who reported not 
being allergic to anything at all); (2) diagnostic status for most cases (although 
we identified our case group based on self-reported questionnaire, 181(85.7%) 
of them were reported as being diagnosed by a doctor (see chapter 3)); (3) case 
and control selection from the same cohort (helps to minimize potential biases); 
(4) minimised technical batch effects (metabolite collection and measurement 
were done in the same facilities and thus the test results are less likely to be 
affected by possible batch effects). 
 
4.4.4 Assessment of the known metabolite hits  
As previously explained, many factors such as small sample size, unknown 
metabolites, time interval between reaction time and metabolite measurement, 
batch effects and self-reported data are limitations of this study. Furthermore, 
we were not able to establish any biological relationships between the two 
known metabolite hits and beta-lactam allergic pathways.  
Taking into account the small case sample size in our study and self-reported 
data, as a final step, I decided to check all the positive findings in previously 
published studies to see if they reported the same metabolites being associated 
with any traits.  
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Although the two known significant metabolites were identified as being 
xenobiotics, an epigenome-wide association study (EWAS) between DNA 
methylation and metabolic traits (metabotypes) in human blood, conducted in 
2013, identified 4-vinylphenol sulfate metabolite as being associated with CpG 
loci (Petersen et al., 2014). The study was conducted on 1814 participants from 
the KORA cohort. They measured 649 blood metabolites and looked for 
association with methylation at 457004 CpG sites. The study suggested that 
variability in 4-vinylphenol sulfate is more under environmental control than it 
is under genetic control (Petersen et al., 2014).  
Knowing all the biases of self-reported data, and different biological pathways 
for immediate and delayed beta-lactam related allergic reaction, the question of 
whether this MWAS hit could be a false positive or not still remains. Below I 
compare two alternative interpretations of our findings.  
The hit is a false positive 
The main finding of our TwinsUK MWAS results is that there is a systemic pan-
metabolite reaction to beta-lactam allergy status. Under this interpretation one 
could argue that the significant hits found in the MWAS scans were just down to 
chance, and that these findings would not be replicated in other cohorts. In other 
words, the results that happened to float to the top in terms of strength of 
association, 4-vinylphenol sulfate included, should not be given too much weight, 
as these metabolites happened by chance to appear at the top end of a list that 
was subject to considerable inflation in test statistics.  
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The hit is a true positive 
Alternatively, we can also consider that there is a possibility that 4-vinylphenol 
sulfate is a genuinely strong signal that would be replicated if the study were 
repeated. Under this interpretation, and taking account of reports of a previously 
published epigenome-wide association signal involving 4-vinylphenol sulfate 
(Petersen et al., 2014), then our MWAS result could also have a non-genetic 
mechanism. In this context, having a beta-lactam allergic reaction could be 
interpreted as an "environmental shock" which altered the metabolome in some 
semi-permanent way (i.e. in a way that could still be detected years later, when 
the serum samples were taken). 4-vinylphenol sulfate would then be a marker 
for that environmental effect.  
Follow-up studies 
The MWAS approach is relatively new and open to improvement. In the case of 
our TwinsUK MWAS scan on beta-lactam allergic cases, we can propose a list of 
suggestions to improve future studies: 
• Better phenotyped data 
Clinically proven and tested cases will improve the power of the study 
and will give more confidence in interpretation of the signals detected.  
 
• Better knowledge of the metabolites 
Having more known metabolites and knowledge of their biological 
pathways will also improve the interpretation of future MWAS scans. 
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• More sensitive metabolite measurements; 
Having more sensitive metabolite measurement tools will increase the 
number of measured metabolites and decrease the potential influence of 
batch effects and other measurement related bias. 
 
• Sample collection 
Collecting samples from different tissues will help to detect more 
metabolites in tissue-specific contexts. 
 
• Time of sample collecting 
Collecting the samples right after the allergic reaction will help to detect 
more accurately the relevant metabolites responding in the short term to 
the reaction. 
Finally, we note that the two unknown metabolite hits are not identified yet. 
Therefore part of the interpretation of this chapter depends on the identification 
of these two unknown metabolites in the future.  Also future studies are required 
to validate the existence of systematic metabolomic differences between allergic 
























5.1  Introduction  
Results from a number of candidate gene studies including an Immunochip study 
on a large number of immune-related genes so far suggests that genetic 
variability in the genes which encode for important immunological markers of an 
allergic response may play a role in the susceptibility to immediate allergy to 
beta-lactam antibiotics (see Chapter 1). These include tumour necrosis factor-α 
(TNF-α), Inteleukin-4 (IL-4), IL-4 receptor (IL-4R), IL-10, and IL-13 (Gueant et 
al., 2014, Oussalah et al., 2016).  
In Chapter 3, I performed a genome-wide association study (GWAS) on self-
reported TwinsUK data. The genome-wide scan yielded a single strong signal in 
chromosome 15. The dataset that was used in chapter 3 was quite large; 
however it was based on a self-reported phenotype (for further information 
please see chapter 3). 
To complement the results of the twins GWAS, I conducted a separate GWAS (i.e. 
I ran these GWASs in parallel, not one after the other) on beta-lactam allergy 
using a different clinically-defined cohort. By running another GWAS on the same 
phenotype but different cohort, I aimed to replicate the results from chapter 3.  
In this study, cases were recruited from the Guy’s allergy clinic. The GWAS study 
was restricted to 50 cases who were identified as being truly allergic to beta-
lactams. Power plays a significant role in GWAS studies, and most successful 
GWASs have required larger sample sizes (Daly, 2010a). However, there have 
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been pharmacogenetics GWAS studies showing a contribution of genetic variants 
in drug response, even with a very small sample size, which suggests that effect 
size of pharmacogenetic traits may be bigger than for other complex traits. For 
example, a study conducted in 2008 found that a common variant in SLCO1B1 
was strongly associated with an increased risk of stain-induced myopathy by just 
using 85 cases and 90 controls (for more detail please see chapter 1) (Link et al., 
2008). . 
In the TwinsUK GWAS, we had a larger sample size in comparison to our clinical 
sample, but it was thought that by having a clinically well-defined phenotype and 
increasing our control size we could to some extent overcome the power issue in 
our GWAS study. I ran a GWAS scan on all cases using the assumption that there 
are shared genetic loci involved in allergic response to beta lactams, regardless 
of which specific beta lactam is administered.  In order to look for any genetic 
effects that might be specific to this particular beta-lactam I ran another GWAS 
scan just on cases with amoxicillin allergy  (‘’amoxicillin-only’’)  
5.2 Material and Methods 
5.2.1 Ethics approval 
Ethics approval for the study, including permission to contact the patients, was 
given by the NRES (National Research Ethics Service) formerly St. Thomas’ 
Ethics Committee (reference 11/LO/0112) (See Appendix J).  
During the recruitment process, written consent was obtained from participants 
for the use of information in medical studies (see Appendix K). During the same 
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process, patients were provided with a patient information leaflet, which 
contained information about the study and the use of their genetic data (see 
Appendix L). A health questionnaire was another document provided at the time 
of the recruitment, which contained a series of question regarding their current 
health status and any other existing health problems (see Appendix M). 
5.2.2 Phenotype definition 
In my study, the medical condition being investigated is immediate allergy to 
beta-lactam antibiotics. For better selection of our cases it is essential to know 
the specific phenotypic characteristics of the condition. For retrospective 
recruitment, it is also essential to know the data source and all distinguishing 
criteria.  
The Guy’s allergy clinic is the only beta-lactam allergy clinic in the southern UK.  
The patient records contain all available medical records such as GP’s referral 
letters, history of all medical conditions, and treatments given.  GP’s referral 
letters to the allergy clinic typically contain: 
(1) The history of allergy with all symptoms; 
(2) Name of medication given; 
(3) A request for clinical evaluation of drug allergy.  
After evaluation, the consultant produces a letter, which contains information on 
the clinical history of the patient regarding the drug reaction, symptoms, and 
administered/used medications. These letters also include all step-by-step 
diagnostic tests, results and the patient’s health condition before, during, and 
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after any tests. For our retrospective recruitment we reviewed all patients’ 
records from 2005 to 2011, which also included all other drug allergies. These 
records were for patients who had followed all diagnostic steps in the Guy’s 
clinic.  
As previously mentioned after taking a detailed history from each subject, skin 
prick and intra-dermal tests were applied. In some cases, a specific IgE test was 
performed. Patients were confirmed as having allergic reaction on the basis of a 
positive skin test, or specific IgE.  Note that having a negative skin test or 
negative specific IgE test was not enough to confirm patient as tolerant. As 
explained in chapter 1, the accuracy of the skin prick test and specific IgE test are 
not 100%. When the patient has a clear history of an allergic reaction but the 
results of skin test or specific IgE are negative, a drug provocation test is needed 
to confirm the allergy status.  
5.2.2.1 Case selection and genotyping 
 Case selection 
I selected cases by employing the participant inclusion/exclusion criteria written 
in the protocol. Cases were selected from the clinical records available in the 
Guy’s Hospital allergy clinic. 
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Patient selection based on protocol 
Up to 150 cases with a history of immediate allergic reaction to beta-lactams 
were retrospectively or prospectively recruited from the allergy clinics held at 
Guy’s Hospital.  
Inclusion criteria: 
1. Age: > 18 and < 80 years. 
2. History of immediate allergic reaction following administration of beta-
lactams and at least one positive skin testing with one or more of the beta-
lactam – derived reagents tested.  
Definitions 
• Immediate reaction: a history of anaphylaxis or urticaria and/or angioedema 
immediately following administration of beta-lactam antibiotics 
• Anaphylaxis: occurs if subject presents two or more of the following 
symptoms: palm/sole or generalised pruritus, generalized erythema, 
difficulty to breathe, speak or swallow, cardiovascular symptoms 
(hypotension) and/or loss of consciousness. 
• Urticaria: Wheals in one or several parts of the body. 
• Angioedema: Localized oedema in one or several parts of the body. 
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• Beta-lactam skin testing includes penicillin allergenic determinants 
(benzylpenicillin, PPL, MDM, amoxicillin) and suspected beta-lactams. 
• Positive skin testing: A wheal 3mm greater than the negative control (Lopez-
de-Andres et al.). 
• Atopy: Symptoms of rhinoconjuctivitis and /or asthma to common allergens 
(pollen, house dust mites, animals) 
Exclusion criteria:  
1. Age <18 or >80 years 
2. Inability to comprehend or comply with the protocol 
The main source of data (for case selection) was consultant letters to GPs 
summarising the diagnosis of patients, archived from 2005 to 2011. There were 
1764 visits in total to the drug allergy clinic and to the drug provocation clinic. 
All visits were recorded in a patient information manager (PIM) tool, and could 
be sorted by: date of clinic, consultant’s name and clinic name.  
Using the PIM, I extracted hospital/NHS numbers for all patients who visited the 
beta-lactam allergy clinic from 2005 to 2011. Each record was quickly scanned 
for any keywords that served as clues of allergy to beta-lactam antibiotics or a 
test for one. All records with these keywords were printed. Printed medical 
records were reviewed and records of interest (cases) were identified who were 
confirmed as having immediate (type I) allergy to beta-lactam antibiotics (i.e. 
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positive skin prick test, positive specific IgE test or positive DPT result). After 
identifying all possible cases, required information such as address, phone 
number, GP’s contact details, date of birth, age, gender, and ethnicity were 
extracted using the PIM.  
A total number of 1431 medical records were reviewed. Out of these records, 
145 individuals were identified as suffering from immediate allergy to one or 
more beta-lactam antibiotics and 7 cases of delayed allergy to beta-lactam 
antibiotics (Table 5.1). A total of 262 patients were identified as beta-lactam 
tolerant and 190 individuals did not complete all the routine diagnostics for the 
clinician to make the appropriate decision. The remainder of records was cases 
of allergy to other drugs unrelated to beta-lactam antibiotics. Out of 145 allergic 
cases, I identified 31 duplicates, thus I retrospectively identified a total of 104 




Table 5.1 Drug allergy clinic review from 2005 to 2011 
 
 
Drug allergy clinic from 2005 to 2011 
 
 























This table shows summarises all available patients records in the Guy’s allergy clinic 
from 2005 to 2011. Only 104 patients out of 1431 were confirmed with immediate 
allergy to beta-lactam antibiotics. 
  
 
Identified cases were asked to attend the clinic in order to donate blood for our 
study, or else were sent postal blood kits and instructed to return them to us 
through their GPs for DNA extraction. Each case was asked to fill in a simple 
health questionnaire (see Appendix O) and consent form (see Appendix M) as 
well as donating blood. We did not include 52 patients due to lack of response to 
our letters and calls, 2 patients due to unwillingness to provide a blood sample 
and 2 patients who were black African. A total of 48 cases were recruited for the 
study (please see Table 5.2).   
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Case genotyping  
I extracted DNA from whole frozen EDTA-treated blood, using the Nucleon 
Genomic DNA Extraction Kit BACC3. DNA extraction was performed according to 
the Standard Operating Procedure of the Genomic Laboratory of the Department 
of Twin Research  & Genetic Epidemiology at KCL. 
After DNA extraction, these individuals were genotyped on the Illumina Omni2.5 
platform at the BRC Genomics Core facility (NIHR Biomedical Research Centre at 
Guy's and St Thomas' NHS Foundation Trust and King's College London, 
16th floor, Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT). 
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Table 5.2 Detailed clinical information on the 48 GWAS cases  recruited from the Guy’s 
allergy clinic 





















1 F 26 13 16 NA 0 NA PEN IM SKIN BP 
2 F 51 8,19 3,13,18 2,3 1 2,6 PEN IM SKIN NA 
3 F 77 1,2 18 NA 0 NA PEN IM SKIN MDM 
4 F 73 1,3 9,14 NA 0 NA PEN IM SKIN AX, AUG 
5 F 61 3,5,10,12 9,10,19,22 NA 0 4,6 PEN IM SKIN BP 
6 F 37 8,22 3,6 2,4 1 2 AUG IM SKIN AUG 





1,2,3 1 6 CEFU IM SKIN CEFU, CEFO 
8 F 54 5,16,18 1,10,22 3 1 4,5,6 CEP IM SKIN AX 
9 M 57 3,5,14,15 7,10,13,19,22 NA 0 2 PEN IM SKIN PPL 
1
0 
F 52 2,3,5,18,19 1,10,12,19 3 1 2 PEN IM HI PEN 
1
1 
F 64 3,5,8 3,9,10,19 NA 1 2 AX IM, DE SKIN PPL 
1
2 
F 39 9,2 10,12,13,17,18 NA 0 6,7 PEN IM SKIN NA 
1
3 










2,3 1 8 PEN IM SKIN BP 
1
5 
F 64 19 1,8,12 3 1 6 AX IM SKIN AX 
1
6 
F 42 8,17,19 NA 1,2,3 1 2,3,6,8 AX IM SKIN AX 
1
7 
M 66 NA 6,10 NA 0 6 AX IM RA 0 
1
8 
F 48 NA NA NA 1 NA AX IM SKIN AX 
1
9 
F 47 NA 14 NA 1 NA CEF IM SKIN PPL, CEFU 
2
0 
F 63 6,16 15 NA 0 6 AUG IM SKIN BP, AX 
2
1 








1,2 1 1,2,3,6,8 PEN IM SKIN BP 
2
3 
F 36 NA NA NA 1 4,6 PEN IM SKIN NA 
2
4 
F 45 NA 14 NA 0 2,8 AX IM SKIN AX 
2
5 
F 73 3,5 10,12,19 2 1 6,7 PEN IM SKIN FLUC 
2
6 





F 69 22 10,12 NA 0 2,3 FLU IM SKIN FLUC 
2
8 
M 62 5 1,10 NA 0 NA PEN IM SKIN AX, MDM 
2
9 
F 55 3,8,17,18,19 1,3,13,15,22 1,2,3 1 2,3,4,5,6,8 PEN IM,DE SKIN BP, CEFO 
3
0 
F 66 18 5 NA 0 1,6 PEN IM DPT PEN 
3
1 
F 57 NA 1 NA 0 NA PEN IM SKIN BP 
3
2 




F 33 8,17 NA 1,2 1 6 PEN IM SKIN BP 
3
4 
F 38 17,20,21 4,8 1,4 1 NA AX,CEP IM SKIN AX 
3
5 
M 74 3,8,22 3,6,10 NA 0 NA AX IM SKIN AX 
3
6 
M 64 2,3,5,8 
1,3,6,10,12,13,
19 





F 54 18 8 NA 1 NA AX IM SKIN AX 
3
8 
M 52 19 6,10,13,22 3 1 NA FLU IM SKIN FLUC 
3
9 
F 33 8 3 2 1 NA AX IM RA, HI +RA 
4
0 
F 61 19 10 3 1 2 AX IM SKIN AX 
4
1 
F 68 2,3,5,11 10,19 NA 0 NA CEFU IM SKIN, RA AX 
4
2 
M 75 4,6,710,12 NA NA 0 6 PEN IM SKIN PPL 
4
3 
F 58 17,19,22 1,8,9 1,3 1 2,6,8 
AUG, 
PEN 






3,13,16 1,2,4 1 6 PEN IM DPT PEN 
4
5 
M 66 3,8,13,19 1,16,19 NA 1 2,6 AUG IM SKIN PPL 
4
6 
M 78 22 6,9,22 NA 0 6 PEN IM SKIN BP, PENG 
4
7 
M 63 NA NA NA 0 NA AX IM SKIN AX 
4
8 
F 58 8,19,22 3 2,3 1 NA AX IM SKIN MDM, BP 
Existing Medical Conditions: 1, Cancer; 2, Cardiovascular Disease; 3, High Blood Pressure; 4, Alcohol/Drug Abuse; 5, High Cholesterol; 
6, Lung/Respiratory Disease; 7, Infectious Disease; 8, Asthma; 9, Immune Disorders; 10, Obesity; 11, Stroke; 12, Diabetes; 13, 
Depression; 14, Liver Disease; 15, Kidney Disease; 16, Neurological Disorders; 17, Eczema; 18, Menopause; 19, Hay Fever; 20, Contact 
Dermatitis; 21, Urticaria; 22, Other 
Current Medication: 1, Vitamins/Minerals; 2, NSAIDs; 3, Asthma Medication; 4, Oral Contraceptives; 5, Sedatives/Sleep Aids; 6, 
Prescription Pain Medication; 7, Oral Hypoglycemics; 8, Hormones; 9, Diuretics; 10, Statins; 11, Herbs; 12, Aspirin; 13, Antihistamines; 
14, Thyroxin; 15, Steroids (Nasal/Topical); 16, Antidepressants; 17, Insulin; 18, Antibiotics; 19, Other Blood Pressure Tablets; 20, 
Anticoagulants; 21, Antifungals 
Co morbid allergic Conditions: 1, Eczema; 2, Asthma; 3, Hayfever; 4, Urticaria 
Atopy* was defined based on a personal history of atopy/or clinical records 
Atopy: Atopic case If the cases have one or more of the following conditions - Eczema, Asthma, Hayfever, Urticaria. 
Non Atopic definition If cases do not have any of the following conditions - Eczema, Asthma, Hayfever, Urticaria. 
1, Atopic; 0, Non Atopic 
Known Allergies: 1, Nickel/Metals; 2, Flowers/Trees/Grasses; 3, Fragrance; 4, Latex; 5, Rubber; 6, Medicines; 7, Insects; 8, Animals 
Culprit Drug: Culprit Drug Definition = The actual drug that causes the allergic reaction at the first place 
AX, Amoxicillin; PENI, Unrecalled penicillin; AMP, Ampicillin;  AUG, Augmentin; CEP, Cephalosporins; CEF, Cefuroxime; FLUC, 
Flucloxacillin 
Type of reaction: IM, Immediate reaction; DE, Delayed reaction 
Name of Test: SKIN, Skin test; RA, RAST test; DPD, Drug Provocation Test/Challenge Test; HI, History/NO test strong supporting history 
of the reaction 
Positive Test Results: PPL, penicilloy-polylysine; MDM, minor determinants BP benzyl-penicilloyl; AX, Amoxicillin; PEN, Penicillin; 
PENG, Unrecalled penicillin; AMP, Ampicillin; AUG, Augmentin; CEP, Cephalosporins; CEF, Cefuroxime; FLUC, Flucloxacillin; CEFU, 
Cefuroxime; CEFO, Cefotaxime; CEFT, Ceftazidime; CEFTR, Ceftriaxone 
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This table contains information about the current health status, any existing atopic 
conditions of the patients, comprehensive information of their beta-lactam allergic 
reactions, and the results of the allergic test that was performed by the clinicians. It also 
contains Information regarding current health status extracted from the health 
questionnaire, which was filled in by the participants at the time of recruitment. The table 
above also contains information about the participants’ age and gender. The first column 
gives information of any existing medical conditions. 
The ‘current medications’ section gives a list of medications that participants were 
currently using and information on other existing allergic conditions. In the ‘atopic’ 
column, if any of the participants had one or more co-morbid allergic conditions, they are 
listed as being atopic, otherwise they are listed as non-atopic. In the ‘known allergies’ 
section, we questioned the patients for any known allergic reactions to any of the listed 
substances.  The last four columns provide information on their beta-lactam allergic 
reaction. The ‘culprit drug; section gives the name of the actual beta-lactam that caused 
the allergic reaction in the first place. The ‘type of reaction’ section is categorised into 
immediate and delayed reactions, based on the interval between taking the drug and 
showing the first signs of allergic reaction. The next column describes the type of the test 
which was used to confirm and identify the patients’ allergic reaction. The final column 
displays the positive test results for any of the tested beta-lactams. 
 Following recruitment the participant, a detailed questionnaire was completed by each 
participant. The questionnaire contained information which was extracted to complete 




5.2.2.2 Control selection and genotyping 
Our original intention was to recruit up to 150 matched, beta-lactam tolerant 
controls from the allergy clinic at Guy’s Hospital. Our original inclusion criteria 
were age ( > 18 and <80 years); no clinical history of immediate allergy reaction 
to beta-lactam antibiotics; and negative skin testing to beta-lactam antibiotics 
and tolerant of beta-lactam antibiotics. Our exclusion criteria were age (<18 or 
>80 years); immediate reaction to beta-lactam antibiotics; and inability to 
comprehend or comply with the protocol. 
However, the number of selected cases didn’t reach the protocol requirement 
and therefore in order to increase the study power we decided to use a larger 
control group than what was planned at the beginning. Having a large selected 
control group required more recruitment time and cost, which was out of our 
study budget. Taking account of the required time and money for control 
selection, and also taking account of the relatively low prevalence of beta-lactam 
allergy among patients taking beta-lactams, we decided to use the WTTCC2 
control data (a publically available set of UK population controls). The WTCCC2 
data includes 2,737 healthy blood donors from the UKBS (United Kingdom Blood 
Service) collection and 2,930 individuals from the 58C (1958 Birth Cohort) 
dataset. These individuals were genotyped on both the Illumina 1M and 
Affymetrix 6.0 genotyping arrays, as part of the Wellcome Trust Case-Control 
Consortium 2 study. 5,175 individuals from the WTCCC2 dataset passed our 
quality control filters (following the same protocol as described in Genetic 
Analysis of Psoriasis et al., 2010). 
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5.2.3 Quality control for cases 
I checked all 48 cases for gender mismatches, and found no mismatched 
individuals. Thus we did not eliminate any individuals in this stage. After 
filtering, we had 13 males and 35 females.  
After applying minor allele frequency (MAF)<0.015 and SNP missingness 
(GENO)>0.025 filters to our data, 74789 SNPs failed the missingness test 
(GENO>0.025), also 903293 SNPs failed the frequency test (MAF<0.015). After 
frequency and genotyping pruning, there were 1427979 SNPs left. 
I used a threshold of p<=1e-06 for the test of departure of SNP genotype 
frequencies from Hardy-Weinberg Equilibrium (HWE). 3 markers were excluded 
based on the HWE test (p<=1e-06) and a total of 1427976 SNPs were left. 
To screen out poor quality DNA samples, I used the --mind command in PLINK 
‘mind’ sets the maximum rate of per-individual missingness. I used ‘mind’>0.03 
(this allows individuals with <3% missing SNP data to pass). No individuals were 
removed for low genotyping (MIND>0.03). 
5.2.4 Population structure check – case data merged with HapMap3 
data – performed using MDS 
In GWAS analysis, there is always a risk of generating a false positive result that 
arises from genetic differences between different ancestry backgrounds, rather 
than genes associating with disease. This is particularly a concern when case and 
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control data are combined from different sources, as they were here (Weale, 
2010). 
 In order to overcome this issue in our analysis, I used multidimensional-scaling 
(MDS) as a method to detect population stratification (PS). The MDS method 
visualises observed genetic distance among individuals. MDS analysis was 
performed by using PLINK.  
Before merging our case data with our control data (WTCCC2), I checked for any 
ancestry issues in our case data. We restricted our data to SNPs that overlapped 
with the control data (WTCCC2). The steps involved in this process are outlined 
below. 
5.2.4.1 Determination of overlap of SNPs with WTCCC2 
In this stage, in order to determine overlap set of SNPs, I sorted the .bim files for 
cases and controls (Illumina 1M SNPs only), then by using “join” command I 
arrived at the common set of SNPs on both datasets. There are 463962 SNPs that 
intersect (overlapped).  
5.2.4.2 Creation of a merged Case + HapMap Phase 3 dataset  
The HapMap 3 dataset represent populations with large communities in the UK 
(i.e. European (CEU), African (YRI), Asian (JPT+CHB) and Indian (GIH)) (Duan et 
al., 2008). By using the --bmerge command, I merged our case data with the 
HapMap3 data and created a new file. The HapMap data contained 257 males, 
274 females.48 cases and 112 CEU, 113 YRI, 86 JPT, 84 CHB, 88 GIH controls.  
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5.2.4.3 Application of MDS to the new merged dataset 
I applied MDS to the merged dataset and checked the first two MDS axes (MDS1 
vs MDS2) and also MDS1 vs MDS3. As can be seen in both figures, all cases 
cluster with CEU. In figure 5.1 and 5.2,the black colour represents our cases, the 
red colour represents CEU, green colour represents YPI, blue colour represents 






Figure 5.1  Results of MDS analysis for major ancestral population clustering.   
In this figure the black colour represents our cases, the CEU population is marked as red, 
the green colour represents the YPI population, the cyan colour stands for the GIH 
population and finally the blue colour represents the East Asian (JPT+CHB) population. All 





Figure 5.2 Results of MDS analysis for major ancestral population clustering.  
In this figure the black colour represents our cases, the CEU population is marked as red, 
the green colour represents the YPI population the cyan colour stands for the GIH 
population and finally the blue colour represents the East Asian (JPT+CHB) population. All 
cases cluster with CEU, which indicates that all our cases are likely of European ancestry.   
 
As a result of the population structure check, no individuals was removed. All 
individuals appeared to be of European ancestry, and all had reasonably 
complete genotype information.  
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5.2.5 Quality control and merging of control data 
All the QC steps for our control dataset were applied to an ‘intersect’ control 
dataset based on a set of overlap SNPs (see section 5.2.3). First I created a 
reduced 1958 Birth Cohort (58C) dataset by using the -extract command, then by 
using the same command I created a reduced version of the National Blood 
Service (NBS) dataset as well. The new datasets were called 58Csmall and 
NBSsmall (as both datasets were smaller than the original datasets). By using the 
–bmerge command, I then merged the two ‘small’ datasets into a single version 
of our control data (WTCCC2). 
I then applied the same QC steps to our control data set that I had used for the 
case data (see case QC section). Finally, by using the –bmerge command, I 
merged the final case dataset and final control dataset together for further GWAS 
analysis. 
5.2.6 Power Calculations  
Because of the small case sample size, before running the GWAS scan, we needed 
to determine what effect sizes we could pick up in the GWAS scan with 48 cases 
and 5139 controls. Statistical power calculation is an analysis to calculate the 
probability that the test can correctly reject the null hypothesis (H0) and accept 
the alternative hypothesis (H1).  
To calculate our study power we used the Quanto program 
(http://biostats.usc.edu/Quanto.html), which can calculate required sample size 
and power for genetic studies. Assuming a log-additive genetic model and a 
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population prevalence of 0.01, and setting a genome-wide significance threshold 
of 5e-8, for a common SNP (MAF=0.5) we found our study had 80% power to 
pick up a Genotypic Odds Ratio of 4.3 and 90% power to pick up a Genotypic 
Odds Ratio of 4.9, while for a rare SNP (MAF=0.05) we found our study had 80% 
power to pick up a Genotypic Odds Ration of 6.3, and 90% power to pick up a 
Genotypic Odds Ratio of 7.0. We therefore determined that our study was only 
powered to detect very strong GWAS signals. 
 
5.2.7 GWAS scan on all cases  
We started by running a simple GWAS scan without any covariates. We applied 
logistic regression using SNP alleles coded (0,1,2) for each genotype 
(“1”=heterozygotes) – i.e. a log-additive trend model, and no covariates for 
population structure were added. 
By not using any covariates, it was possible that background inflation in our QQ 
plots and Manhattan plots would be generated. However, as shown in the next 
section, there was in fact no evidence for genomic inflation. We therefore 
proceeded with this model for GWAS scan on all cases. By using all cases, this 
scan assumes that common genetic loci underline the genetics of beta-lactam 
allergy, regardless of the specific beta-lactam being administered. 
 
 184 
5.2.8 GWAS Fisher’s Exact Test (FET) scan restricted to amoxicillin 
cases only 
The GWAS scan on all allergic cases in our clinical cases showed no positive 
findings (see results section).  
Therefore we decided to run another GWAS scan on just amoxicillin allergy 
cases. The reasoning behind this was that a less heterogeneous phenotype might 
yield hits that were masked by the previous analysis. This GWAS scan was 
performed on 11 amoxicillin allergic cases. Due to the small sample size in this 
test we decided to use Fisher’s Exact Test to achieve this scan. Fisher Exact Test 
is a statistical exact test applicable to all sample sizes, including small sample 
size. This test is well-behaved in low-n situations, and thus one can calculate the 
exact significance of the deviation from a null hypothesis even with a small 









5.3.1 Characteristics of the 48 GWAS cases 
Table 5.3 summarises some characteristics of the 48 GWAS cases recruited from 
the Guy’s Hospital allergy clinic from 2005 to 2011. More complete information 
is provided in Table 5.2. 
 
Table 5.3 Characteristics of the GWAS cases 
 
Name of register 
 









Kind of ascertainment 
 











(13 (27%)/35 (73%)) 
 
 
Allergy to particular drug 
 
PEN (45.83%), AUG (6.25%), CEFU 
(4.16%), CEP (4.16%), AX (27.08%), CEF 









Immediate 46 (95.8%)/delayed 






AX, Amoxicillin; PEN, Penicillin; AUG, Augmentin; CEFU, Cefuroxime; CEP 




5.3.2 Q-Q plot and Manhattan plot for all cases 
Figure 5.3 shows a QQ plot for our GWAS scan on all cases. A QQ plot displays the 
observed p-values for each SNP, ordered from highest to lowest on a –log10 
scale, against expected p-values under a global null hypothesis (i.e. the p-values 
expected if there were no true association signals in the data (Ehret, 2010)). 
Since the points adhere to the 1:1 line in the lower left portion of the plot, this 
indicates there is no evidence for genomic inflation affecting all SNPs. The upper 
end of the plot shows some “hits” – i.e. association signals that can’t be explained 
under the global null hypothesis.  However, these “hits” could still be false 




Figure 5.3 QQ plot for the GWAS scan on all cases.  
The negative logarithms of the observed (y axis) and the expected 
(x axis) ordered p-values are plotted for each SNP. The red line indicates 
the expected distribution under the global null hypothesis. The grey 
shaded region represents the 95% concentration band. As can be seen in 
this plot, there is no genomic inflation in lower end of the plot, while some 
apparent “hits” appear at the upper end of the plot. 
 
In running the GWAS scan on all cases, we did not explicitly correct for 
population structure, but even so the QQ plot was free of any evidence of 
inflation. If we had seen any inflation in the plot, we would have introduced 
population structure covariates, such as PC or MDS axes, into the analysis to 
correct the inflation (Weale, 2010). But in the event, we found that the GWAS 
scan on all cases did not show any genomic inflation. Genomic inflation is a 
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problem that increases with sample size so one reason for the lack of inflation 
may simply be the very small number of cases in the analysis. Figure 5.4 provides 
a Manhattan plot for the GWAS scan on all cases.  
 
Figure 5.4 Manhattan plot for the GWAS scan on all cases.  
The x-axis shows the chromosomal position and the y-axis shows the –
log10 p-value. Chromosomes are shown in alternate colours. The red 
horizontal line indicates a threshold of genome-wide significance at a p-
value of p<5e-8. Each point represents a p-value for the SNP association 
test. There are two significant hits in this plot, but they appear sporadic 








5.3.2.1 Top hits and LocusZoom plots 




Table 5.4 The top 30 hits for the GWAS scan on all cases.  Hits are listed 
from lowest to highest p-value.   
CHR          SNP                 BP         A1         TEST     NMISS       OR          P  
   1    rs6657114   147377718    A        ADD     5176      12.32          7.008e-19 
   1   rs12404733   247690417    C        ADD     5133     0.1538          2.684e-08 
   9   rs10810585   16671045    C        ADD     5160     0.2105          8.367e-08 
  10   rs11008285   31130983    C        ADD     5160     0.1541          9.245e-08    
   1   rs10458392   162092110    C        ADD     5093     0.2254          9.316e-08 
   7   rs10260314   148280705    C        ADD     5137     0.1219          1.14e-07 
   9    rs7871217   18929692    C        ADD     5164     0.2265          3.067e-07 
  20    rs4925203   60451598    A        ADD     5160     0.2386          3.417e-07 
  16    rs9925071    5784107    G        ADD     5184      3.176          3.728e-07 
  8     rs939341   61032713    C        ADD     5158     0.1685           4.007e-07 
  17    rs3764421   29167653    C        ADD     5117      0.152          4.312e-07 
   3   rs10865893   40113022    C        ADD     5155     0.2809          4.973e-07 
   1    rs2840945   225859141    C        ADD     5114     0.2662          5.515e-07 
   1       rs8453   115259599    A        ADD     5177     0.2383          9.754e-07 
   8    rs9325854   19151139    A        ADD     5182      4.317          2.454e-06 
  16    rs4556797   80037987    G        ADD     5127     0.2292          2.77e-06 
  16    rs6540308   86554024    C        ADD     5139       0.28          4.201e-06 
   4    rs2278924   183932844    C        ADD     5166     0.2843          5.472e-06 
   1    rs2258497   167408073    C        ADD     5184      2.906          5.619e-06 
  15   rs17270362   61050486    A        ADD     5187      2.599          6.214e-06 
   1     rs870873   167399503    G        ADD     5186      2.973          6.805e-06 
   1     rs953809   167403625    A        ADD     5186      2.995          6.941e-06 
   4   rs16893097   16156964    A        ADD     5139     0.2208        8.645e-06 
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  15   rs12437690   61055432    A        ADD     5184      2.553        9.529e-06 
  16   rs11076173   56919235    A        ADD     5180      2.913        1.005e-05 
   9    rs1403561   15011825    G        ADD     5184      2.718        1.023e-05 
   9     rs784935   116434346    C        ADD     5139      0.296        1.215e-05 
   8    rs2006919   17975812    A        ADD     5147      3.528        1.546e-05 
   3    rs1199333   138091701    C        ADD     5166     0.3308        1.707e-05 
   7     rs219254   150992226    A        ADD     5180      2.469        1.811e-05 
CHR, chromosome; SNP, SNP name; BP, SNP position in base-pairs; A1, Minor Allele; ADD, genetic model 
additive trend test; OR, Odds Ratios; P, p-value. 
 
 
5.3.2.2 LocusZoom plots for the two top hits with p<5e-8 
As can be seen in our top hits table, the first hit (SNP name: rs6657114) is 
located on chromosome 1, and the reported p-value in the table is 7.008e-19. 
Figure 5.5 is a LocusZoom plot (http://locuszoom.sph.umich.edu/locuszoom/) of 
the above hit, but unfortunately the SNP is not well supported by other SNPs. The 
LocusZoom plot shows that this is a “singleton” signal, and that SNPs in high 





Figure 5.5 LocusZoom plot for the first SNP on the top hits list.  
The main panel shows association p-values on the –log10 scale on the 
vertical axis, and the chromosomal position along the horizontal axis. 
Genes within the region are shown in the lower panel. The SNP is not 
supported with other SNPs, therefore the signal is likely not a real hit. 
 
 
The next hit in our top hits table (SNP name: rs12404733) is also located on 
chromosome 1, and the reported p-value is 2.684e-08. Figure 5.6 is a LocusZoom 
plot of the above hit. The LocusZoom plot shows that this is also a  “singleton” 




Figure 5.6 LocusZoom plot for the 2nd top hit. The SNP is not supported by 
other SNPs, therefore the signal is likely not a real hit.  
The main panel shows association p-values on the –log10 scale on the 
vertical axis, and the chromosomal position along the horizontal axis. 
Genes within the region are shown in the lower panel. Each filled circle 




5.3.2.3 LocusZoom plots for hits with 5e-8<p<5e-6 
I created LocusZoom plots for all hits with p<5e-6, but unfortunately none of the 
SNPs are well supported by other SNPs and they appear to be “singleton” signals. 
This pattern is consistent with these hits being false positive signals generated 
by systematic biases in genotype calling between cases and controls. This 
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presumably results from the fact that the cases and controls were collected and 
processed separately and typed on different genotyping platforms. 
5.3.2.4 Checking the hit for the TwinsUK GWAS in our clinical GWAS 
We checked the hit SNP (rs12438477) from the TwinsUK data for any evidence 
of significant association, but unfortunately the same SNP is not present in the 
clinical GWAS result. We therefore checked for any possible LD proxy. By using 
the SNAP tool (http://www.broadinstitute.org/mpg/snap/), we found out that 
SNP rs12438477 is on the Illumina 1M chip and there are no other LD proxies 
(r2<0.8) on any Illumina chips. It is likely that the SNP was removed during the 
QC steps.  
Therefore, to look for any evidence of an association signal in the GWAS scan on 
all cases, we created a LocusZoom plot (Figure 5.7) of the region around 







Figure  5.7  LocusZoom plot for the hit from TwinsUK GWAS.  
There is no evidence for an association signal in the clinical GWAS data. 
The main panel shows association p-values on the –log10 scale on the 
vertical axis, and the chromosomal position along the horizontal axis. 
Genes within the region are shown in the lower panel. Each filled circle 
represents the p-value for one SNP in the clinical GWAS scan on all cases. 
 
 
5.3.3 Checking the signals of other candidate gene studies in our GWAS 
scans  
In order to check if any of the significant SNPs from previous studies are 
replicated in our data, we created a LocusZoom plot for each of the candidate 
genes and significant SNPs from previously published studies using our data. 
Table 5.5 compares the findings of previously published studies with our all-
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cases GWAS, amoxicillin-only GWAS and TwinsUK GWAS. Unfortunately the 
previously reported positive results were not replicated in any of our data sets.
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Table 5.5 Comparison of previously published findings with our data 

















HLA-DRA rs7192 6 32519624 NO NO NO 
 
Replicated in IP in 2014 
Immunochip study 
(Gueant et al., 2015) 
 
C5 rs17612 9 1222765747 NO NO NO 
 
Replicated in IP in 2014 
Immunochip study 
(Gueant et al., 2015) 
 
ZNF300 rs4958427 5 150258780 NO NO NO 
 
Replicated in IP in 2014 
Immunochip study 





rs7754768 6 32528157 NO NO NO 
 
Discovery hit in 2014 
Immunochip study, but 
not genotyped in 
replication phase 





rs9268832 6 32535767 NO NO NO 
 
Candidate in candidate 








6 32521437 NO NO NO 
 
Candidate in candidate 






rs2213586 6 32521072 NO NO NO 
 
Candidate in candidate 








6 32521128 NO NO NO 
 
Candidate in candidate 




HLA-DRA Rs7195 6 32520517 NO NO NO 
 
Candidate in candidate 










NO NO NO 
 
Replicated in IP in 2014 
Immunochip study 
(Gueant et al., 2015) 
 
NOD2 rs2066845 - - NO NO NO 
 
Candidate in candidate 
gene study (Oussalah et 
al., 2016) 
 
NOD1 rs2907749 - - NO NS NO 
 
Candidate in candidate 






















- - NO NO NO 
 












- - NO NO NO 
 





- - NO NO NO 
 






- - NO NO NO 
 
(Ming et al., 2011) 
 
Table showing the comparison of previously published findings with our data. All the 
significant SNPs and candidate genes in previous beta-lactam allergy studies have been 
checked for replication in all three data set (all-cases scan, amoxicillin-only scan, TwinsUK 
scan). Unfortunately none of the previously reported SNPs or genes are replicated in any 
of our data sets. 
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5.3.4 Results for amoxicillin-only scan 
5.3.4.1 Top hits for GWAS scan on amoxicillin-only cases 
Table 5.6 shows the first 30 top hits for the amoxicillin-only scan. Unfortunately, 





















Table 5.6 The top 30 hits for the GWAS scan of amoxicillin-only scan. 
CHR=chromosome; SNP=SNP rsID; BP=position (Build37); A1=Allele1; 
F_A(F_U)=case(control) allele freq; Allele 2; P=p-value; OR=Odds ratio 
 
CHR SNP BP A1 F_A F_U A2 P OR 
1 rs2840945 225859141 C 0 0.4616 A 2.27E-06 0 
20 rs4925203 60451598 A 0 0.4415 G 3.19E-06 0 
2 rs2121434 149557825 G 0.6818 0.2295 A 8.39E-06 7.193 
18 rs4941279 62181984 A 0.8182 0.3668 G 1.96E-05 7.77 
11 rs11216667 117876198 A 0 0.4025 C 2.28E-05 0 
1 rs10798986 34241397 C 0.5455 0.1558 A 2.91E-05 6.502 
1 rs6425668 181119835 G 0 0.3817 A 3.02E-05 0 
17 rs7216522 43108705 G 0.8636 0.4234 A 3.25E-05 8.625 
14 rs12894797 80792090 G 0.9091 0.4919 A 5.30E-05 10.33 
14 rs12896139 80792909 G 0.9091 0.4939 A 5.60E-05 10.25 
2 rs6739054 11220562 G 0.6818 0.2672 A 5.91E-05 5.877 
6 rs2816369 53088181 A 0.4091 0.0896 C 6.46E-05 7.034 
15 rs10902565 100773585 A 0.6818 0.2699 G 6.72E-05 5.796 
15 rs16954285 70499098 A 0.4545 0.1151 G 7.30E-05 6.404 
1 rs6657114 147377718 A 0.2727 0.03403 C 7.59E-05 10.65 
14 rs12050217 96728753 G 0.5909 0.2026 A 7.65E-05 5.685 
15 rs10459644 70512623 A 0.4091 0.09373 G 9.18E-05 6.694 
16 rs11862936 5961636 G 0.7273 0.3162 A 9.21E-05 5.768 
3 rs4679561 59422456 A 0.8182 0.4029 G 9.69E-05 6.67 
2 rs7580383 125457240 G 0.04545 0.4387 A 0.0001025 0.06093 
1 rs621070 218337199 A 0.3636 0.07278 G 0.0001027 7.28 
11 rs7937026 96634323 A 0.2273 0.02209 G 0.0001071 13.02 
2 rs4499362 149568396 A 0.5909 0.2118 G 0.0001238 5.376 
17 rs916660 43158674 A 0.8636 0.4565 G 0.0001245 7.54 
18 rs8092218 62191653 G 0.8636 0.4598 A 0.0001336 7.44 
1 rs12048806 192410674 A 0.4091 0.09866 G 0.0001365 6.325 
2 rs12692166 236258449 A 0 0.3533 G 0.0001386 0 
5 rs6883772 158131574 G 0 0.3423 A 0.000144 0 
7 rs1155597 126613163 A 0.7727 0.359 C 0.0001474 6.07 
18 rs2868934 10204383 A 0.5 0.153 G 0.000149 5.537 
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5.3.4.2 QQ plot for the amoxicillin-only GWAS scan. 
Figure 5.8 is the QQ plot for the amoxicillin-only scan. All the SNPs in the upper 
end are still in the grey zone area (95% concentration band), indicating a lack of 
any genome-wide significant hit in the results. The QQ plot in figure 5.8 is 
slightly deflated, which is typical of FET tests.  Overall, there is little evidence for 
any real GWAS hits here, reflecting the fundamental problem with lack of power 




Figure 5.8 QQ plot for the amoxicillin-only scan.  
The negative logarithms of the observed (y axis) and the expected 
(x axis) ordered p-values are plotted for each SNP. The red line indicates 
the expected distribution under the global null hypothesis. The grey 
shaded region represents the 95% concentration band. There is no 
genomic inflation in lower end of the plot. There is no evidence of any 









5.3.4.3 Manhattan plot for the amoxicillin-only GWAS scan 
Figure 5.9 displays the Manhattan plot for the amoxicillin-only GWAS scan. 
There are no SNPs passing the genome-wide significant threshold, again 
showing that there are no significant hits in this scan.  
 
 
Figure 5.9 Manhattan plot for the amoxicillin-only GWAS scan.  
The x-axis shows the chromosomal position and the y-axis shows the –
log10 p-value. Chromosomes are shown in alternate colours. The red 
horizontal line indicates a threshold of genome-wide significance at a p-
value of p<5e-8. Each point represents a p-value for the SNP association 










5.4.1 GWAS scans  
Cases recruited from Guy’s Hospital allergy clinic are similar to the previous 
cohort study used by Gueant et al., 2015. In both studies allergic work-up was 
performed according to the European Network for Drug allergy guidelines. 
Patients have been recruited after confirming of having a positive history of 
immediate beta-lactam allergy. Skin tests were performed with major and minor 
determinants of benzyl penicillin, amoxicillin and culprit drug when a 
cephalosporin involved. In the case of negative skin test, provocation test was 
performed with culprit drug in order to complete diagnosis. Also all recruited 
patients were white. 
We have conducted one of the first GWAS studies of well-defined beta-lactam 
allergy. There is another ongoing similar unpublished study lead by Dr. Munir 
Pirmohamed at Liverpool University. Despite the lack of well-defined whole 
genome studies on beta-lactam allergies, the positive findings from the TwinsUK 
GWAS, which I have previously discussed in Chapter 3, encouraged me to run 
another GWAS by using clinically well-defined cases in the hope that we could 
replicate the positive result of the TwinsUK GWAS. 
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 I therefore recruited allergic cases from the Guy’s allergy clinic. This study was 
conducted with 48 cases (see methods section). We used the large WTCCC2 
dataset as our control group (see methods section). We included 48 cases, which 
is comparatively low but, as I discussed in the Introduction chapter, there are 
examples of successful pharmacogenetics GWAS studies which also had a low 
number of cases. 
Our case recruitment protocol is similar to that of Gueant et al. (2015). In both 
studies, allergic work-up was performed according to the European Network for 
Drug Allergy guidelines. Patients were recruited after confirming a positive 
history of immediate beta-lactam allergy. Skin tests were performed with major 
and minor determinants of benzyl penicillin, amoxicillin and the culprit drug 
when a cephalosporin was involved. In the case of a negative skin test, a 
provocation test was performed with the culprit drug in order to complete 
diagnosis. Also, all recruited patients were white. 
In light of previous successful GWAS studies in the pharmacogenomic field with 
limited case numbers, it was hoped that by using well-defined cases and a large 
control group we would potentially have a study that was sufficiently powered 
to detect a strong pharmacogenetic signal. However, no evidence of significant 
hit was obtained either from the combined beta-lactam allergy cases from the 
amoxicillin allergy cases in their own.  
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5.4.2 Limitations of the clinical GWAS scan  
Here I discuss some of the limitations of this GWAS scan, which may have 
contributed to the negative results that we obtained. 
• Small case sample size; 
 As explained before, sample size, especially the number of the smaller 
sample group (here cases), plays a large role in the power of a study. This 
was confirmed by our power calculations, which showed that we only 
had adequate power to detect very large genetic association effects 
(OR>4.3). 
 
• Control selection; 
In our GWAS we used the WTCCC2 control dataset as our control group. 
There is no information about allergy status for the WTCCC2 cohort. In 
the case of using any unselected control data, there is always a possibility 
of having a number of cases among the control group; and this would 
especially be a problem for high-prevalence phenotypes, this is a minor 
problem if the prevalence of cases in the general population is small, as 
illustrated by previous examples of the successful use of unselected 
controls for rare adverse drug reaction GWASs (e.g. (Nelson et al., 2009)). 
Previous studies have suggested that the prevalence of beta-lactam 





• Batch effects; 
In this study, cases and controls were collected separately and genotyped 
in different labs and different platforms. Batch effects could be therefore 
another reason for not having a positive result as batch effects can give 
rise to false negative as well as false positive results.  
 
• Lack of imputation; 
Due to lack of time we didn’t impute our data, however this was a 
negative study with ~500k SNPs. It is unlikely that we missed any 
possible signals due to lack of imputation.  Imputation is valuable as a 
fine-mapping tool, but this only applies in cases where an actual signal is 
detected. 
 
5.4.3 Comparing the TwinsUK GWAS to the clinical GWAS 
There were no positive findings in our clinical GWAS, as we could not replicate 
the results for the self-reported TwinsUK GWAS and we did not generate any 
new genome-wide significant results after QC. The discrepancies in the findings 
might be explained by the following factors. 
• Sample size; 
There was a small case sample size in the clinical GWAS as compared to 
TwinsUK GWAS. As explained before, sample size plays a significant role 
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in the power of a study. In the TwinsUK GWAS we had self-reported 
phenotypes, but the number of cases was larger than the clinical GWAS. 
 
• Phenotype definition; 
The TwinsUK GWAS was conducted on self-reported beta-lactam allergic 
cases. However in the clinical GWAS we recruited well defined and 
clinically tested cases.  
 
• Control selection; 
 As explained in chapter 3, for the TwinsUK GWAS, we selected super 
controls (all controls were selected as being allergy free), but in our 
clinical GWAS we used the WTCCC2 control dataset. In the case of the 
WTCCC2 cohort, we did not have any information about allergy status. 
Therefore there is a possibility of having a number of cases within the 
control group. 
 
• Mismatching phenotype definition; 
In one of the TwinsUK GWAS scans, we included all delayed cases as well 
as immediate allergic cases, thus assuming that there are some common 
pathways in immediate and delayed allergic reactions. However in the 
clinical GWAS, only immediate allergic cases were included. 
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• Batch effects; 
In the clinical GWAS, cases and controls were collected separately and 
genotyped in different labs and different platforms. However data for 
TwinsUK GWAS were collected and genotyped at the same lab and 
corrected for any existing batch effects.  
 
5.4.4 Checking the results of the previous studies in the clinical GWAS  
As I explained before, many factors, such as small sample size, batch effects and 
a poorly defined control group, are limitations of this negative study. Taking into 
account the small case sample size in our study and the lack of power, as a final 
step, we decided to check all the positive findings of the previously published 
studies to see if we could replicate those results even if there was only a weaker 
signal in our study. However as shown in Table5.5, previously published results 
are not replicated in our clinical GWAS. 
To conclude, there were no positive findings in our clinical GWAS, as we could 
not replicate the results for the TwinsUK GWAS nor any previously published 
positive studies, and we did not generate any new genome-wide significant 
results after QC. As more studies are performed on this phenotype, we hope that 













6.1 Strengths and limitations of the study 
The investigations presented in this thesis have several strengths and 
advantages. Having access to the data of a large number of twins in the TwinsUK 
cohort, and data from the Guy’s allergy clinic, was one of the obvious strengths 
of this study. Twin studies provide us with one of the most powerful designs for 
heritability estimation. Participants from the allergy clinic have been tested and 
screened for beta-lactam allergy, out of which 48 were considered for the 
purpose of this thesis. 
Designing and validating a detailed and unique questionnaire for the assessment 
and phenotyping of beta-lactam allergy was another strong point of this study. 
This unique questionnaire was used to eliminate an appreciable percentage of 
the self-reported cases from the allergic category, and proof of the benefit of 
doing this was demonstrated by the improvement in the heritability estimate 
that followed from applying the revised phenotype definitions to the TwinsUK 
cohort. 
Our investigations also have some limitations that have been mainly discussed 
in each chapter. By using the new specific beta-lactam allergy questionnaire we 
were able to overcome some of the limitations of the old questionnaire. 
However, a number of limitations still remained with the use of the new 
questionnaire. These limitations have been discussed in detail in Chapter 2.  
The strengths and limitations of the TwinsUK GWAS scan on seriousness as a 
quantitative trait have been discussed in detail in Chapter 3. The strength and 
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limitations of MWAS on TwinsUK beta-lactam allergy data have been discussed 
in detail in Chapter 4.  The limitations of the clinical GWAS scan have been 
discussed in detail in chapter 5.  
 The main limitation pointed out by several practitioners and researchers during 
this study was using the self-reported twins cohort, rather than a clinically 
defined phenotype, a problem that still remained even though I took efforts to 
improve the quality of information obtained from the second questionnaire I 
designed. 
The other limitation of this study, with respect to the low prevalence of the true 
allergic cases, was the low number of the confirmed allergic cases in the clinical 
GWAS, which likely resulted in low GWAS power. Using the WTCCC2 cohort as 
our control group for the clinical GWAS was another possible imperfection of 
this study. By using a population-based cohort as our control group, there was a 
potential of having  ‘allergic controls’ in our study. However, since the 
prevalence of true beta-lactam allergy is not high, the low case number was 
probably the more problematic issue. 
 
6.2 Future work 
Perhaps the most important research question that can be considered as an 
extension to the works of this thesis concerns the role and connection of the 
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genomewide-significant associated signal located in the TwinsUK GWAS, which 
requires confirmation via a replication study (see discussion chapter 3).  
Also of interest would be a follow up study to the MWAS.  This would help to 
establish whether the result reported here is biologically valid or due to 
unknown batch effects.  If the former, it would be of interest to follow up the two 
unknown metabolite hits in the TwinsUK MWAS, to establish their origin.  
The observations in this thesis lead us to accept the hypothesis of beta-lactam 
allergy as being a complex trait that is under both genetic and environmental 
factors. In this study, we tried to uncover the genetic component of beta-lactam 
allergy. As explained before, we demonstrated evidence for the involvement of 
genetic factors in this trait, but the role of a wide variety of environmental 
factors was not studied. A detailed epidemiological study to understand the 
contribution of lifestyle could therefore  be another follow-up for this work. 
As one of the limitations of this study, I explained how well-defined phenotypes 
can improve the power of GWAS, and how not having a well-defined control 
group can affect the results. Therefore future work to find new genetic risk 
factors could be more focused on the different sub-types of beta-lactam allergy 
and both the common and distinct biological pathways for them.  
The work done in this thesis may also be applied in different ways. For 
heritability estimation, regardless of the current allergy status, administering 
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the same specially designed questionnaire for all twins in the TwinsUK cohort 
will improve still further the quality of the allergy severity phenotype.  
Referring the self-reported allergic twins to the allergy clinic and applying the 
clinical tests (skin and challenge test), or checking the blood samples for specific 
IgE could also add more accuracy to our result. In this case, re-doing the 
TwinsUK GWAS by using the truly allergic cases and comparing the result with 
the self reported GWAS could be of interest. 
By applying clinical tests on self-reported twins and having clinically proved 
cases, we could join our cases from clinical GWAS with clinically proved 
TwinsUK GWAS cases. Having a high number of cases and using our super-
controls from the TwinsUK GWAS, we could run another GWAS with more 
power. In the next step we could apply metabolomic profiling on our clinical 
cases and join them with twins’ data and apply another MWAS with more power. 
Future studies are generally required to validate the existence of systematic 
metabolomic effects. 
The findings of the investigations carried out in this thesis may serve as a basis 
for future research in related topics. The results of the TwinsUK GWAS and 
MWAS of the thesis, should they be validated in independent populations, could 
be used as potential biomarkers for safer clinical practice. Another avenue is 
collaboration with other studies using the data available in this field. Meta-
analysis of our data with future studies could be used to overcome the power 
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issue in this research and facilitate further advances in the genetic epidemiology 
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Volunteer Information Sheet 
 
1. Study Title 
 
Twins UK  
 
2. Invitation Paragraph 
 
You are being invited to take part in a research study within the 
Department of Twin Research as you are currently registered on our twin 
database. Please take time to read the following information carefully and 
discuss it with friends, family or your GP if you wish to do so. Please ask 
us if there is anything that is not clear or if you would like to have more 
information. You will find a contact number at the end of this Information 
Sheet. 
 
3. What is the purpose of this study? 
 
The purpose of the study is to explore the genetic and environmental 
causes of a wide range of diseases and conditions. By using your DNA 
profile and the clinical and questionnaire data we can compare similarities 
and differences between identical (MZ) and non-identical (DZ) twin pairs 
to estimate the importance of genetic and environmental influences in a 
wide range of common conditions.  This information can also be used to 
identify new genes and environmental factors associated with disease. 
Family members can also be used in the study to find out how diseases 
are influenced by genetic and environmental factors across the 
generations.  Family members may be invited to participate.  
 
4. Why have I been chosen? 
 
You have been chosen to take part in this study as you are registered on 
our database. You may have previously had a visit at the Department of 
Twin Research. For this study we want to include all the twins (and those 
parents and sisters already registered) on our database and get up to 
date information on everybody. 
 
5. Do I have to take part? 
 
No, it is up to you to decide whether or not to take part in this study. If you 
decide that you do wish to participate, you will be given this information 
sheet to keep and we will ask you to sign a consent form. You will be 
given a copy of the consent form. You are free to withdraw at any stage 
Department  of Twin Research & Genetic Epidemiology  
St Thomas' Hospital Campus  
4th Floor South Wing Block D 
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and this will not affect any future medical care or further research you may 
wish to participate in within the Department of Twin Research. 
 
 
6. What will happen to me if I take part? 
 
You will be invited to attend a visit at either the Department of Twin 
Research at St. Thomas’ Hospital in London or one of our satellite centres 
throughout the UK, whichever is the most convenient for you to attend.  
During this visit we will collect saliva, buccal (mouth) cells, blood, urine, 
hair and nail samples from you and we will ask you to complete a series 
of self completed questionnaires. 
 
You will undergo a variety of psychological and physiological tests which 
may include  height, weight, blood pressure measurements, grip strength, 
photocopy of your hands, fingerprinting, facial photographs, electro-
cardiogram (ECG), carotid ultrasound and measurement of the pulse 
using a probe, lung function test, distorted tune test for tone deafness, 
hearing tests, taste test, eye tests, a series of cognitive tests, bone 
mineral density scans and an exercise test involving walking and running 
on a treadmill at different gradients whilst having your heart rate 
measured. We may perform heat and pressure sensitivity tests using a 
heat probe on the forearm, brushing the skin with a brush or blunt probes, 
placing an extremity in an iced water bath. We may perform two 4mm skin 
biopsies on the abdomen under local anaesthetic and collect hair follicle 
samples for the purpose of stem cell research. This will enable us to 
investigate the way our genetic material determines cell function and how 
genetic malfunctions occur and cause disease.  With the understanding of 
these genetic mechanisms we hope to find ways of overcoming or 
reversing these defective mechanisms. You may also be asked to take 
part in a trial involving taking a dietary supplement. We will inform you 
about the exact tests undertaken on your visit at the time of initial contact 
and you are free to opt out of any tests that you do not wish to have 
performed. With your express permission we may request additional 
information from your medical records.  
   
7. What do I have to do? 
 
All we ask is that you attend the unit having fasted overnight. This means 
no food or drink, except water, from midnight the night before your visit. 
You need to provide us with a generous urine sample, which has been 
produced 2 hours after you first went to the toilet.  If you need to take any 
regular medication, please take them as you would normally do, 
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preferably with water only. If you are diabetic, please do not fast but 
inform us of this prior to your visit. 
You will be required to complete a questionnaire prior to attending any of 
the centres. This will take about 30 minutes to fill in and may require you 
to find additional information, e.g. what drugs are you using now, in the 
past, and for how long have you used them. 
 
8. What is the drug or procedure that is being tested? 
 
Depending on the disease we are researching when you come for your 
visit, you may receive drugs such as eye drops or a local anaesthetic 
(numbing medicine) similar to that used at the dentist.  We do not use any 
experimental drugs in any part of our study.   
 
9. What are the side effects of taking part? 
 
You should not experience any side effects whilst taking part in this study.  
You may feel a slight discomfort when the blood is being taken, but this 
should subside soon afterwards.  The pain test might leave a small area 
of reddening but this will fade quickly after the test. The skin biopsy may 
be tender over a few days and may leave a slight scar.   
 
None of the other tests performed such as height, weight, blood pressure 
measurements, grip strength, lung capacity test, eye tests, and carotid 
ultrasound will cause you any harm. 
 
10. What are the possible disadvantages and risks of taking part? 
 
There are no disadvantages and risks associated with this study. If you 
are pregnant, are planning to become pregnant or are of childbearing age, 
we may not perform certain tests on you, such as a Bone Mineral Density 
scan, or we may ask you to make the appointment for a later date. The 
bone mineral density scan delivers a small dose of radiation approximate 
to that received during a Trans-Atlantic Flight. 
 
11. What are the possible benefits of taking part? 
 
You will be informed of clinically relevant results of the tests performed on 
you during the visit. A copy of these results will also be sent to your GP. 
  
12. What happens when the research study finishes? 
 
Once the study has finished, your name will still remain on our database 
and you may be invited to participate in future projects. You will be 
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informed of further developments within the Department of Twin Research 
via regular annual Newsletters. You may also receive further 
questionnaires which will ask about any new diseases we are 
researching.  
 
13. What if something goes wrong? 
 
If you feel that you have been unfairly treated during your visit to any of 
the Centres, please direct your complaint to the Department of Twin 
Research who will investigate the nature of the complaint. You will receive 
feedback about your complaint within 21 working days. If you are harmed 
by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action but you may have to pay for it. 
 
14. Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the 
research will be kept strictly confidential. You will have been allocated a 
specific twin number and this will be used for all your data stored on our 
database.  All information which leaves this department, except the results 
which are sent to you and your GP, will be anonymous, your name and 
address will have been removed and replaced by this unique study 
number, so that you can not be identified. All analyses are performed on 
large datasets, so no individual can be identified. 
 
15. What will happen to the results of the research study? 
 
The samples of blood, hair urine, nail, saliva, buccal (mouth) smear or 
tissue  for  DNA/RNA analysis and the information collected during your 
visit will be stored centrally or at collaborating establishments. They will be 
used for further research into common diseases and traits and will be 
accessible to independent researchers and collaborators who wish to use 
the enormous potential of the twin design to identify the action of 
individual genes, environmental exposures and their interaction by 
performing further tests on these samples. Your DNA will not be used for 
any experiments with regards to human cloning.  Other academic centres 
and commercial companies, who are collaborating with us in our research, 
may request access and have rights to the data, including DNA and other 
samples, we have collected and to our research conclusions. The 
Department of Twin Research is now part of the Guy’s and St Thomas’ 
Hospital National Institute for Health Research (NIHR)  Biomedical 
Resource Centre (BRC), a government funded  initiative through the NHS 
to promote the sharing of knowledge, anonymous data and samples with 
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other leading scientific institutions. to support leading edge research 
focused on the needs of the  patient and public.   
 
The results of the genetic research, such as the types of genes you have 
or the sequence of your DNA, may be stored in an electronic archive (the 
European Genome-Phenome Archive at the European Bioinformatics 
Institute, Hinxton, Cambridge). This data will always be stored in an 
anonymised form but may be made accessible to bona fide researchers at 
other research establishments via a managed access system. 
  
The data/intellectual property collected as a result of your participation will 
always reside with the Hospital and Kings College London.  We often rely 
on the expertise of commercial companies to share data for writing of 
papers and to advance our research. In the rare event of any commercial 
profits, funds will come back to the hospital and the university for the 
further advancement of research. 
 
You will not have claim to either the material that we collected or the result 
arising from the study.  If you decide to withdraw your future consent for 
biological sample collection, previous samples cannot be removed or 
destroyed and will continue to be used for future research.   We shall 
ensure that all personal data and results are anonymised and cannot lead 
to the identification of a single individual. 
 
16. Who is organising and funding the research? 
 
The study is organised by the Department of Twin Research at St. 
Thomas’ Hospital in London and at present funding for this research 
project has been provided by the Wellcome Trust, a registered Charity 
and the Biomedical Resource Centre.  
 
17. Who has reviewed the study? 
 
The study has been reviewed and approved by the St. Thomas’ Hospital 
Ethics Committee. 
 
18. Contact for further information 
 
If you require any further   information   about this study or would like 
some questions   answered, please do not hesitate to contact the 
Department of Twin Research on Tel. 020 7188 5555 Monday to Friday 
between 9am to 5pm.     
 
 Thank you for taking the time to read this Information Sheet 
Appendix(B(
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Department Twin Research & Genetic Epidemiology  
St Thomas' Hospital Campus 
4th Floor South Wing Block D 
    Westminster Bridge Road  





Study Number: EC04/015 
Patient Identification Number for this trial: 
 
CONSENT FORM 
Title of Project: TwinsUK 
 
Name of Researcher: Prof Tim Spector  
Please Initial 
     













Name of Person taking consent Date Signature 




Researcher Date Signature 
 
 




I confirm that I have read and understood the information sheet version 7 dated 
04.04.12 for the above study and have had the opportunity to ask questions. 
   
2 
I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal 
rights being affected. 
 
3 
I understand that relevant sections of my medical notes, health related 
records and data collected during TwinsUK, may be looked at by responsible 
individuals from collaborating companies, regulatory authorities, the NHS 
Trust and the NIHR Bioresource, where it is relevant to my taking part in this 




  I agree that the samples I have donated and the information gathered about me 
can be  sharedwith the NIHR Bioresource and bone fide researchers and 
stored for use in future research studies aimed at identifying the interactions 
between genes, the environment and disease. 
 
5 
I agree to my GP being informed of my participation in the study and to 
receiving my clinically relevant results. 
 
6 
I agree to have the assessments stated in the information sheet performed 
and consent to take part in the above study. 
  _ _ 
  _ _ 
  _ _ 
  _ _ 
  _ _ 





For! research! purposes! we! ask! all! twins! to! complete! this! short! questionnaire! so! we! can! collect! further!
information!from!which!to!ascertain!your!zygosity!(i.e.!whether!you!are!an!identical!or!nonIidentical!twin),!

























    e) In childhood, which of the following would best describe you and your twin? (Please select 
one) 
(0) Ο As alike as peas in a pod 
(2) Ο Ordinary sibling likeness (like sisters or brothers) 
(1) Ο I don’t know 
!
!
NOTE:  We will contact you for further information if your Zygosity on completing this Questionnaire is 



























PARTICIPANT INFORMATION SHEET 
 
LREC reference: 11-LO-0112 
 
Study title: Genetic Epidemiology of Immediate Allergy to Beta-Lactam Antibiotics 
 
You are being invited to take part in a research study.  Before you decide to take part, it is important 
for you to understand why the research is being done and what it will involve.  Ask us if there is 
anything that is not clear or if you would like more information.   
 
What is the purpose of the study? 
 
Beta-lactam antibiotics, including penicillin and cephalosporins, are the most widely used antibiotics to 
treat common infections. Unfortunately, in up to 10% of the people they cause a marked, unwanted, 
and immediate allergic reaction. Such adverse reactions not only represent as a significant burden to 
the patient but also increase the overall cost of treatment markedly. Recent studies have shown that 
some people face greater risk of suffering such adverse events which can be due to a combination of 
factors including genetic, environmental exposure (diet, infection, interactions with other drugs), as 
well as other epidemiological (age, sex) aspects. 
 
The purpose of this study is to uncover genetic and environmental factors that increase the risk of 
allergy to beta-lactam antibiotics. More specifically, we will attempt to identify genetic variations – 
mutations – as well as environmental or epidemiological factors that are associated with the immediate 
allergic response to beta-lactam antibiotics. The results will improve clinical prediction of immediate 
allergic responses to these commonly prescribed drugs and so reduce the incidence of these unwanted 
responses. 
 
Why have I been invited? 
 
You have been invited to take part in this study because you have previously had an immediate reaction 
following administration of beta-lactam antibiotics.  If you have not had an immediate reaction to one of 
these antibiotics, you have been invited to join the study as a control participant. 
 
Do I have to take part? 
 
It is totally up to you to decide whether or not to take part.  If you agree to participate in the study you 
will be given this information sheet to keep and asked to sign a consent form (attached).  If you do 
decide to take part you are still free to withdraw at any time and without having to give a reason.  
Whether you decide not to take part or initially agree to take part and later change your mind, the 
standard of your care in hospital, either presently or at any time in the future, will not be affected in 
any way. 
Dr. Kourosh R Ahmadi PhD 
St Thomas' Hospital 
Dept Twin Research & Genetic 
Epidemiology 
Lambeth Palace Rd 
London SE1 7EH 
Tel:   020 7188 6728 
Email: kourosh.ahmadi@kcl.ac.uk  
 
Dr. Rosario Caballero MD PhD 
Guy's Hospital 
Dept of Allergy & Respiratory  
Science 
St Thomas Street 
London SE1 9RT 
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What will happen to me if I take part? 
 
If this is your first visit to the Allergy clinic and you have not previously had a beta-lactam allergy test, 
and agree to participate in this study, you will be asked to: 
 Sign a consent form. 
 Undergo a clinical examination. During this examination we will check your vital signs 
including pulse rate, blood pressure and blood oxygen (using a finger clip).  
 Have skin tests to see whether or not you are allergic.  
In these tests, we start with skin prick tests, followed by intra-dermal tests. Skin prick tests 
are done placing on the skin of your forearm a small drop of 5 different beta-lactam drugs 
(benzylpenicillin, benzylpenicilloyl poly-L-lisine, minor determinant mixture, amoxicillin, 
and other beta-lactam antibiotics when necessary). Fluid from these drops are introduced 
onto the surface of the skin by pricking with a sterile aluminium lancet. The skin prick is 
mildly painful and very rapid. If you are allergic to a particular drug, the site forms a small 
itchy blister (positive result). If you are not allergic, nothing happens and we carry on with 
intra-dermal tests. Intra-dermal tests are done by injecting 0.05ml (a tiny volume like a 
splash of water) of the same 5 beta-lactam drugs into our forearm. If you have a positive 
result to any beta-lactam antibiotics at any stage, then skin testing with that specific 
antibiotic is stopped. The skin testing procedure takes 1 hour. Any positive itchy reaction 
will settle and resolve within 10 mins (see section “What are the side effects of taking part”). 
   Give a sample of blood of 20 ml (about 2 tablespoonfuls) which will be used to extract 
DNA, for carrying out genetic profiling, or to carry out further biochemical tests useful 
for characterising the allergy.  
 
If you have been seen in the Allergy clinic previously and have already been diagnosed as allergic to 
beta-lactam antibiotics; if you agree to take part in this study you will be: 
 Asked to visit the clinical research facilities at Guy’s Hospital.  
 At the visit, we will initially answer any outstanding questions you may have about the 
study; 
 If you are still happy to participate, we will ask you to sign a consent form which will 
allow you to participate in the study; 
    We will collect 20 ml of blood (about 2 tablespoonfuls) which will be used to extract 
DNA, for carrying out genetic profiling, or to carry out further biochemical tests useful 
for characterising the allergy. 
 
How long will the visits last? 
 
The visit should take no longer that 1 hour. 
 
What are the side effects of taking part? 
 
Some people find skin testing slightly uncomfortable. As mentioned above, if you are allergic to a 
particular drug, the test site forms a small itchy blister. This can be itchy for about 10 minutes. Most 
people tolerate this very well but if necessary a dose of antihistamine will be given after the testing to 
minimise the discomfort.  
 
Skin testing carries a small risk of provoking a more widespread allergic reaction, with generalised itchy 
skin rash, chest tightness and low blood pressure.  This is extremely uncommon.  In the rare case in which 
it occurs, it happens within 30 minutes of injection of the allergen, which is why we ask you to remain in 
the clinic for half an hour.  It is readily and rapidly treatable and we are experienced in doing this. Skin 
testing will have been performed as part of your routine drug allergy clinic assessment.  
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Finally, you may feel a slight discomfort when blood is being taken, but this should subside soon 
afterwards. 
 
What are the possible benefits of taking part? 
 
The results of this study should help identify individuals who have a greater risk of beta-lactam antibiotic 
allergy and so inform medical practitioners in their choice of antibiotic drug prescription. 
  
What if I want to withdraw from the study? 
 
You may withdraw from the study at any time.  You do not have to give a reason. Withdrawing from the 
study will not influence your current or future treatment in any way. Should you wish to withdraw from 
the study after giving us your blood sample, we will destroy any blood or DNA and so will not be able to 
use these samples further in any of our investigations 
 
Will my participating in this study be kept confidential? 
 
All information which is collected about you during the course of this research will be kept strictly 
confidential.  Any information about you which leaves the hospital will have your name and address 
removed so that you cannot be recognised from it.   
 
Storage of your blood sample 
 
As part of the studya blood sample will be collected as described earlier. We ask for your permission to 
store any surplus blood or DNA extracted from the blood in our laboratories for future use in other 
genetic studies into allergy.  The samples will be identifiable as having come from you, but will be used 
only for the purpose of research and not for any diagnostic purpose.  No personal information will be 
given to any third party without your written consent. Samples will be stored for no more than 10 years 
after which left over samples will be destroyed.  Please note that you can withdraw your consent for us to 
store your samples at any time, when they would then be destroyed and this will communicated back to 
you by a letter.   
What will happen to the results of this research study? 
 
Eventually the results of the study will be published in a medical journal.  You will be welcome to receive 
from us any resulting publications if you so wish, but the study results will be entirely anonymous and 
you will not be able to identify your individual results. 
 
Who is organising and funding the research? 
 
The study is being funded in part by Biomedical Research Centre maintenance funding.  Guy's and St 
Thomas' NHS Foundation Trust, along with its academic partner King's College London, is one of five 
new  comprehensive Biomedical Research Centres in the UK funded by the National Institute for Health 
Research. These centres have a strong focus on translational research, taking advances in basic medical 
research out of the laboratory and into the clinical setting so that they can benefit patients.  They form a 
key part of the Department of Health's new strategy for research and development in the NHS.  
 
Who has reviewed the study? 
 
The study was reviewed and approved by the National Research Ethics Service, South East London REC 
2. 
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Contact for further information 
 
For further information about this study, please contact Dr Kourosh Ahmadi (email: 
kourosh.ahmadi@kcl.ac.uk or telephone on 020 7188 6728) or Dr Rosario Caballero (email: 
rosario.caballero@kcl.ac.uk or telephone on 020 7188 5075). 
 
Thank you for your time in reading this information sheet and considering participating in this 
research study. 
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LREC Reference number:  104/H07224/48.  
 
Study title: Genetic epidemiology of β-lactam antibiotic allergy 
 
Name of Researcher: Dr Rosario Caballero & Dr Kourosh R Ahmadi 
Please initial box 
1. I confirm that I have read and understand the information sheet for the 
above study and have had the opportunity to ask questions.   
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 




3. I understand that sections of any of my medical notes may be looked at 
by responsible individuals from regulatory authorities where it is 
relevant to my taking part in research.  I give permission for these 




4. I agree that my tissue, including Blood and DNA or RNA, may be 
stored and used in this study. (The storage will be covered by a Human 




5. I agree that any samples collected as part of this study may be stored 
anonymously for use in future, related studies, by the principle 
investigators. 
 
   




__________________________ _____________  ________________________ 
Name of Patient    Date    Signature 
 
 
__________________________ _____________  ________________________ 
Name of Person taking consent  Date    Signature 
(if different from researcher)  
 
 
__________________________ _____________  ________________________ 
Researcher    Date    Signature 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
Dr. Rosario Caballero MD PhD 
Guy's Hospital 
Dept of Allergy & Respiratory 
Science 
2nd Floor, Thomas Guy House 
St Thomas Street 
London SE1 9RT 
Tel:   020 7188 5075 





Dr. Kourosh R Ahmadi PhD 
St Thomas' Hospital 
Dept Twin Research & 
Genetic Epidemiology 
Lambeth Palace Rd 
London SE1 7EH 
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PARTICIPANT INFORMATION SHEET 
 
LREC reference: 104/H07224/48 
 
Study title: Genetic epidemiology of β-lactam antibiotic allergy 
 
You are being invited to take part in a research study.  Before you decide to take part, it is 
important for you to understand why the research is being done and what it will involve.  Ask us 
if there is anything that is not clear or if you would like more information.   
 
What is the purpose of the study? 
 
Betalactam antibiotics, including penicillins and cephalosporins, are widely used to treat 
common infections. Unfortunately, in up to 10% of the people they elicit a marked, unwanted 
allergic reaction. Such adverse reactions not only represent as a significant burden to the patient 
but also increase the overall cost of treatment markedly. Recent studies have shown that certain 
sections of the population face greater risk of suffering such adverse events which can be due to 
a combination of factors including genetic, environmental exposure (diet, infection, interactions 
with other drugs), as well as other epidemiological (age, sex) aspects. 
 
The purpose of this study is to uncover genetic and environmental factors that increase the 
susceptibility to allergy to betalactam antibiotics. More specifically, we will attempt to identify 
common and rarer genetic variants as well as damning environmental or epidemiological factors 
that are associated with betalactam allergy. The results should not only increase our 
understanding of a key biological system but also facilitate clinical prediction of adverse allergic 
responses to two of the most commonly prescribed drugs in the clinic. 
 
Why have I been invited? 
 
You have been invited to take part in this study because you have a history of immediate reaction 
following administration of penicillin or cephalosporin antibiotics.  If you have no history of 
immediate reactions with these antibiotics, you have been invited to participate as a control 
participant. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you agree to participate in the study you 
will be given this information sheet to keep and asked to sign a consent form (attached).  If you 
do decide to take part you are still free to withdraw at any time and without having to give a 
reason.  Whether you decide not to take part or initially agree to take part and later change your 
Dr. Rosario Caballero MD PhD 
Guy's Hospital 
Dept of Allergy & Respiratory 
Science 
2nd Floor, Thomas Guy House 
St Thomas Street 
London SE1 9RT 
Tel:   020 7188 5075 





Dr. Kourosh R Ahmadi PhD 
St Thomas' Hospital 
Dept Twin Research & 
Genetic Epidemiology 
Lambeth Palace Rd 
London SE1 7EH 
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mind, the standard of your care in hospital, either presently or at any time in the future, will not 
be affected in any way. 
 
What will happen to me if I take part? 
 
If you agree to take part in this study you will be asked to re visit the allergy clinic. At the visit, 
we will ask you to: 
• Sign a consent form; 
• Ask any questions you have regarding the study; 
•    Give a sample of urine and 30 ml of blood (about a tablespoonful) which will be 
used to extract DNA and RNA or to carry out further biochemical tests deemed 
useful for characterising the allergy. 
 
How long will the visits last? 
 
The visit should take no longer that 1 hour. 
 
What are the side effects of taking part? 
 
You are not at risk of any side effects during the visit. 
 
What are the possible benefits of taking part? 
 
The results of this study should aid in identifying individuals that face a greater risk of suffering 
from antibiotics allergy and so inform medical practitioners in their choice of drug prescription and 
regime. 
  
What if I want to withdraw fro the study? 
 
You may withdraw from the study at any time.  You do not have to give a reason. Withdrawing 
from the study will not influence in any way any current or future treatment you may be receiving, 
or will receive at the hospital.   
 
Will my participating in this study be kept confidential? 
 
All information which is collected about you during the course of this research will be kept strictly 
confidential.  Any information about you which leaves the hospital will have your name and address 
removed so that you cannot be recognised from it.   
 
Storage of your blood sample 
 
As part of the study, urine and blood sample will be collected to enable us to carry out the study. 
We ask for your permission to store any surplus blood, urine, DNA or RNA in our laboratories for 
future use in other, similar studies.  The samples will be identifiable as having come from you, but 
will be used only for the purpose of research and not for any diagnostic purpose.  No information 
will be divulged to any third party without your written consent.  These samples might be made 
available, with the permission of Head of Department, to any member of the departmental research 
team for similar related studies, but not to any third party in another department or to a commercial 
organisation.  Samples may be stored indefinitely.  Please note that you can withdraw your consent 
for us to store your samples at any time, when they would then be destroyed.  The storage of your 
tissues is covered by a departmental licence issued by the Human Tissues Authority. 
 
What will happen to the results of this research study? 
 
Version 02; 12/7/2010 
Page 3 of 3 
Eventually the results of the study will be published in a medical journal.  You are quite welcome to 
receive from us any resulting publications if you so wish, but you should know that your 
participation would be entirely anonymous. 
 
Who is organising and funding the research? 
 
The study is being funded in part by Biomedical Research Centre maintenance funding.  Guy's and 
St Thomas' NHS Foundation Trust, along with its academic partner King's College London, is one 
of five new National Institute for Health Research  comprehensive Biomedical Research Centres in 
the UK. These centres have a strong focus on "translational research" taking advances in basic 
medical research out of the laboratory and into the clinical setting so that they can benefit patients.  
They form a key part of the Department of Health's new strategy for research and development in 
the NHS.  
 
Who has reviewed the study? 
 
The study was reviewed and approved by the North West London Research Ethics Committee 1. 
 
Contact for further information 
 
For further information about this study, please contact Dr Kourosh Ahmadi (email: 
kourosh.ahmadi@kcl.ac.uk or telephone on 020 7188 6728) or Dr Rosario Caballero 
(rosario.caballero@kcl.ac.uk or telephone on 020 7188 5075). 
 
Thank you for your time in reading this information sheet and considering participating in 
this research study. 
 
Please keep this information sheet and a copy of your consent form for future reference. 
Appendix(M(!
Allergy Questionnaire 
Allergy Study Questionnaire V2 01 12 10 
 
Name:  NHS #: Date: ___ / ___ / ______ DOB: ___ / ___ / ____ 
Age: ________ Sex: F  Male  F  Female  Occupation:  _________________________ 
Race: F  White F  Black F  Asian F  Mixed  F  Other 
   
Existing Medical    
Conditions: F  Cancer F  Stroke  
 F  Cardiovascular Disease F  Diabetes 
 F  High Blood Pressure  F  Depression 
 F  Alcohol/Drug Abuse  F  Liver Disease  
 F  High Cholesterol  F  Kidney Disease 
 F  Lung/Respiratory Disease  F  Neurological Disorders  
 F  Infectious Disease  F  Eczema 
 F  Asthma  F  Menopause  
 F  Immune Disorders  F  Hay Fever  
 F  Obesity   F  Contact Dermatitis  
 F  Other  F  Urticaria  
If you ticked yes   
Please expand: _________________________________________________________________ 
 _________________________________________________________________ 
Current  Medication:   
 F  Vitamins/Minerals F  Herbs 
 F  NSAIDs F  Aspirin  
 F  Asthma Medication  F  Antihistamines 
 F  Oral Contraceptives  F  Thyroxin  
 F  Sedatives/Sleep Aids  F  Steroids (Nasal/Topical) 
 F  Prescription Pain Medication  F  Antidepressants   
 F  Oral Hypoglycemics   F  Insulin  
 F  Hormones  F  Antibiotics  
 F  Diuretics  F  Other Blood Pressure Tablets 
 F  Statins F  Anticoagulants  
 F  Other  F  Antifungals  
If you ticked yes   
Please expand: _________________________________________________________________ 
 _________________________________________________________________ 
  
Existing Medical   
Conditions: F  Eczema F  Asthma F  Hayfever F  Urticaria 
Food Allergy: F  Suspected F  Known _________________________________________ 
Known Allergies:  F  Nickel/Metals F  Flowers/Trees/Grasses F  Fragrance  F  Latex 
 F  Rubber  F  Medicines F  Insects F  Animals 
 F  Other __________________________________________________________ 




F  No 
 
F  Yes:  Drugs/Date ____________________________________ 
   
Family History: Allergies and Asthma:  F  Yes F  No  
 
 
Eczema:                        F  Yes F  No 
Hay Fever:                    F  Yes F  No      
Antibiotics Allergy       F  Yes F  No 
 
